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ABSTRACT 
Drug substitution is mainly economically not medically-driven; it can benefit healthcare 
services but does not directly benefit individual patients. Many healthcare providers have 
been promoting drug substitution in an attempt to contain their costs. This practice has 
been approved and supported on the basis of the presumption that the cheaper drug is not 
inferior to the more expensive one and the premise that any saving that does not 
compromise the quality of care is essentially appropriate. However, substitutions become 
problematic when the cheaper drug is known to have different effects and side effects, or 
even when there is just uncertainty about such effects.  
This thesis explores issues surrounding generic and therapeutic substitution from the 
ethical, patients’ and physicians’ point of view and from the potential differences in 
formulations between the branded and generic medicines. A series of studies such as a 
review of the ethical issues in drug substitution, multicentre surveys to explore patients’ 
and physicians’ views on drug substitution and other in-vitro and in-vivo comparisons 
between the actual formulations of the branded medicines and their generic counterparts 
were included in this thesis. The main objective was to encourage safe and effective 
generic and therapeutic substitution by validating the appropriateness and the potential 
impact of these substitutions on patients’ clinical outcomes and thus to promote high 
quality strategic logistic planning and effective management of drug formularies in 
hospitals.  
It was confirmed in this thesis that promoting generic and therapeutic substitution on 
economic grounds alone is unethical because it can be potentially harmful to patients and 
is incompatible with patient-centred medicine. As a consequence, multicentre surveys 
were conducted to assess patients’ views on generic substitution in hospital settings. A 
total of 163 renal transplant patients were surveyed using 36 multiple-choice questions at 
Barts and The London Renal Transplant Clinic, in the UK. This group of patients was 
specified because they may be particularly affected by drug substitution. Any small 
changes in the medicinal effect of this group of patients can negatively impact their 
clinical outcome. It was revealed in this survey that 84% of participating patients felt that 
generic medicines were not equivalent or only equivalent sometimes and they were 
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uncertain that generics had the same quality as branded medicines. In addition, many 
patients admitted that they would refuse the generic substitution of ciclosporin when it 
became available in the UK. Another multicentre survey in the United Arab Emirates 
(UAE) using 188 renal patients revealed that 68% of participating patients felt that 
generics were not equivalent or only equivalent sometimes, and they were uncertain that 
generics had the same quality as branded medicines. Therefore, many patients admitted 
that they would refuse the generic substitution of ciclosporin when become available. 
These beliefs were highly marked in patients with less education, less communication 
with healthcare professionals and who suspected that the cheaper drug substitution was 
implemented only to save costs.  
In another prescription based survey in the UAE, a random sampling of 1000 written 
prescriptions was analysed to determine physicians’ attitudes towards generic medicines 
and prescribing. It was explored in this study that prescribers were not yet ready to 
promote appropriate generic substitution. They were still prescribing generic medicines 
on occasions where health complications may occur as well as increase healthcare 
expenditure. As a result, improving awareness and education among physicians is 
compulsory to implement appropriate generic prescribing and substitution.  
In-vitro dissolution study was also conducted in this thesis to detect any potential 
differences in dissolution behaviour between the branded medicines and their generic 
counterparts. A total of 37 medicines (13 innovator medicines and 24 generic 
counterparts) were collected locally and internationally and tested according to the 
British Pharmacopeia, European Pharmacopeia and the US Pharmacopeia with the rate of 
dissolution determined by ultra-violet Spectrophotometer. It was marked in this study that 
some generic medicines showed significant differences in dissolution rate at 60 and 120 
minutes compared to their branded counterparts. Other generics violated the EMA and 
the FDA guidelines for industry when they failed to achieve 85% dissolution at 60 
minutes and to keep the same dosage form as their branded counterparts.  
Moreover, a bioequivalence study was carried out in this thesis using 24 healthy 
volunteers under fasting conditions to compare Resclar 500 mg (Neopharma, UAE) with 
its branded Klacid® 500 mg (Abbott Laboratories Ltd, England), both are macrolide 
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antibiotics contain 500 mg clarithromycin per tablet. It was confirmed in this study that 
Resclar 500 mg met the regulatory definition of bioequivalence with Klacid® 500 
mg as the innovator product based on a single dose comparative bioavailability 
study under fasting conditions in the selected healthy volunteers. Therefore, 
Resclar 500 mg could provide an acceptable prescribable alternative to Klacic® 
500 mg.  
In conclusion, the results presented in this thesis suggested that randomly and 
economically-driven drug substitution can be potentially deleterious to patients and 
should not be promoted. Factors such as physicians and patients education, monitoring, 
severity of the disease and efficacy of generic medicines are essential to promote safe and 
effective drug substitution. Thus, to achieve excellent strategic logistic planning and 
effective management of drug formularies in hospitals, generic and therapeutic 
substitution should be solely based on providing patients with the best possible care and 
quality medicines.  
Publications 
Page 7 of 446 
 
Publications 
Articles: 
1. Al Ameri, M. N., Nayuni, N., Kumar, A., Perrett, D., Tucker, A. and Johnston, A. 
2012. The differences between the branded and generic medicines using solid 
dosage forms: In-vitro dissolution testing. Results in Pharma Sciences, 2, 1-8.  
2. Al Ameri, M., Whittaker, C., Mohamed, W., Makramalla, E., Tucker, A., 
Yaqoob, M. and Johnston, A. Renal patients’ views on generic prescribing and 
substitution: Example from the United Arab Emirates (UAE). The Eastern 
Mediterranean Health Journal, World Health Organisation (WHO). Accepted on 
2nd November 2011, manuscript No: 11/112. 
3. Al Ameri, M. N., Whittaker, C., Tucker, A., Yaqoob, M. and Johnston, A. 2011. 
A survey to determine the views of renal transplant patients on generic 
substitution in the UK. Transplant International, 24, 770-779. 
4. Al Ameri, M., Epstein, M. and Johnston, A. 2011. Generic and therapeutic 
substitution: a response to our critic. International Journal of Clinical Pharmacy, 
33, 881-881. 
5. Alameri, M., Epstein, M. and Johnston, A. 2010. Generic and therapeutic 
substitutions: are they always ethical in their own terms? Pharmacy World & 
Science, 32, 691-5. 
Abstracts: 
1. Al Ameri, M., Whittaker, C., Tucker, A., Yaqoob, M. and Johnston, A. June 
2011. A survey to determine the patients’ views on generic substitution. British 
Journal of Clinical Pharmacology, 71 (6), 981. 
2. Al Ameri, M. N., Whittaker, C., Tucker, A., Yaqoob, M. and Johnston, A. March 
31, 2011. A. Survey of transplant patients' views on generic immunosuppressants 
in the UK. ESPRIT news; [cited April 7th, 2011]; Available from: 
http://tinyurl.com/3oc2bom. 
Publications 
Page 8 of 446 
3. Al Ameri, M., Whittaker, C., Mohamed, W., Makramalla, E., Tucker, A., 
Yaqoob, M. and Johnston, A. March 31, 2011. Survey of transplant patients' 
views on generic immunosuppressants in the UAE. ESPRIT news; [cited April 
7th, 2011]; Available from: http://tinyurl.com/3oc2bom. 
4. Al Ameri, M., Epstein, M. and Johnston, A. 2010. The ethical issues in generic 
and therapeutic substitution. Pharmacy World & Science 32:212–309, 269, DOI: 
10.1007/s11096-010-9378-9. 
Editorial review 
1. Result in Pharma Sciences. Manuscript No. RINPHS-D-12-00011R1 on June 13, 
2012. 
2. Journal of the Royal Society of Medicine (JRSM). Manuscript ID SHORT-11-131 
on December 14, 2011. 
3. British Medical Journal (BMJ). Manuscript No. MEDETHICs/ 2010/042127 on 
January 17, 2011.  
4. British Medical Journal (BMJ). Manuscript No. BMJ/2010/844944 on December 
22, 2010.  
Oral presentations: 
1. Al Ameri, M., December 17, 2011. The differences between the branded and 
generic solid dosage form medicines: In-vitro dissolution testing. Monthly 
Clinical Pharmacology Department Meeting. William Harvey Research Institute, 
London, UK. 
2. Al Ameri, M., December 14, 2011. The differences between the branded and 
generic solid dosage form medicines: In-vitro dissolution testing. Oral 
communication. British Pharmacological Society (BPS) Winter Meeting 2011, 
Westminster Suit, Queen Elizabeth Conference Centre, London, UK. 
Publications 
Page 9 of 446 
3. Al Ameri, M., July 8, 2011. Patients' views on generic substitution in the United 
Arab Emirates (UAE): Focus on renal patients. The 2011 Gulf Research meeting 
in Cambridge, Healthcare Challenges in the Gulf Region, Cambridge, UK. 
4. Al Ameri, M., June 13, 2011. Switching drugs: Patients’ knowledge and the 
medical outcomes, Queen Mary University of London, MSc students in Clinical 
Drug Development, Lecture Venue: 51 - 53 Bartholomew Close, London, UK. 
5. Al Ameri, M., March 17, 2010. Ethical issues in generic and therapeutic 
substitution: The impact on patient outcomes Catalogue page 70. Dubai 
International Pharmaceuticals & Technologies Conference & Exhibition 
(DUPHAT 2010), Dubai, U.A.E. 
6. Al Ameri, M., February 12, 2010. The potential ethical issues in generic and 
therapeutic substitution. Monthly Clinical Pharmacology Department Meeting. 
Endocrine Room, William Harvey Research Institute, London, UK. 
7. Al Ameri, M., December 2nd, 2009. Switching drugs: The impact on patient 
outcomes, Queen Mary University of London, MSc students in Clinical Drug 
Development, Lecture Venue: 51 - 53 Bartholomew Close, London, UK. 
8. Al Ameri, M., May 10, 2009. Because quality matters. Pharmaceutical sector in 
Egypt, Sheraton Hotel, Cairo, Egypt.  
9. Al Ameri, M., March 31, 2009. The pharmacoeconomics of using generics versus 
brands of immunosuppressive agents, Catalogue Page 107. Dubai International 
Pharmaceuticals & Technologies Conference & Exhibition (DUPHAT 2009), 
Dubai, U.A.E. 
Posters in conferences:  
1. Al Ameri, M., Whittaker, C., Mohamed, W., Makramalla, E., Tucker, A., 
Yaqoob, M. and Johnston, A. February 22, 2012. Patients’ views on generic 
substitution in the United Arab Emirates (UAE): Focus on renal patients, Poster 
Publications 
Page 10 of 446 
No. 18 Catalogue Page 18, British Transplantation Society (BTS) Annual 
Congress Meeting 2012, Glasgow, UK. 
2. Al Ameri, M., Nayuni, N., Kumar, A., Perrett, D., Tucker, A. and Johnston, A. 
February 22, 2012. The differences between the branded and generic solid dosage 
form medicines: In-vitro dissolution testing, Poster No. 46 Catalogue Page 46, 
British Transplantation Society (BTS) Annual Congress Meeting 2012, Glasgow, 
UK. 
3. Al Ameri, M., Whittaker, C., Mohamed, W., Makramalla, E., Tucker, A., 
Yaqoob, M. and Johnston, A. December 14, 2011. Renal patients’ views on 
generic substitution: Example from the United Arab Emirates (UAE), Poster No. 
CP055 Page 27. British Pharmacological Society (BPS) Winter Meeting 2011, 
Queen Elizabeth Conference Centre, London, UK. 
4. Al Ameri, M., Whittaker, C., Tucker, A., Yaqoob, M. & Johnston, A. October 19, 
2011. Renal patients’ views on generic substitution in the UK, Poster No. 50 
Catalogue Page 16, William Harvey Day, Queen Mary University of London, 
London, UK. 
5. Al Ameri, M., Whittaker, C., Mohamed, W., Makramalla, E., Tucker, A., 
Yaqoob, M. and Johnston, A. October 19, 2011. Patients’ views on generic 
substitution in the United Arab Emirates (UAE): Focus on renal patients, Poster 
No. 51 Catalogue Page 16, William Harvey Day, Queen Mary University of 
London, London, UK. 
6. Al Ameri, M., Nayuni, N., Kumar, A., Perrett, D., Tucker, A. and Johnston, A. 
October 19, 2011. The differences between the branded and generic solid dosage 
form medicines: In-vitro dissolution testing, Poster No. 52 Catalogue Page 16, 
William Harvey Day, Queen Mary University of London, London, UK. 
7. Al Ameri, M., Whittaker, C., Tucker, A., Yaqoob, M. and Johnston, A. March 9-
11, 2011. A survey to determine the patients’ views on generic substitution in the 
Publications 
Page 11 of 446 
UK: focus on transplant recipients, Poster No. 53. British Transplantation Society 
(BTS) Annual Congress 2011, Bournemouth, UK. 
8. Al Ameri, M., Whittaker, C., Mohamed, W., Makramalla, E., Tucker, A., 
Yaqoob, M. and Johnston, A. March 9-11, 2011. Patients’ views on generic 
substitution in the United Arab Emirates (UAE): focus on renal patients, Poster 
No. 54. British Transplantation Society (BTS) Annual Congress 2011, 
Bournemouth, UK. 
9. Al Ameri, M., Whittaker, C., Mohamed, W., Makramalla, E., Tucker, A., 
Yaqoob, M. and Johnston, A. December 15, 2010. A survey to determine the 
patients’ views on generic substitution, Poster No. CP005 Page 19. British 
Pharmacological Society (BPS) Winter Meeting 2010, Queen Elizabeth 
Conference Centre, London, UK. 
10. Al Ameri, M., Epstein, M. and Johnston, A. November 4, 2009. Ethical issues in 
generic and therapeutic substitution, Poster No. PE-03 Page 269, European 
Society of Clinical Pharmacy (ESCP) Geneva, Switzerland. 
11. Al Ameri, M., Epstein, M. and Johnston, A. October 20, 2009. Ethical issues in 
generic and therapeutic substitution, Poster No. 45 Catalogue Page 16, William 
Harvey Day, Queen Mary University of London, London, UK. 
Membership of Professional Bodies 
1. Member of the Head Committee of the National Formulary, Ministry of Health, 
United Arab Emirates (2006-2008). 
2. European Society of Clinical Pharmacy (ESCP). 
3. Royal Society of Medicine, London. 
4. British Pharmacological Society (BPS). 
5. British Transplantation Society (BTS). 
6. International Society for Pharmaeconomics and Outcomes Research. 
Acknowledgement 
Page 12 of 446 
Acknowledgement 
My first and endless thanks is to almighty Allah for supporting and granting me with all 
the blessing throughout my entire life.  
I would like to thank the government of the United Arab Emirates for giving me the 
opportunity and full support to study PhD in London. Your valuable support is obvious in 
my entire educational life.  
I am deeply thankful to my adored father and dearly loved mother for their support and 
lessons on perseverance, a positive attitude and an indefatigable spirit. I especially would 
like to thank my beloved sincere wife for all her support, motivation and sacrifices she 
has given to me during my entire PhD study. I would like to thank all my kids for their 
presents, patience and support throughout the years of my study and to my brothers and 
sisters in the UAE for their full support and encouragement.  
I wish to gratefully acknowledge and express my gratitude for my supervisor Professor 
Atholl Johnston for his guidance, feedback and encouragement at every stage of my PhD 
study. Professor Johnston believed in the value of these projects and shared his rich 
insights and knowledge to the research questions. I am indeed fortunate to have worked 
with him. I would like to express my heartfelt gratitude to my second supervisor, Dr. 
Arthur Tucker for his full commitment until this thesis is submitted.  
Sincerely, I would like to appreciate and acknowledge the help that I have received from 
my colleagues, especially Dr. Annmarie Hedges who helped me revising this thesis and 
some of my publications. I would like to thank Professor Mesud Akdere from the 
University of Wisconsin–Milwaukee, USA, from whom I got the encouragement to start 
my PhD in London. Brother Mesud, you really helped me to carry on through the 
difficult times in my entire study life.  
Big thank you goes to the UAE Embassy in London and to the management team and all 
my colleagues in Zayed Hospital and all my friends in the UAE. I have indeed great 
pleasure to acknowledge the Pharmacy Department in Zayed Hospital where I worked 
and gained my professional experience as a head of pharmacy since 2002. Special thanks 
go to all volunteers participated in all the studies carried out in this thesis, to all my 
colleagues in the clinical Pharmacology Department in the William Harvey Research 
Institute and to all my friends in London for priceless friendship and support. I will 
always remember you all. 
Table of Contents 
Page 13 of 446 
Table of Contents 
ABSTRACT ....................................................................................................................... 4 
LIST OF ABBREVIATIONS ........................................................................................ 38 
CHAPTER 1 INTRODUCTION ................................................................................... 43 
1.1 GENERIC AND THERAPEUTIC SUBSTITUTION ....................................................... 43 
1.2 PATIENTS’ AND PHYSICIANS’ VIEWS ON GENERIC AND THERAPEUTIC 
SUBSTITUTIONS .............................................................................................................. 46 
1.3 IN-VITRO COMPARISON BETWEEN THE BRANDED AND GENERIC MEDICINES ....... 47 
1.4 IN-VIVO COMPARISON BETWEEN THE BRANDED AND GENERIC MEDICINES ......... 50 
1.5 THE EFFECT OF EXCIPIENTS ON THE BIOEQUIVALENT FORMULATIONS ............... 54 
1.6 ECONOMIC EVALUATION OF MEDICINES ............................................................. 57 
1.7 OBJECTIVES OF THE THESIS ................................................................................ 61 
CHAPTER 2 ETHICAL ISSUES IN GENERIC AND THERAPEUTIC 
SUBSTITUTIONS .......................................................................................................... 63 
2.1 INTRODUCTION .................................................................................................. 63 
2.2 OBJECTIVE ......................................................................................................... 64 
2.3 METHOD ............................................................................................................ 64 
2.4 DEBATABLE PRACTICE ....................................................................................... 65 
2.5 PROMOTING SUBSTITUTION ............................................................................... 65 
2.6 BIOEQUIVALENCE AND NON-INFERIORITY TRIALS .............................................. 67 
2.7 DISCUSSION ....................................................................................................... 67 
2.8 MAIN LIMITATION OF THE STUDY ....................................................................... 71 
CHAPTER 3 A SURVEY TO DETERMINE THE VIEWS OF RENAL 
TRANSPLANT PATIENTS ON GENERIC SUBSTITUTION IN THE UK ........... 72 
3.1 INTRODUCTION .................................................................................................. 72 
3.2 OBJECTIVE ......................................................................................................... 74 
3.3 METHODS .......................................................................................................... 74 
3.4 RESULTS ............................................................................................................ 78 
3.4.1 Patients’ general knowledge of generic medicines and substitution..................................... 82 
3.4.2 Patients’ attitudes towards generic medicines and substitution ........................................... 89 
3.4.3 Professionals’ roles on generic substitution .......................................................................... 94 
Table of Contents 
Page 14 of 446 
3.5 DISCUSSION ..................................................................................................... 104 
3.6 MAIN LIMITATIONS OF THE STUDY ................................................................... 107 
CHAPTER 4 PATIENTS’ AND PHYSICIANS’ VIEWS ON GENERIC 
PRESCRIBING AND SUBSTITUTION: EXAMPLE FROM THE UNITED ARAB 
EMIRATES (UAE) ....................................................................................................... 108 
4.1 A MULTICENTRE STUDY TO DETERMINE RENAL PATIENTS’ VIEWS ON GENERIC 
SUBSTITUTION IN THE UNITED ARAB EMIRATES (UAE) ............................................... 108 
4.1.1 Introduction ......................................................................................................................... 108 
4.1.2 Objective .............................................................................................................................. 110 
4.1.3 Method ................................................................................................................................ 110 
4.1.4 Results ................................................................................................................................. 115 
4.1.5 Discussion ............................................................................................................................ 143 
4.1.6 Main limitations of the study............................................................................................... 145 
4.2 PHYSICIANS’ ATTITUDES TOWARDS GENERIC PRESCRIBING AND SUBSTITUTION: 
EXAMPLE FROM THE UNITED ARAB EMIRATES (UAE) ................................................ 146 
4.2.1 Introduction ......................................................................................................................... 146 
4.2.2 Objective .............................................................................................................................. 148 
4.2.3 Method ................................................................................................................................ 148 
4.2.4 Results ................................................................................................................................. 149 
4.2.5 Discussion ............................................................................................................................ 154 
4.2.6 Main limitations of the study............................................................................................... 157 
CHAPTER 5 THE DIFFERENCES BETWEEN THE BRANDED AND GENERIC 
MEDICINES USING SOLID DOSAGE FORMS—IN-VITRO DISSOLUTION 
TESTING ....................................................................................................................... 158 
5.1 INTRODUCTION ................................................................................................ 158 
5.2 OBJECTIVE ....................................................................................................... 160 
5.3 MATERIAL AND METHODS ............................................................................... 160 
5.4 RESULTS .......................................................................................................... 172 
5.4.1 The dissolution rate of generic medicines compared to their branded counterpart at 60 
minutes  ............................................................................................................................................. 174 
5.4.2 The dissolution rate of generic medicines compared to their branded counterpart at 120 
minutes  ............................................................................................................................................. 181 
Table of Contents 
Page 15 of 446 
5.4.3 Visually detected differences between the branded medicines and their generic 
counterparts ...................................................................................................................................... 188 
5.5 DISCUSSION ..................................................................................................... 196 
5.6 MAIN LIMITATIONS OF THE STUDY ................................................................... 201 
CHAPTER 6 BIOEQUIVALENCE STUDY OF TWO CLARITHROMYCIN 500 
MG FORMULATIONS UNDER FASTING CONDITIONS IN HEALTHY 
SUBJECTS. ................................................................................................................... 202 
6.1 INTRODUCTION ................................................................................................ 202 
6.2 OBJECTIVE ....................................................................................................... 204 
6.3 SUBJECTS AND METHOD .................................................................................. 205 
6.3.1 Study protocol ...................................................................................................................... 205 
6.3.2 Subjects ................................................................................................................................ 205 
6.3.3 Randomisation ..................................................................................................................... 210 
6.3.4 Study treatment ................................................................................................................... 211 
6.3.5 Dietary restrictions .............................................................................................................. 212 
6.3.6 Blood sample collection and analysis ............................................................................... 213 
6.4 RESULTS .......................................................................................................... 214 
6.4.1 Adverse events .................................................................................................................. 225 
6.4.2 The mean blood concentrations of clarithromycin after administering Resclar 500 mg (test, 
Neopharma, UAE) tablets and Klacid
®
 500 mg (reference, Abbott Laboratories ltd, England) tablets in 
all participating subjects. ................................................................................................................... 227 
6.4.3 Concentration and the logarithmic concentration of Resclar 500 mg (test, Neopharma, UAE) 
tablets and Klacid
®
 500 mg (reference, Abbott Laboratories ltd, England) in each participating 
subjects. ............................................................................................................................................. 229 
6.5 DISCUSSION ..................................................................................................... 253 
6.6 MAIN LIMITATIONS OF THE STUDY ............................................................... 258 
CHAPTER 7 GENERAL DISCUSSION AND CONCLUSIONS ............................ 259 
7.1 PATIENTS AND DRUG SUBSTITUTION ................................................................ 261 
7.2 PHYSICIANS AND DRUG SUBSTITUTION............................................................. 263 
7.3 DIFFERENCES IN DISSOLUTION BEHAVIOUR BETWEEN THE BRANDED AND GENERIC 
MEDICINES ................................................................................................................... 267 
7.4 BIOEQUIVALENCE TRIALS ................................................................................ 271 
7.5 REDUCING HEALTHCARE EXPENDITURE BY PROMOTING DRUG SUBSTITUTION . 274 
Table of Contents 
Page 16 of 446 
7.6 CONCLUSIONS .................................................................................................. 276 
CHAPTER 8 PLANNED FUTURE STUDIES .......................................................... 280 
8.1 THE IMPACT OF SWITCHING FROM ATORVASTATIN TO SIMVASTATIN ON PATIENTS’ 
CARDIOVASCULAR OUTCOMES IN THE UK: A STUDY USING THE GENERAL PRACTICE 
RESEARCH DATABASE. ................................................................................................ 280 
8.1.1 Introduction ......................................................................................................................... 280 
8.1.2 Objectives ............................................................................................................................ 282 
8.1.3 Method ................................................................................................................................ 282 
8.1.4 Main limitations of the study............................................................................................... 287 
8.2 THE IMPACT OF SWITCHING FROM VALSARTAN TO LOSARTAN ON PATIENTS’ 
CLINICAL OUTCOMES IN THE UK: A STUDY USING THE GENERAL PRACTICE RESEARCH 
DATABASE ................................................................................................................... 288 
8.2.1 Introduction ......................................................................................................................... 288 
8.2.2 Objectives ............................................................................................................................ 289 
8.2.3 Method ................................................................................................................................ 289 
8.2.4 Main limitations of the study............................................................................................... 291 
8.3 ECONOMIC EVALUATION OF USING BRANDED TAXOTERE® VERSUS GENERIC 
DOCETAXEL: BASED ON DECISION TREE MODEL ........................................................... 292 
8.3.1 Introduction ......................................................................................................................... 292 
8.3.2 Objective .............................................................................................................................. 294 
8.3.3 Method ................................................................................................................................ 294 
8.3.4 Main limitations of the study............................................................................................... 294 
REFERENCES .............................................................................................................. 295 
APPENDICES ............................................................................................................... 316 
 
Appendix 1: The protocol of the survey to determine the renal transplant patients’ 
views on generic substitution in the UK. ........................................................................ 316 
Appendix 2: The William Harvey Research Institute Research Governance 
Compliance Certificate for the survey to determine renal transplant patients’ views on 
generic substitution in the UK. ....................................................................................... 326 
Table of Contents 
Page 17 of 446 
Appendix 3: The ethics’ approval to conduct the survey to determine the renal 
transplant patients’ views on generic substitution in the UK. ........................................ 327 
Appendix 4: The questionnaire (English) used in the survey to determine patients’ 
views on generic substitution in the UK. ........................................................................ 336 
Appendix 5: The protocol of the survey to determine the renal patients’ views on 
generic substitution in the United Arab Emirates for both the UAE General Hospital and 
the UAE University Hospital. ......................................................................................... 341 
Appendix 6: The ethics approval from the UAE General Hospital to conduct a survey 
to determine the renal patients’ and physicians’ views on generic substitution in the 
United Arab Emirates. .................................................................................................... 351 
Appendix 7: The ethics approval granted from the UAE University Hospital to 
conduct a survey to determine the renal patients’ views on generic substitution in the 
United Arab Emirates. .................................................................................................... 352 
Appendix 8: The questionnaire (Arabic and English) used in the survey to determine 
the renal patients’ views on generic substitution in the United Arab Emirates. ............. 355 
Appendix 9: The protocol of the bioequivalence study comparing Resclar 500 mg 
(test product) to Klacid® 500 mg (reference product) in healthy volunteers. ................. 364 
Appendix 10: The Research Ethics Committee (REC) approval for the bioequivalence 
study comparing Resclar 500 mg (test product) to Klacid® 500 mg (reference product). ....  
 ............................................................................................................. 390 
Appendix 11: Raw data for all subjects who participated in the bioequivalence study 
between Resclar 500 mg, test product (Neopharma, UAE) and Klacid® 500 mg, reference 
product (Abbott Laboratories Ltd, England). ................................................................. 391 
Appendix 12: Subjects who withdrew from the bioequivalence study between Resclar 
500 mg, test product (Neopharma, UAE) and Klacid® 500 mg, reference product (Abbott 
Laboratories Ltd, England). ............................................................................................ 396 
Table of Contents 
Page 18 of 446 
Appendix 13: Variation from the study protocol for the bioequivalence study 
between Resclar 500 mg, test product (Neopharma, UAE) and Klacid® 500 mg, reference 
product (Abbott Laboratories Ltd, England). ................................................................. 397 
Appendix 14: The informed consent and other forms used in the bioequivalence study 
between Resclar 500 mg, test product (Neopharma, UAE) and Klacid® 500 mg, reference 
product (Abbott Laboratories Ltd, England). ................................................................. 400 
Appendix 15: The protocol to evaluate the effect of switching from atorvastatin to 
simvastatin on patients’ cardiovascular outcomes using General Practice Research 
Database (GPRD). ......................................................................................................... 416 
Appendix 16: The granted approval from the MHRA (the UK Medicines and 
Healthcare products Regulatory Agency) regarding the use of the General Practice 
Research Database to evaluate the impact of switching statins on patients’ cardiovascular 
outcomes. ............................................................................................................. 429 
Appendix 17: The protocol of switching from valsartan to losartan using the General 
Practice Research Database. ........................................................................................... 431 
Appendix 18:  The response of the MHRA (the UK Medicines and Healthcare 
products Regulatory Agency) regarding the use of the General Practice Research 
Database to compare valsartan to losartan. ..................................................................... 443 
Appendix 19: Publications and certificates awarded during the PhD study at the Queen 
Mary University of London. ........................................................................................... 446 
LIST OF FIGURES 
Figure 1: Schematic diagram of the dissolution process. ............................................. 48 
Figure 2: A demonstration of equivalence and non-inferiority trials. .......................... 51 
Figure 3: Inter-individual differences in drug-metabolising ability in normal healthy 
subjects. ....................................................................................................................... 52 
Table of Contents 
Page 19 of 446 
Figure 4: The same drugs (ciclosporins) with different excipients. ............................. 55 
Figure 5: The same drugs (ciclosporins) with different excipients. ............................. 55 
Figure 6: A plot of blood concentrations in a patient taking phenytoin (400 mg/day), 
with different excipients as shown from left to right (lactose, calcium sulphate, lactose) 
(Tyrer et al., 1970). ........................................................................................................... 56 
Figure 7: The effect of the presence of increasing concentrations of Cremophor RH40 
on Pgp (A) and CYP3A4 (B) inhibition, n=3 at each concentration (Wandel et al., 2003).  
 ....................................................................................................................... 57 
Figure 8: The age distribution of patients (n=30) who participated in the pilot study 
to validate the method of the survey to determine the views of renal transplant patients on 
generic substitution in the UK. ......................................................................................... 78 
Figure 9: The percentage of male and female participating patients (n=163). ............. 80 
Figure 10: The age distribution of the participating patients (n=163). ...................... 80 
Figure 11: The time of organ transplant of the participating patients (n=154). ......... 81 
Figure 12: The number of medications taken by the participating patients (n=154). 81 
Figure 13: The level of education of the participating patients (n=147). ................... 82 
Figure 14: Answers of patients when asked if they were aware that there are different 
forms of the same medicine available, produced by different manufacturers? (n=160). . 84 
Figure 15: The answers of patients when asked if they understand the terms “generic” 
and “branded” in relation to medicines? (n=142). ............................................................ 84 
Figure 16: The answers of patients when asked if they were aware of the generic 
substitution practice (n=146). ........................................................................................... 85 
Figure 17: The answers of patients when asked if they were currently taking any 
generic prescription medications (n=147). ....................................................................... 85 
Table of Contents 
Page 20 of 446 
Figure 18: The answers of patients when they were asked if they thought that generic 
medicines were equivalent and had the same quality as the branded medicines (n=146). 86 
Figure 19: The answers of patients when asked if they were conscious that a generic 
form of ciclosporin is available in the UK (n=150). ......................................................... 86 
Figure 20: The answers of patients when asked if they would agree to switch their 
current branded ciclosporin to a generic form to save the NHS money (n=135). ............ 87 
Figure 21: The answers of educated and less educated patients when asked if they 
were aware of the generic substitution practice (n=136). ................................................. 88 
Figure 22: The answers of educated and less educated patients when asked if they 
would accept the generic substitution of ciclosporin (n=124). ......................................... 89 
Figure 23: The answers of patients when asked about their satisfaction with the 
generic alternative that they were taking (n=55). ............................................................. 91 
Figure 24: The answers of patients when asked about if they had experienced any 
differences in terms of the effectiveness or side effects between the branded and generic 
medicine (n=56). ............................................................................................................... 91 
Figure 25: The answers of patients when asked about the differences between the 
branded and generic medicines that they have experienced (n*=52). ............................... 92 
Figure 26: The answers of patients when asked if they thought adapting to these 
differences was a concern (n=57). .................................................................................... 92 
Figure 27: The answers of patients when asked if they thought that receiving a 
generic medicine might affect how regularly they took their medicines (n=148). ........... 93 
Figure 28: The answers of patients when asked about how much they would favour or 
oppose a requirement that they always be notified if their medicine was changed to a 
generic form (n=144). ....................................................................................................... 93 
Table of Contents 
Page 21 of 446 
Figure 29: The responses of patients when asked about their potential acceptance of 
generic substitution if they were diagnosed with mild versus chronic disease, irrespective 
of their renal transplant. .................................................................................................... 94 
Figure 30: The responses of patients when asked if their doctors ever had changed 
their medicine to a generic form (n=141). ........................................................................ 97 
Figure 31: The responses of patients when asked if anyone had provided them with 
background information about their generic medicine (n=67). ........................................ 98 
Figure 32: The responses of patients when asked about how far they felt that their 
doctor involved them in decisions regarding their medications (n=152). ........................ 98 
Figure 33: The responses of patients when asked if their doctors monitored the effect 
of their medicine after switching them to a generic medicine (n=58). ............................. 99 
Figure 34: The responses of patients when asked about the main professional who 
had provided them with background information about their generic medicine (n=31). . 99 
Figure 35: The responses of patients when asked in what form they got the 
information on their generic medicine (n= 37). .............................................................. 100 
Figure 36: The responses of patients when asked if they considered the information 
provided about their generic medicine was sufficient (n=29). ....................................... 100 
Figure 37: The responses of patients when asked if anyone discussed the reasons for 
switching their medicine to the generic form (n=65)...................................................... 101 
Figure 38: The responses of patients when asked about the main professional who 
discussed the reasons for switching their medicine to the generic form (n=29). ............ 101 
Figure 39: The responses of patients when asked about their opinion of the potential 
reasons for switching their medicine to the generic form (n=96). .................................. 102 
Figure 40: The responses of patients when asked if their doctor had ever told them to 
make sure that they always receive the same brand of any medicine (n=142). .............. 102 
Table of Contents 
Page 22 of 446 
Figure 41: The responses of patients when asked if they would agree to switch their 
medicine to a generic alternative if their doctor felt that the two medications were 
interchangeable (n=72). .................................................................................................. 103 
Figure 42: The responses of patients when asked if they thought that they should be 
consulted about being given generic medicines (n=142). ............................................... 103 
Figure 43: The responses of patients when asked about the most healthcare 
professional that they would agree with to initiate their generic substitution. ............... 104 
Figure 44: The age distribution of the participating patients (n=186). .................... 117 
Figure 45: The percentage of the UAE citizens who participated in the UAE 
University Hospital (n=86). ............................................................................................ 117 
Figure 46: The time of organ transplant of the participating patients (n=186). ....... 118 
Figure 47: The number of medications taken by the participating patients (n=148). ....  
 ................................................................................................................. 118 
Figure 48: The level of education of the participating patients (n=161). ................. 119 
Figure 49: The responses of patients when asked if they were aware of the 
availability of different forms of the same medicine, produced by different manufacturers 
(n=185). ................................................................................................................. 121 
Figure 50: The responses of patients when asked if they understood the terms 
“generic” and “branded” in relation to medicines (n=185). ........................................... 121 
Figure 51: The responses of patients when asked if they were aware of the generic 
substitution practice (n=185). ......................................................................................... 122 
Figure 52: The responses of patients when asked if they were aware that generic 
substitution involves switching between brand and generic medicines (n=182). ........... 122 
Table of Contents 
Page 23 of 446 
Figure 53: The responses of patients when asked if they knew whether they were 
taking any generic prescription medications (n=183). .................................................... 123 
Figure 54: The responses of patients when asked if they thought that generic 
medicines were equivalent and had the same quality as the branded medicines (n=182). ...  
 ................................................................................................................. 123 
Figure 55: The responses of patients when asked if they were aware of the 
availability of the generic form of ciclosporin in most of the hospitals abroad (n=138).124 
Figure 56: The responses of patients when they were asked if they would agree to 
switch their current branded ciclosporin to a generic form to save the local health 
authority money (n=178). ............................................................................................... 124 
Figure 57: The answers of educated and less educated patients when asked if they 
were aware of the generic substitution practice (n=157). ............................................... 126 
Figure 58: The answers of educated and less educated patients when asked if they 
would accept the generic substitution of ciclosporin (n=124). ....................................... 126 
Figure 59: The answers of educated and less educated patients when asked if they 
were satisfied with generic substitution (n= 62). ............................................................ 127 
Figure 60: The responses of patients when asked about their satisfaction with the 
generic alternative that they were taking (n=70). ........................................................... 129 
Figure 61: The responses of patients when asked if they had experienced any 
differences in terms of the effectiveness or side effects between the branded and generic 
medicine (n=72). ............................................................................................................. 130 
Figure 62: The responses of patients when asked about the differences between the 
branded and generic medicines that they had experienced (n=107). .............................. 130 
Figure 63: The responses of patients when asked if they thought adapting to these 
differences was a concern (n=52). .................................................................................. 131 
Table of Contents 
Page 24 of 446 
Figure 64: The responses of patients when asked if they thought that receiving a 
generic medicine might affect how regularly they took their medicines (n=174). ......... 131 
Figure 65: The responses of patients when they were asked if it was a concern for 
them to be prescribed generic medicines (n= 153). ........................................................ 132 
Figure 66: The responses of patients when asked about the potential reasons for 
switching their medicine to the generic form (n=153).................................................... 132 
Figure 67: The responses of renal patients when asked about their potential 
acceptance of generic substitution if they were diagnosed with mild versus chronic 
disease, irrespective of their renal transplant. ................................................................. 133 
Figure 68: The responses of patients when asked if their doctors had ever changed 
their medicine to a generic form (n=179). ...................................................................... 136 
Figure 69: The responses of patients when asked if their doctors monitored the effect 
of their medicine after switching them to a generic medicine (n=106). ......................... 136 
Figure 70: The responses of patients when asked about how far they felt that their 
doctor involved them in decisions regarding their medications (n=175). ...................... 137 
Figure 71: The responses of patients when asked about if anyone provided them with 
background information about their generic medicine (n=105). .................................... 137 
Figure 72: The responses of patients when asked about the main professional who 
had provided them with background information about their generic medicine (n=168). ...  
 ................................................................................................................. 138 
Figure 73: The responses of patients when asked about the main form in which they 
had received their information (n=76). ........................................................................... 138 
Figure 74: The responses of patients when asked if they considered the information 
provided about their generic medicine sufficient (n=63). ............................................... 139 
Table of Contents 
Page 25 of 446 
Figure 75: The responses of patients when asked if anyone discussed the reasons for 
switching their medicine to the generic form (n=100).................................................... 139 
Figure 76: The responses of patients when asked about the main professional who 
had discussed the reasons for switching their medicine to the generic form (n=194). ... 140 
Figure 77: The responses of patients when asked if their doctors had ever told them to 
make sure that they always receive the same brand of any medicine (n=175). .............. 140 
Figure 78: The responses of patients when asked if they would favour or oppose a 
requirement that patients always be notified if their medicine was changed to a generic 
form (n=178). ................................................................................................................. 141 
Figure 79: The responses of patients when asked if they would agree to switch their 
medicine to a generic alternative if their doctor felt that the two medicines were 
interchangeable (n=104). ................................................................................................ 141 
Figure 80: The responses of patients when asked if they thought that they should be 
consulted about being given generic medicines (n=189). ............................................... 142 
Figure 81: The responses of patients when asked about the most healthcare 
professional that they would agree with to initiate their generic substitution. ............... 142 
Figure 82: The volume of branded and generic prescribing in Abu-Dhabi General 
Hospital, United Arab Emirates (UAE). ......................................................................... 150 
Figure 83: A comparison of the level of branded prescribed medicines to the 
generically prescribed medicines in the UAE General Hospital. ................................... 152 
Figure 84: Low-head tablet dissolution test apparatus (model PT-DT70) from Pharma 
Test Company. ................................................................................................................ 161 
Figure 85: The paddle method (apparatus type 2) (Brief, 2010). ............................. 165 
Figure 86: Validation of the dissolution method using repeatability procedure by 
testing the same drug in three replicates on the same day. ............................................. 166 
Table of Contents 
Page 26 of 446 
Figure 87: Validation of the dissolution method using repeatability procedure by 
testing the same drug in three replicates on different days (0, 15 and 30 days). ............ 166 
Figure 88: The UV Spectrum of Ponstan 500 mg at 285 nm after using 0.1 mL of the 
dissolved sample and 2.9 mL of the medium (0.05 M Tris buffer). ............................... 167 
Figure 89: The UV Spectrum of Adalat 10 mg at 340 nm after using 3 mL of the 
dissolved sample. ............................................................................................................ 168 
Figure 90: The UV Spectrum of Amoxil 500 mg at 272 nm after using 1 mL of the 
dissolved sample and 2 mL of the medium (water). ....................................................... 168 
Figure 91: The UV Spectrum of Losec 20 mg at 302 nm after using 3 mL of the 
dissolved sample. ............................................................................................................ 169 
Figure 92: The UV Spectrum of Voltaren 50 mg at 276 nm after using 1 mL of the 
dissolved sample and 2 mL of the medium (0.1 N hydrochloric acid). .......................... 169 
Figure 93: The UV Spectrum of Mobic 7.5 and 15 mg at 362 nm after using 3 mL of 
the dissolved sample. ...................................................................................................... 170 
Figure 94: The UV Spectrum of Ciproxin 250 mg at 276 nm after using 0.6 mL of the 
dissolved sample and 2.94 mL of the medium (0.1 N hydrochloric acid). ..................... 170 
Figure 95: The UV Spectrum of Xeloda 500 mg at 304 nm after using 0.3 mL of the 
dissolved sample and 2.7 mL of the medium (water). .................................................... 171 
Figure 96: The UV Spectrum of Zocor 20 mg at 238 nm after using 1 mL of the 
dissolved sample and 2 mL of the medium (0.01M sodium dihydrogen orthophosphate 
containing 0.5% w/v of sodium dodecyl sulphate, pH 7.0). ........................................... 171 
Figure 97: The UV Spectrum of Claritine 10 mg at 280 nm after using 3 mL of the 
dissolved sample. ............................................................................................................ 172 
Figure 98: The differences in dissolution rate between branded Xeloda® 500 mg and 
its generic counterparts. .................................................................................................. 178 
Table of Contents 
Page 27 of 446 
Figure 99: The differences in dissolution rate between branded Mobic® 15 mg and its 
generic counterparts. ....................................................................................................... 178 
Figure 100: The differences in dissolution rate between branded Mobic® 7.5 mg and 
its generic counterparts. .................................................................................................. 179 
Figure 101: The differences in dissolution rate between branded Losec® 20 mg and 
its generic counterparts. .................................................................................................. 179 
Figure 102: The differences in dissolution rate between branded Adalat® 10 mg and 
its generic counterpart. .................................................................................................... 180 
Figure 103: The differences in dissolution rate between branded Voltaren® 50 mg 
and its generic counterparts. ........................................................................................... 180 
Figure 104: The differences in dissolution rate between branded Augmentin® 1000 mg 
and its generic counterparts. ........................................................................................... 184 
Figure 105: The differences in dissolution rate between branded Ponstan® 500 mg 
and its generic counterparts. ........................................................................................... 184 
Figure 106: The differences in dissolution rate between branded Amoxil® 500 mg 
and its generic counterparts. ........................................................................................... 185 
Figure 107: The differences in dissolution rate between branded Claritine® 10 mg 
and its generic counterparts. ........................................................................................... 186 
Figure 108: The differences in dissolution rate between branded Ciproxin® 250 mg and 
its generic counterparts. .................................................................................................. 186 
Figure 109: The differences in dissolution rate between branded Zocor® 20 mg and 
its generic counterparts. .................................................................................................. 187 
Figure 110: The differences in dissolution rate between branded Augmentin® 375 mg 
and its generic counterpart. ............................................................................................. 187 
Table of Contents 
Page 28 of 446 
Figure 111: The differences in size between the branded Augmentin® 375 mg (B, left), 
14.60 mm (length) X 6.18 mm (width) X 4.80 (depth)and its generic counterpart (G, 
right), 20.12 mm (length) X 8.62 mm (width) X 6.05 mm (depth). ............................... 188 
Figure 112: The differences in size between the branded Xeloda® 500 mg (B, left), 
14.47 mm (length) X 7.00 mm (width) X 4.12 mm (depth) and its generic counterpart (G, 
right), 18.22 mm (length) X 7.87 mm (width) X 4.71 mm (depth). ............................... 189 
Figure 113: The differences in tablet size between the branded Voltaren 50 mg (B, 
left), 6.72 mm (diameter) X 2.04 mm (depth) and its generic counterpart (G, right), 7.59 
mm (diameter) X 1.82 mm (depth). ................................................................................ 189 
Figure 114: The differences in size between the branded Mobic® 7.5 mg (B, left), 7.53 
mm (diameter) X 1.07 mm (depth)and its generic counterpart (G, right), 5.14 mm 
(diameter) X 1.03 mm (depth). ....................................................................................... 189 
Figure 115: The differences in shape and colour between the branded Ponstan® 500 
mg (B, left) and its generic counterpart (G, right). ......................................................... 190 
Figure 116: The differences in shape between the branded Zocor® 20 mg (B, left) 
and its generic counterpart (G, right). ............................................................................. 190 
Figure 117: The differences in colours between the branded Losec® 20 mg (B, left) 
and its generic counterpart (G, right). ............................................................................. 191 
Figure 118: The differences in shape, colour and dosage form between the branded 
Mobic® 15 mg (B, left) and its generic counterpart (G, right). ....................................... 191 
Figure 119: The differences in packaging between the branded Augmentin® 375 mg 
(left and top) and its generic counterparts (right and bottom). ....................................... 191 
Figure 120: The differences in packaging between the branded Losec® 20 mg (left) 
and its generic counterpart (right) and between the branded Ciproxin® 250 mg (top) and 
its generic counterpart (bottom). ..................................................................................... 192 
Table of Contents 
Page 29 of 446 
Figure 121: The differences between the branded Adalat® 10 mg (left) and its 
generic counterpart (right) after 10 minutes dissolution. ................................................ 192 
Figure 122: The differences between the branded Losec® 20 mg (left) and its 
generic A counterpart (right) after 60 minutes dissolution. ............................................ 193 
Figure 123: The differences between the branded Mobic® 15 mg (left) and its 
generic A counterpart (right) after 60 minutes dissolution. ............................................ 193 
Figure 124: The differences between the branded Ciproxin® 250 mg (left) and its 
generic A counterpart (right) after 120 minutes dissolution. .......................................... 193 
Figure 125: The differences between the branded Zocor® 20 mg (left) vs. generic A 
(middle) and generic B (right) after 120 minutes dissolution. ........................................ 194 
Figure 126: The differences between the branded Zocor® 20 mg (left) vs. generic A 
(middle) and generic B (right) after 300 minutes dissolution. ........................................ 194 
Figure 127: The differences between the branded Augmentin® 375 mg (left) and its 
generic A counterpart (right) after 30 minutes dissolution. ............................................ 194 
Figure 128: The differences between the branded Voltaren® 50 mg (left) and its 
generic A counterpart (right) after 120 minutes dissolution. .......................................... 195 
Figure 129: The differences between the generic A of Voltaren® 50 mg (left) and 
generic B of Voltaren 50 mg (right) after 60 minutes dissolution. ................................. 195 
Figure 130: The differences between the branded Xeloda® 500 mg (left) and its 
generic A counterpart (right) after 60 minutes dissolution. ............................................ 195 
Figure 131: The structural formula of clarithromycin(Chemical Book, 2010). ......... 202 
Figure 132: Disposition of subjects. ........................................................................... 209 
Table of Contents 
Page 30 of 446 
Figure 133: The mean plasma concentrations of clarithromycin 500 mg after a single 
dose of a generic formulation Resclar 500 mg (test) and Klacid® 500 mg (reference) in 
fasting healthy volunteers (n=24). .................................................................................. 227 
Figure 134: The log mean plasma concentrations of clarithromycin 500 mg after a 
single dose of Resclar 500 mg (test) and Klacid® 500 mg (reference) in fasting healthy 
volunteers (n=24). ........................................................................................................... 227 
Figure 135: The mean plasma concentrations of clarithromycin 500 mg after a single 
dose administration of Klacid® 500 mg (test) in fasting healthy volunteers. ................. 228 
Figure 136: The mean plasma concentrations of clarithromycin 500 mg after a single 
dose administration of Klacid® 500 mg (test) in fasting healthy volunteers. ................. 228 
Figure 137: Concentration of Resclar compared to Klacid® in subject 1................... 229 
Figure 138: Logarithmic concentration of Resclar compared to Klacid® in subject 1. ....  
 ................................................................................................................. 229 
Figure 139: Concentration of Resclar compared to Klacid® in subject 3................... 230 
Figure 140: Logarithmic concentration of Resclar compared to Klacid® in subject 3. ....  
 ................................................................................................................. 230 
Figure 141: Concentration of Resclar compared to Klacid® in subject 4................... 231 
Figure 142: Logarithmic concentration of Resclar compared to Klacid® in subject 4. ....  
 ................................................................................................................. 231 
Figure 143: Concentration of Resclar compared to Klacid® in subject 5................... 232 
Figure 144: Logarithmic concentration of Resclar compared to Klacid® in subject 5. ....  
 ................................................................................................................. 232 
Figure 145: Concentration of Resclar compared to Klacid® in subject 6................... 233 
Table of Contents 
Page 31 of 446 
Figure 146: Logarithmic concentration of Resclar compared to Klacid® in subject 6. ....  
 ................................................................................................................. 233 
Figure 147: Concentration of Resclar compared to Klacid® in subject 8................... 234 
Figure 148: Logarithmic concentration of Resclar compared to Klacid® in subject 8. ....  
 ................................................................................................................. 234 
Figure 149: Concentration of Resclar compared to Klacid® in subject 9................... 235 
Figure 150: Logarithmic concentration of Resclar compared to Klacid® in subject 9. ....  
 ................................................................................................................. 235 
Figure 151: Concentration of Resclar compared to Klacid® in subject 10................. 236 
Figure 152: Logarithmic concentration of Resclar compared to Klacid® in subject 10. ..  
 ................................................................................................................. 236 
Figure 153: Concentration of Resclar compared to Klacid® in subject 11................. 237 
Figure 154: Logarithmic concentration of Resclar compared to Klacid® in subject 11. ..  
 ................................................................................................................. 237 
Figure 155: Concentration of Resclar compared to Klacid® in subject 12................. 238 
Figure 156: Logarithmic concentration of Resclar compared to Klacid® in subject 12. ..  
 ................................................................................................................. 238 
Figure 157: Concentration of Resclar compared to Klacid® in subject 13................. 239 
Figure 158: Logarithmic concentration of Resclar compared to Klacid® in subject 13. ..  
 ................................................................................................................. 239 
Figure 159: Concentration of Resclar compared to Klacid® in subject 14................. 240 
Figure 160: Logarithmic concentration of Resclar compared to Klacid® in subject 14. ..  
 ................................................................................................................. 240 
Table of Contents 
Page 32 of 446 
Figure 161: Concentration of Resclar compared to Klacid® in subject 15................. 241 
Figure 162: Logarithmic concentration of Resclar compared to Klacid® in subject 15. ..  
 ................................................................................................................. 241 
Figure 163: Concentration of Resclar compared to Klacid® in subject 16................. 242 
Figure 164: Logarithmic concentration of Resclar compared to Klacid® in subject 16. ..  
 ................................................................................................................. 242 
Figure 165: Concentration of Resclar compared to Klacid® in subject 17................. 243 
Figure 166: Logarithmic concentration of Resclar compared to Klacid® in subject 17. ..  
 ................................................................................................................. 243 
Figure 167: Concentration of Resclar compared to Klacid® in subject 18................. 244 
Figure 168: Logarithmic concentration of Resclar compared to Klacid® in subject 18. ..  
 ................................................................................................................. 244 
Figure 169: Concentration of Resclar compared to Klacid® in subject 19................. 245 
Figure 170: Logarithmic concentration of Resclar compared to Klacid® in subject 19. ..  
 ................................................................................................................. 245 
Figure 171: Concentration of Resclar compared to Klacid® in subject 20................. 246 
Figure 172: Logarithmic concentration of Resclar compared to Klacid® in subject 20. ..  
 ................................................................................................................. 246 
Figure 173: Concentration of Resclar compared to Klacid® in subject 21................. 247 
Figure 174: Logarithmic concentration of Resclar compared to Klacid® in subject 21. ..  
 ................................................................................................................. 247 
Figure 175: Concentration of Resclar compared to Klacid® in subject 22................. 248 
Table of Contents 
Page 33 of 446 
Figure 176: Logarithmic concentration of Resclar compared to Klacid® in subject 22. ..  
 ................................................................................................................. 248 
Figure 177: Concentration of Resclar compared to Klacid® in subject 23................. 249 
Figure 178: Logarithmic concentration of Resclar compared to Klacid® in subject 23. ..  
 ................................................................................................................. 249 
Figure 179: Concentration of Resclar compared to Klacid® in subject 24................. 250 
Figure 180: Logarithmic concentration of Resclar compared to Klacid® in subject 24. ..  
 ................................................................................................................. 250 
Figure 181: Concentration of Resclar compared to Klacid® in subject 25................. 251 
Figure 182: Logarithmic concentration of Resclar compared to Klacid® in subject 25. ..  
 ................................................................................................................. 251 
Figure 183: Concentration of Resclar compared to Klacid® in subject 27................. 252 
Figure 184: Logarithmic concentration of Resclar compared to Klacid® in subject 27. ..  
 ................................................................................................................. 252 
LIST OF TABLES 
Table 1: The content of the questionnaire used in the survey to determine the views of 
renal transplant patients in the UK.................................................................................... 75 
Table 2: Demographics of the participating patients (n=163). ................................... 79 
Table 3: Questions and responses evaluating renal patients’ general knowledge of 
generic medicines and substitution. .................................................................................. 83 
Table 4: Questions and responses evaluating renal patients’ attitudes towards generic 
medicine and substitution. ................................................................................................ 90 
Table 5: Questions and responses evaluating healthcare professionals’ roles on renal 
patients’ acceptance of generic substitution. .................................................................... 96 
Table of Contents 
Page 34 of 446 
Table 6: The content of the questionnaire used in the survey to determine the views of 
renal transplant patients in the UAE. .............................................................................. 112 
Table 7: Demographics of the participating patients (n=67). ................................... 116 
Table 8: Questions and responses evaluating renal patients’ general knowledge of 
generic medicines and substitution. ................................................................................ 120 
Table 9: Questions and responses evaluating renal patients’ attitudes towards generic 
medicine and substitution. .............................................................................................. 128 
Table 10: Questions and responses evaluating healthcare professionals’ roles on 
renal patients’ acceptance of generic substitution. ......................................................... 134 
Table 11: A list of medicines included in the study to evaluate physicians’ attitudes 
towards generic prescribing and substitution. ................................................................. 149 
Table 12: The total prescribed medicines in the sampled prescriptions collected from 
the UAE General Hospital. ............................................................................................. 150 
Table 13: A comparison of the level of prescriptions written in the branded form to that 
in the generic form at the UAE General Hospital. .......................................................... 153 
Table 14: Characteristics of the branded medicines (reference products) used in the 
dissolution study. ............................................................................................................ 162 
Table 15: In-vitro dissolution procedures for different medicines.............................. 163 
Table 16: The preparations of different dissolution medium. ..................................... 164 
Table 17: The average percentage of the dissolution rate comparing the branded 
(reference products) medicines to their generic counterparts (test products). ................ 173 
Table 18: The average percentage of the dissolution rate of the generic medicines 
(test products) compared to their branded counterparts (reference products) at 60 minutes. 
 ................................................................................................................. 176 
Table of Contents 
Page 35 of 446 
Table 19: The mean, standard deviation and the coefficient of variation for the 
dissolution percentage of the tested medicines at 60 minutes. ....................................... 177 
Table 20: The average percentage of the dissolution rate of the generic medicines 
(test products) compared to their branded counterparts (reference products) at 120 
minutes. ................................................................................................................. 182 
Table 21: The mean, standard deviation and the coefficient of variation for the tested 
medicines at 120 minutes. ............................................................................................... 183 
Table 22: Demographic data and individual values for the eligible 24 subjects for the 
bioequivalence study between Resclar 500 mg (Neopharma, UAE) and Klacid® 500 mg 
(Abbott Laboratories Ltd, England). ............................................................................... 206 
Table 23: The defined three groups of subjects’ withdrawal. ..................................... 209 
Table 24: Randomisation plan for the bioequivalence study between Resclar 500 mg 
(Neopharma, UAE) and Klacid® 500 mg (Abbott Laboratories Ltd, England). ............. 211 
Table 25: Identity of the study medications included the the bioequivalence study 
between Resclar 500 mg (Neopharma, UAE) and Klacid® 500 mg (Abbott Laboratories 
ltd, England). ................................................................................................................. 212 
Table 26: Study plan and design. ................................................................................ 212 
Table 27: Standardised diets served during the study. ................................................ 213 
Table 28: Individual plasma concentrations of clarithromycin 500 mg versus time after 
single dose administration of Resclar 500 mg (test product). ......................................... 216 
Table 29: Individual plasma concentrations of clarithromycin 500 mg versus time after 
single dose administration of Klacid® 500 mg (reference product). ............................... 219 
Table 30: Individual pharmacokinetics of clarithromycin after single dose 
administration of Resclar 500 mg (test product)............................................................. 222 
Table of Contents 
Page 36 of 446 
Table 31: Individual pharmacokinetics of clarithromycin after single dose 
administration of Klacid® 500 mg (reference product). .................................................. 223 
Table 32: Pharmacokinetic parameters (mean ± SD) of Resclar 500 mg (test, 
Neopharma, UAE) tablets and Klacid® 500 mg (reference, Abbott Laboratories ltd, 
England). ................................................................................................................. 224 
Table 33: Bioequivalence confidence intervals of Resclar 500 mg (test, Neopharma, 
UAE) tablets and Klacid® 500 mg (reference, Abbott Laboratories ltd, England). ........ 224 
Table 34: Adverse events that occurred during the bioequivalence study between 
Resclar 500 mg (A) and Klacid® 500 mg (B). ................................................................ 226 
Table 35: Drug codes for atorvastatin and simvastatin obtained from the GPRD 
database. ..................................................................................................................... 283 
Table 36: Clinical codes for cholesterol. ..................................................................... 285 
Table 37: Codes for major cardiovascular events (angina, myocardial infarction, 
stroke or heart failure) and the key covariates obtained from the GPRD database. ....... 286 
Table 38: Clinical codes of myocardial infarction obtained from the GPRD database. ...  
 ..................................................................................................................... 286 
Table 39: Clinical codes for diabetes obtained from the GPRD database. ................. 287 
Table 40: Drug codes for losartan and valsartan obtained from the GPRD database. 290 
Table 41: Clinical codes for hypertension obtained from the GPRD database. .......... 290 
Table 42: Study schematic. ............................................................................................ 391 
Table 43: Schedule of assessment of each period. ...................................................... 392 
Table 44: The clinical assessment for all subjects for the bioequivalence study 
between Resclar 500 mg, test product (Neopharma, UAE) and Klacid® 500 mg, reference 
product (Abbott Laboratories Ltd, England). ................................................................. 393 
Table of Contents 
Page 37 of 446 
Table 45: Study drug administration times for all subjects for the bioequivalence 
study between Resclar 500 mg, test product (Neopharma, UAE) and Klacid® 500 mg, 
reference product (Abbott Laboratories Ltd, England). .................................................. 394 
Table 46: Adverse events for the bioequivalence study between Resclar 500 mg 
(test, Neopharma, UAE) tablets and Klacid® 500 mg (reference, Abbott Laboratories ltd, 
England). ................................................................................................................. 395 
Abbreviations 
 
Page 38 of 446 
 
List of Abbreviations  
ACE Inhibitors Angiotensin converting enzyme inhibitors 
ABCD  Appropriate blood pressure control in diabetes trial 
ADME  Absorption, distribution, metabolism and elimination 
AE  Adverse events 
ALLHAT  
Antihypertensive and lipid-lowering treatment to prevent heart attack 
trial 
ANOVA  Analysis-of-variance 
ARB  Angiotensin II receptor blocker 
ASCOT-BPLA  
Blood pressure-lowering arm of the anglo-scandinavian cardiac 
outcomes trial 
AUC  Area under the plasma concentration-time curve 
AUC0-t  
Area under the plasma concentration-time curve from zero hours to 
time 
AUC0-∞  
Area under the plasma concentration-time curve from zero hours to 
infinity 
BPAR  Biopsy proven acute rejection 
CI  Confidence interval 
CHI  Commission for health improvement 
Cmax  Maximum drug concentration 
CRF  Case report form 
CsA  Ciclosporin A 
Abbreviations 
 
Page 39 of 446 
CS  Clinical safety study 
CV  Coefficient of variation 
CYP450 Cytochrome P450 
CYP3A4  Cytochrome P3A4 
DOH or DH  Department of health, UK 
ECG  Electrocardiogram 
EMA  European Medicines Agency 
FACET  Fosinopril versus amlodipine cardiovascular events trial 
FDA  Food and drug administration 
g  Gram 
Generic A  The generic counterpart of the branded medicine 
Generic A1:  
The generic medicine with the same manufacturer, different batch 
number from the generic A 
Generic B  The second generic counterpart of the same branded medicine 
GLP  Good Laboratory Practice 
GMP  Good Manufacture Practice 
GPRD  General Practice Research Database 
PK  Pharmacokinetics study outcome 
h  Hour 
HCL  Hydrochloride 
Abbreviations 
 
Page 40 of 446 
HIV  Human immunodeficiency virus 
ICH  International Conference on Harmonisation 
ICH GCP  
International Conference on Harmonisation-Good Clinical Practice 
guidelines 
IPRC  The International Pharmaceutical Research Centre, Amman, Jordan 
ISAC  The Independent Scientific and Advisory Committee 
IVIVC  In-vitro-In-vivo Correlation 
Kg  Kilogram 
LC-MS/MS  Liquid chromatography tandem mass spectroscopy 
L  Liter 
LIFE  
The losartan intervention for endpoint reduction in hypertension 
study 
Log  Logarithm 
M  Molar 
mcg Microgram 
mg  Milligram 
µg  Microgram 
MHRA  The UK Medicines and Healthcare products Regulatory Agency 
mL  Milliliter 
mm  Millimeter 
Abbreviations 
 
Page 41 of 446 
MOH  Ministry Of Health 
MRC  Medical Research Council 
N Normal 
ng  Nanogram 
NHS  National Health Service (England) 
nm  Nanometer 
nM  Nanomolar 
Na  Sodium 
NaOH  Sodium hydroxide 
NSAIDs  Non-steroidal anti-inflammatory drugs 
PACT  Prescribing Analysis and Cost 
P-gp  P-glycoprotein 
pH  Measure of the acidity or basicity of a solution 
QALY  Quality Adjusted Life Years 
REC  Research Ethics Committee 
r.p.m  Round/rotation per minute 
SD  Standard deviation 
STOP-2  Swedish trial in old patients with hypertension-2 trial 
t1/2  Plasma elimination half life 
Abbreviations 
 
Page 42 of 446 
TC  Total cholesterol 
tmax  Time to maximum drug concentration 
TSH  Thyroid stimulating hormone 
UAE  United Arab Emirates 
UK  United Kingdom 
USA, US  United States of America 
UV  Ultraviolet 
UV/Vis  Ultra/visible 
VALUE  Valsartan antihypertensive long-term use evaluation study 
WHO  World Health Organisation 
 
Chapter 1 Introduction 
Page 43 of 446 
1 Chapter 1 Introduction  
1.1 Generic and therapeutic substitution 
Over recent decades the cost of healthcare has been climbing globally. For example, the 
United Kingdom’s (UK) spending on drugs represents over 10% of its NHS (National 
Health Service) total budget and has increased steadily over recent decades (Nabholtz et 
al., 1999). Another example is from the Gulf Region where the healthcare expenditure is 
predicted to rise from £8.7 billion in 2008 to £37.2 billion in the next two decades 
(Alittihad Newspaper, March 5th, 2011). This increase, definitely, would encourage 
many countries to reduce their healthcare expenditure (Nabholtz et al., 1999). A major 
strategy for lowering healthcare costs is by switching to drugs with a lower acquisition 
cost, thus accepting the generic equivalence of the branded drugs (Kazzim et al., 2006).  
This strategy of drug substitution is proven to be effective since it is often easier to 
intervene on the expenditure of medicines because of their identified cost (Andersson et 
al., 2005, Haas, 2005, Tilson et al., 2005). However, it is argued that it may be difficult to 
determine the extent of any long term savings because drug substitution may involve 
spending or costs in addition to the simple product acquisition costs. There are two main 
groups of drugs—brand named (branded) and generics. Brand name drugs are placed on 
the market after granting the marketing authorisation by a competent authority based on 
approved efficacy, safety and quality. As soon as the patent of the branded drug expires, a 
generic drug is allowed to be submitted for registration. A marketing authorisation for a 
solid generic drug form can be granted by a competent authority only on confirmed 
bioequivalence. However, for generic solutions, the bioequivalence studies are waived on 
the assumption that their release of the active ingredient from the drug product is self-
evident and that the solutions do not contain any excipient that significantly affects drug 
absorption (Food and Drug Administration, 2003, European Medicines Agency, 2001). 
A generic drug means a drug that has the same qualitative and quantitative composition 
of the active ingredient and the same pharmaceutical form as the reference branded drug, 
and whose bioavailability with the reference drug has been demonstrated by an 
appropriate bioequivalence study (European Medicines Agency, 2001). Drug substitution 
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in this thesis usually refers to generic and therapeutic substitution. Generic substitution is 
defined as switching between a branded product and a generic version of the same drug 
(such as switching from Taxotere® to docetaxel) (Suh, 1999). Therapeutic substitution 
means switching between drugs either within the same class (such as switching from 
atorvastatin to simvastatin) or from different classes (such as an angiotensin converting 
enzyme [ACE] inhibitor for an angiotensin receptor blocker [ARB]), the clinical effect of 
which is considered to be broadly equivalent (Kereiakes and Willerson, 2003).  
Generic drugs are usually less expensive than their branded counterparts. Generic drugs’ 
prices have historically increased less than those for the branded drugs (Kreling et al., 
2001). Since generic and therapeutic substitution might impact the clinical outcomes, it 
could create a conflict between the interests of patients, clinicians and those of 
payers/providers (AlAmeri et al., 2010, Aldhous and Francisco, 2008). According to the 
literature, patients suspect that substitution that is done only for financial reasons might 
compromise their quality of care. They believe that cheaper medicine must be inferior to 
the more expensive branded medicines (Meredith, 2003). 
Many healthcare providers have been promoting generic and therapeutic substitution in 
an attempt to contain their costs (Dombrowski, 2008, National Health Service, 2009). In 
2003, the Commission for Health Improvement (CHI) in the UK reported that generic 
prescribing should be at an average of 76.38 to 79.07% as increasing the level of generic 
prescribing has been a long term objective of the Department of Health (DOH) 
(Commission for Health Improvement, 2002/3). However, in 2008, it was reported that 
generic prescribing had reached 83% of all prescribed items in community pharmacies in 
England (National Health Service, 2009). Furthermore, recently, the DOH in England 
considered and then abandoned the idea of automatic generic substitution of medicines by 
pharmacists (Department of Health, 2010, Department of Health Press Release, 14 
October 2010). Accordingly, pharmacists and other dispensers who receive a prescription 
containing a branded medicine would be obliged to dispense an equivalent generic 
version of the medicine instead. 
The current bioequivalent guidelines of the European Medicines Agency (EMA) and the 
Food and Drug Administration (FDA) indicate that a generic drug should have 80%-
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125% bioavailability of the original innovator drug (European Medicines Agency, 2001, 
Food and Drug Administration, 2009). However, approving the generic versions of 
critical dose drugs such as ciclosporin has been questioned by many authors (Bartucci, 
1999, Cattaneo et al., 2005, Johnston and Holt, 1999, Kahan, 1999, Kamerow, 2011, 
Sabatini et al., 1999). Critical dose or narrow therapeutic index drugs are defined as drugs 
where small differences in dose or concentration can lead to serious therapeutic failures 
and/or serious adverse effects which could result in inpatient hospitalization or significant 
disability or death (Kahan, 1999).  
According to the FDA, “A drug shall be considered to be bioequivalent to a listed drug if 
the rate and extent of absorption of the drug do not show a significant difference from the 
listed drug” (Food and Drug Administration, 2009). Within the FDA, bioequivalent drugs 
are rated by codes such as “A” or “B” to indicate whether a drug will produce the same 
clinical effects and carries the same risk of adverse events when given to patients. For 
example, if a drug is rated as “A”, it is considered to be therapeutically equivalent and 
interchangeable with its reference product. If a drug is rated as “B”, it is not considered 
therapeutically equivalent or interchangeable because there are some actual or potential 
differences that have been identified. Further efficacy and safety assessment should be 
carried out (Food and Drug Administration, 2009).  
According to the EMA, a medicinal product is considered equivalent to the original 
product if it contains the same amount of the same active ingredient(s) in the same 
dosage forms that meet the same or comparable standards. It also confirmed that 
“equivalence does not necessary imply bioequivalence as differences in the excipients 
and/or manufacturing process can lead to faster or slower dissolution and/or absorption” 
(European Medicines Agency, 2001). As generic drugs contain the same active 
substance, it is not necessary to repeat the preclinical tests and the clinical trials done for 
the original drug. Instead, they are replaced by bioequivalence/non-inferiority trials 
(Lesaffre, 2008).  
In addition to the bioequivalence study, a generic manufacturer has to prove that its 
generic drug has the same dosage form, same route of administration, same amount of 
active ingredient(s) and follow Good Manufacturing Practice (GMP) guidelines. Generic 
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drugs are usually considered bioequivalent to the branded drugs if they have the same 
quality, efficacy and safety. However, colours, flavours and other inactive ingredients 
(excipients) of the generic product may be different from the original version. Even after 
full approval of a generic drug as therapeutically equivalent and bioequivalent, cost-
effectiveness studies are important to define true cost differences using methods for 
economic evaluation of healthcare with respect to generic substitution (Olyaei et al., 
1999).  
1.2 Patients’ and physicians’ views on generic and therapeutic 
substitutions  
Policies concerning generic and therapeutic substitution have been introduced in several 
countries. The extent to which such policies are effective depends on the actions taken by 
both prescribers and patients’ acceptance. For example, a study undertaken in New 
Jersey, USA, investigated how physicians and patients acted during generic substitution. 
It reported that 77% of the prescribing physicians had approved substitution and 97% of 
the patients who had been offered substitution gave their consent. This blend of 
agreement between prescribers and patients on drug substitution had led to increase the 
percentage of generic prescribing (Andersson et al., 2005, Suh, 1999).  
Although there are few studies in the literature evaluating patients views on generic 
substitution, there is some evidence suggesting that a proportion of patients are reluctant 
to switch their current medications (Al Ameri et al., 2011b, Andersson et al., 2005). 
Recently, a number of cases have been reported in which generic drugs have been found 
to be inferior to the original branded drugs or associated with a higher volume of side 
effects (Kovarik et al., 2006, Olling et al., 1999, Phillips et al., 2007, Qazi et al., 2006). 
As consequence, some patients consider the use of generic drugs as being risky especially 
in treating chronic conditions (Haskins et al., 2005, Andersson et al., 2005).  
Many patients are distrustful of generics because they consider these drugs to be less 
effective and to be associated with increased adverse events (AlAmeri et al., 2010). 
Therefore, switching patients to alternative drugs may require additional clinician time in 
providing reassurance to patients. Otherwise, switching may result in compromising 
patients’ adherence and may also result in further switches back to the original branded 
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drugs (AlAmeri et al., 2010). A systematic literature review was conducted, in the UK 
from 1980 to 1995, to determine the prevalence of potentially inappropriate long term 
prescribing in general practice. It revealed that the prevalence of potentially inappropriate 
prescribing varied by indicator and chronic condition but drug dosage outside the 
therapeutic range consistently recorded the highest rates (Buetow et al., 1996).  
Costs can also influence the appropriateness of prescribing as explained in the 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT). This trial concluded that diuretics, at much lower cost, could be more 
effective than angiotensin-converting enzyme (ACE) inhibitors or calcium channel 
blockers in the treatment of hypertension (Wright, 2002). The idea of reducing healthcare 
costs is valid; however, a conflict between healthcare providers and individual patients 
can occur when switching medications is purely based on economic ground (AlAmeri et 
al., 2010, Sacristan et al., 1997).  
In general, several decades ago, many clinicians would have rejected the notion that cost 
of treatments should ever influence their choice of intervention for a patient. However, 
recently, this has conflicted with the limited resources available in many healthcare 
systems, especially public funded system like the UK NHS, free at the point of delivery 
(Walley, 2010). As a result of the global budget constraint and population growth in the 
world, all healthcare authorities and the pharmaceutical industries will have to work in a 
recessionary environment. This challenging situation also creates real opportunities to 
adopt new methods and strategies to contain the cost of spending. 
1.3 In-vitro comparison between the branded and generic 
medicines 
Dissolution is an example of in-vitro test which can be used to identify formulations that 
may present potential bioequivalence problems. It is defined as the amount of substance 
that goes into solution per unit time under standardised conditions of liquid/solid 
interface, solvent composition and temperature (Pharmainfo.net, 2008). Dissolution is 
considered as the rate limiting step for a drug to be absorbed from solid dosage form 
following oral administration. It is the process of transporting the drug substances from 
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the gastrointestinal lumen into the systemic circulation (Brief, 2010). Absorption is the 
first step before the distribution, metabolism and elimination (ADME) of drugs in the 
human body. It usually depends on the stages of disintegration, disaggregation, drug 
release from the pharmaceutical form, its dissolution under physiological conditions and 
permeability through the biological membranes (Figure 1) (Oliveira et al., 2009).  
Tablet/Capsule
Gastrointestinal barrier
Blood
Non disintegration
Disintegration
Dissolution
Granules
Tablet
Capsule
 
Figure 1: Schematic diagram of the dissolution process. 
Dissolution usually involves two consecutive steps: liberation of the solute or drug from 
the formulation matrix (disintegration), followed by dissolution of the drug 
(solubilisation of the drug particles) in the liquid medium (Brown et al., 2004). 
Disintegration usually plays a vital role in the dissolution process since it determines to a 
large extent the area of contact between the solid and liquid (Pharmainfo.net, 2008). 
However, there is no automatic correlation between disintegration and dissolution, 
especially for drugs with poor solubility (Pharmainfo.net, 2008). Therefore the cohesive 
properties of the formulated drug play a major role in the first step of dissolution.  
For the pharmaceutical industry, the in-vitro dissolution test is a very important stage to 
predict a drug’s in-vivo performance. Bioavailability which describes the rate and extent 
of active drug that is absorbed, may be altered by any factor that changes the 
disintegration and dissolution drug process (Oliveira et al., 2009). There are many 
variables that can affect the dissolution rate of a drug. These include the characteristics of 
the active ingredient (particle size, bulk density, crystal form), drug product composition 
(drug loading, the identity, type and level of excipients), the drug product manufacturing 
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process (compression forces, equipment) and the effect of the storage conditions such as 
temperature and humidity on stability (Brown et al., 2004, Guo et al., 2000, 
Pharmainfo.net, 2008). For a new compound, dissolution testing is performed mainly to 
evaluate the stability of formulations, rate of drug release, monitoring product 
consistency and establishing in-vitro-in-vivo correlations (Brown et al., 2004). This type 
of correlation would observe changes in in-vitro dissolution rates to predict in-vivo 
product performance quality. To utilise the dissolution test as a surrogate for 
bioequivalence, in-vitro-in-vivo correlation must be predictive of in-vivo performance of 
the drug (Uppoor, 2001). However, extended release performance obtained in-vitro does 
not necessarily mean that the formulation will perform similarly in-vivo (Zahirul and 
Khan, 1996). 
The importance of dissolution testing, for example, has recently directed the UK MHRA 
(Medicines and Healthcare products Regulatory Agency) to suspend the license of the 
generic Teva (levothyroxine 100 mcg) tablets over dissolution fears. Levothyroxine is 
typically used to treat hypothyroidism. The dissolution testing of Teva product showed 
that it differed from other products in the amount of levothyroxine that is released over 
time. Therefore, some patients have experienced a loss of control of thyroid stimulating 
hormone (TSH) levels. Therefore, the interchangeability between Teva and its branded 
counterpart was questioned by the MHRA and its license was suspended (Walley et al., 
2004).  
Another study was conducted to compare the relative bioavailabilities of two generic 
rifampicin preparations (treatment for tuberculosis) with the original branded 
Rimactane®. It revealed that there were no statistically significant differences in the main 
bioavailability parameters between Rimactane® and the generic preparations studied. 
Both compounds fulfilled the bioequivalence criteria based on the 90% confidence 
intervals. However, the percentage of released rifampicin in the dissolution test was very 
much different between different capsules tested (Pahkla et al., 1999). Another 
dissolution study was carried out with ten brands of ciprofloxacin tablets revealed that 
four of the brands did not attain 70% dissolution throughout the period of the 
determination, while the other brands had above 70% dissolution at less than 45 minutes. 
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It confirmed that one of the brands was obviously a fake product (Adegbolagun et al., 
2007).  
1.4 In-vivo comparison between the branded and generic 
medicines 
Generic and therapeutic drugs are usually approved based on equivalence and non-
inferiority trials. These are in-vivo trials comparing branded medicines to their generic 
counterparts using healthy volunteers. A bioequivalence trial is a clinical trial that aims to 
show that the experimental treatment is not different, within defined limits (80-125%), in 
characteristics from the standard treatment. Unlike non-inferiority, equivalence trials are 
not appropriate for therapeutic drugs (Lesaffre, 2008). The term “non-inferiority trial” is 
used to refer to a randomised trial that compares an experimental treatment with a proven 
effective treatment hypothesising that whereas the experimental treatment may not prove 
to be superior to the control, it may prove to be statistically and clinically not inferior in 
effectiveness (Pocock, 2003). A non-inferiority trial presupposes that if the experimental 
treatment is not inferior to the control, then it must be as good as the latter, (Figure 2) 
(Blakwelder, 2002).  
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An equivalence trial is intended to show the experimental treatment is not different, within defined limits, in 
characteristics than the standard treatment (Dark blue arrows). A non-inferiority trial is intended to prove 
that whereas the experimental treatment may not prove to be superior to the control (Green Arrow); it may 
prove to be statistically and clinically not inferior in effectiveness (Red Arrow). 
Figure 2: A demonstration of equivalence and non-inferiority trials. 
There are three types of bioequivalence trials. These include average, population and 
individual bioequivalence trials. Generally, subjects undergo sequences of observation as 
periods in which a series of blood samples are drawn at various times after administering 
a single dose of a formulation. The commonly computed statistics include the area under 
the time-concentration curve (AUC), the maximum plasma concentration (Cmax) and the 
time to maximum concentration (tmax). When the true mean of the marginal 
bioavailability distribution of the test and reference formulations in the population of 
subjects are sufficiently close, this is called the ‘average’ bioequivalence. According to 
the FDA sufficiently close means that a 90% confidence interval for the ratio of the true 
mean bioavailability (especially AUC) lays entirely between the limits of 0.8 and 1.25. 
This indicates that a generic drug should have 80%-125% bioavailability of the original 
drug.  
‘Population’ bioequivalence is when the formulations whose marginal bioavailability 
distributions are the same, take into account the inter-individual variations. Moreover, 
‘Individual’ bioequivalence of two formulations means that a patient currently on one 
formulation can be switched to another formulation without a material change in 
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response; it takes into account the intra-individual variations (Gould, 2000). In drug-
metabolising ability in normal healthy subjects, there are wide inter-individual 
differences. These can arise from genetically determined differences in the basal level of 
expression of an enzyme and can give rise to about a two to three-fold difference in 
bioavailability, systemic clearance and half-life. As shown in Figure 3, on average, an 
‘equivalent’ medication will yield an 80-125% dose of active compound compared to that 
found in a branded drug. However, in a real life situation, many individuals with inter-
individual variations may end up receiving doses outside this range, which clinically may 
increase or decrease the therapeutic and the side effects.  
10.80 1.25
Less More
 
Many individuals will fall within the acceptable range of equivalent medicines (Dark Characters); others 
will end up receiving doses outside this range, which clinically may increase the side effects (Right Red 
Characters) or decrease the therapeutic effects (Left Red Characters).  
Figure 3: Inter-individual differences in drug-metabolising ability in normal healthy 
subjects. 
For example, a study demonstrated that switching between branded and generic 
ciclosporin has a clinically-relevant impact on co-administered sirolimus 
pharmacokinetics. It found that the Cmax and AUC of sirolimus were significantly lowered 
by 29% and 28% respectively in the presence of Gengraf™ versus Neoral® (Kovarik et al., 
2006). Another study compared the biopsy-proven rate of acute rejection (BPAR) at six 
months after kidney transplantation between the branded immunosuppressant Neoral® 
and the branded-generic (pseudo-generic) Gengraf™. It was found that BPAR was 
significantly higher in patients who received Gengraf™ compared to Neoral®, 39% to 
25% respectively (Taber et al., 2005). Yet, the FDA considers Gengraf™ to be 
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bioequivalent and interchangeable with Neoral® (Food and Drug Administration, 2009, 
Roza et al., 2002).  
Another parameter that may affect bioequivalence is the amount and type of food taken 
with medication. For example, a study which compared the effect of food on the 
bioavailability of different oral ciclosporin A formulations revealed that the mean 
bioavailability of ciclosporin A from Cicloral (ciclosporin-immunosuppressant agent) 
was significantly lower compared to Neoral®. The same study examined the influence of 
a fat-rich meal on the bioavailability of Cicloral and Neoral® found that in contrast of 
Neoral®, the bioavailability of Cicloral increased by more than 20% when administered 
after a fat-rich meal compared with fasting administration. It was concluded that 
bioequivalence could not be proven either between Cicloral and Neoral®, or between fed 
versus fasting administration of Cicloral (Kees et al., 2004).  
A similar study evaluated the effect of the time of meal consumption on the 
bioavailability of a single oral 5 mg tacrolimus dose. It revealed that the time of presence 
of food in the gastrointestinal tract can affect absorption of tacrolimus. For example, in 
the fasting state the absorption of tacrolimus provided the greatest bioavailability, one 
hour after a meal showed a relatively minor impact on the extent of absorption but 
ingesting tacrolimus immediately after a meal had a more pronounced influence. 
Therefore, the authors suggested the ingestion of oral tacrolimus in a consistent manner 
with respect to the time of meal consumption (Likic et al., 2009). Many other studies 
have been conducted to evaluate the safety, efficacy and bioequivalence of generic drugs. 
A large number of studies were conducted to evaluate the potential impact of generic and 
therapeutic substitution on patients’ clinical outcomes. Many have concluded that generic 
substitution might cause unexpected and negative side effects (Berg et al., 2008b, Phillips 
et al., 2007, Richton-Hewett et al., 1988).  
Like generic substitution, therapeutic substitution may also affect clinical outcomes. For 
example, three trials have compared calcium channel blockers and angiotensin-
converting enzyme (ACE) inhibitors: the ABCD, the FACET and the STOP-2 trials 
(Snow et al., 2003). In the ABCD (Appropriate Blood Pressure Control in Diabetes trial), 
patients were randomly assigned to nisoldipine or enalapril. The achieved blood pressure 
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in both groups was the same; however, the rate of myocardial infarction was higher in the 
nisoldipine than the enalapril group. Likewise, in the FACET (Fosinopril versus 
Amlodipine Cardiovascular Events Trial) patients were randomly assigned to fosinopril 
or amlodipine. It was found that diastolic blood pressure was similar, while systolic blood 
pressure control was better in the amlodipine group than in the fosinopril group.  
In the STOP-2 (Swedish Trial in Old patients with Hypertension-2 trial) three drug 
groups were compared: calcium channel blockers, ACE inhibitors and β-blockers plus 
diuretics. It revealed that there was no difference in the treatment groups in the achieved 
blood pressure or in the risk for total cardiovascular events or total mortality. However, 
risk for myocardial infarction was lower in the ACE inhibitor group than in those treated 
with calcium channel blockers (Snow et al., 2003). In another study patients were 
randomly assigned to atenolol (β-blocker) or captopril (ACE inhibitor). Blood pressure 
was similar in both groups but patients who were on the β-blocker gained more weight 
and had to consume more glucose lowering agents (Snow et al., 2003).  
1.5 The effect of excipients on the bioequivalent formulations 
Excipients refer to substances other than the pharmacologically active drug which include 
binders, fillers, lubricants, sweeteners, preservatives, flavours, colouring, printing inks, 
etc (Iheanacho and Blythe, 2009, Wandel et al., 2003). Although excipients are 
considered the inactive ingredients that do not have a therapeutic effect, some studies 
have revealed that excipients can cause various side effects (Wandel et al., 2003). For 
example, Figure 4 and Figure 5 show visual differences when using different excipients 
in the same drug. 
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Drugs from left to right are Neoral®, Sandimmun®, Gengraf™, Eon formulation®, Cicloral® and Equoral®. 
Figure 4: The same drugs (ciclosporins) with different excipientsi. 
 
Drugs from left to right are ciclosporin powder, Sandimmun®, Neoral® and Cicloral®. 
Figure 5: The same drugs (ciclosporins) with different excipientsii. 
Another example is cited from 1968 when an outbreak of phenytoin (antiepileptic agent) 
toxicity occurred in Australia because of a switch from calcium sulphate to lactose as an 
apparently inert tablet excipient. This change made the phenytoin more soluble and 
                                                 
i
 Adapted from Professor Atholl Johnston 
iiAdapted from Professor Atholl Johnston.  
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increased its systemic availability with an increased incidence of toxicity (Figure 6) 
(Tyrer et al., 1970). 
 
Figure 6: A plot of blood concentrations in a patient taking phenytoin (400 mg/day), 
with different excipients as shown from left to right (lactose, calcium 
sulphate, lactose) (Tyrer et al., 1970). 
In a similar case, a manufacturer reduced the particle size from 20 µm to 3 µm of the 
powder used to formulate tablets of digoxin (narrow therapeutic index cardiac 
glycosides) and caused a twofold increase in the absorption of the drug. As a result many 
patients experienced the symptoms of toxicity and had to have their digoxin dose reduced 
(Johnston et al., 1997, The Times, August 2nd,1972). Therefore, the importance of 
considering the bioavailability of a pharmaceutical formulation especially for critical 
dose and narrow therapeutic index drugs was highlighted by many authors (Holt, 1978, 
Johnston et al., 2004).  
Similar studies have shown that different formulations with different exipients of the 
same drug might have different pharmacokinetic profiles. For example, a study 
comparing the physiochemical properties of generic tacrolimus formulations with its 
branded counterpart drug Prograf® revealed that the dissolution, solubility and content 
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uniformity profiles of generic formulations were different from that of Prograf® (Petan et 
al., 2008). These differences would negatively affect the drug bioavailability and 
effectiveness at the site of action which can, as a result, increase the drug side effects and 
decrease its effectiveness. Another study showed that different formulations of digoxin 
yielded tremendous differences in the dissolution profiles. The study indicated that either 
batch-to-batch or amongst brand bio-in-equivalence originated from differences in 
dissolution rates (Dokoumetzidis and Macheras, 2006).  
Furthermore, excipients can cause drug interactions to occur by altering the absorption of 
the co-administered drug. For example, a study found that Cremophor RH40 which is a 
common excipient might alter drug bioavailability through the inhibition of P-
glycoprotein and CYP3A4. As a result, this will increase the intestinal absorption and the 
side effects of drugs like digoxin and nifedipine (calcium channel blocker), because of 
the inhibition of the transport of the former and the oxidation of the latter (Figure 7) 
(Wandel et al., 2003). 
  
Figure 7: The effect of the presence of increasing concentrations of Cremophor 
RH40 on Pgp (A) and CYP3A4 (B) inhibition, n=3 at each concentration 
(Wandel et al., 2003). 
1.6 Economic evaluation of medicines 
As a result of the recent worldwide constraints in resources, all healthcare authorities and 
pharmaceutical industries will have to get used to work in a recessionary environment. 
This challenging situation also creates real opportunities to adopt new methods and 
strategies to contain the cost of spending. Currently, for instance, the annual growth of 
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global drug sales has slowed due to various reasons. These might include the fact that 
some pharmaceutical companies focussed their line of production on blockbuster drugs to 
generate quick high profits. For example, in 2007, Pfizer reported a global 
pharmaceutical sale of £27 billion, 58% of which was from eight blockbuster products 
(Malik, 2008). However, the patent of a large number of blockbuster drugs will expire in 
the coming years thereby reducing their prices as well as increasing the competition from 
generic drugs.  
Since governments are strongly encouraging generic prescribing, this will intensify the 
competition among generics. Therefore, assessing the cost and effects of a 
pharmaceutical product becomes very important to comply with constraint in resources 
(Walley et al., 2004). The life cycle of a drug always includes its journey from formation, 
design and manufacture, to its introduction into the market and post marketing 
evaluation. The discovery of new drugs and their development as commercial products 
consists of steps stipulated by a time-scale. Any drug discovery process would have a 
patent valid for about 20 years. The earlier a company finishes the development process 
and brings a drug to market the sooner it starts making a profit by having extended sales 
time in the market-place (Burley et al., 1993).  
Drug development usually focuses on molecular restructuring which presents a 
significant amount of success in business and in improving drugs for better compliance. 
For example, nifedipine (calcium channel blocker) has a shorter duration of action and a 
half-life of 2 hours (Martindale, 2011d). A structural modification of this drug molecule 
led to the discovery of amlodipine with a longer half-life (35-50 hours) (Martindale, 
2011a). Similarly, captopril a short acting ACE inhibitor, with a half-life of 2-3 hours 
(Martindale, 2011b) was modified to lisinopril, with a longer half-life of 12 hours. This 
molecular restructuring would ensure safety and compliance of drugs (Martindale, 
2011c).  
Medicines that enter the market place are generally divided into first-in-class and follow-
on-drugs. First-in-class drugs typically represent the introduction of a class of new drug 
such as an active ingredient that acts through a novel mechanism of action with improved 
efficacy and safety. Follow-on is a drug with the same mechanism of action as an existing 
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drug and provides minor and may be important therapeutic advances in such as better 
duration of action or ease of administration (Sams-Dodd, 2007). Nevertheless, the 
availability of many drugs in the class means lower prices. It is often assumed that 
generic competition following patent expiration has the largest effects on revenue. Yet, 
some studies indicated that between patent-competition (between drugs in the same class 
with comparable therapeutic profile) is more important (Sams-Dodd, 2007). However, 
since 1985, the number of first in class drugs has been decreasing (Sams-Dodd, 2007). 
This decrease resulted from the fact that companies have concentrated on the production 
of “me-too” drugs which are easier and cheaper to discover than first in class medicines.  
The first in class drugs usually carry the research and development costs as well as the 
indirect costs of positioning their drug relative to the leader. In addition to the indirect 
costs of a short market-exclusivity period caused by the rapid appearance of followers, it 
was reported that pharmaceutical companies find more revenue from producing generic 
drugs after patent expiration than producing new in class drugs. The production of follow 
on drugs offers a fairly low risk route to market a drug which ensures the revenue from 
the larger markets (Sams-Dodd, 2007).  
Nevertheless, there has been recent increase in the prices of generic medicines for many 
reasons. These include that some brand-name drug companies attempted to produce the 
generic drugs in order to increase the price of generics and promote the sale of the 
branded-drugs. For example, the price for the generic of tamoxifen is only one cent less 
than the branded one, because the manufacturer bought the exclusive rights of the 
generic. Therefore, the same company owns the rights to both branded and generic 
tamoxifen (Lopez, 2001). In this way, consumers are urged to buy the branded rather than 
the generic drugs because of the very little difference in prices.  
It has been reported that 70-80% of brand name manufacturers make generic medications 
inside their institutions which are called pseudo-generics (Beecham, 2000). Branded-
generic or pseudo-generics are generally manufactured by the innovator drug company to 
be the generic version of its own branded drug and priced to compete with other generics. 
The success of the pseudo-generic strategy in capturing market share is impressive 
(Beecham, 2000). Another reason is that some manufacturers and wholesalers contribute 
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to the artificial shortage of generics so that at a later stage they can sell them at higher 
prices. As regulators have started stipulating stringent drug approval requirements; 
companies are not sure of getting approval for their research products in due course of 
time or face recall of treatment during the mandatory post marketing surveillance. Such 
as the recent recall of the branded rofecoxib (Vioxx®) (COX-2 inhibitor used for 
osteoarthritis) because of its action to aggravate ischemic cardiovascular disease (Weir et 
al., 2003). Similarly, the GlaxoSmithKline’s diabetes drug Avandia® (rosiglitazone) 
which was found to have a potential safety issue affecting patients who are known to 
have underlying heart disease (Food and Drug Administration, 2007).  
Chapter 1 Introduction 
Page 61 of 446 
1.7 Objectives of the thesis  
Promoting generic substitution is usually based on an assumption that there are no 
differences between the branded medicines and their generic counterparts. As a result, 
they are considered therapeutically equivalent. Similarly, promoting therapeutic 
substitution is usually based on an assumption that drugs within the same class or from 
different classes are broadly equivalent. As a result, promoting cheaper medicines in all 
cases will always reduce healthcare related costs. However, these assumptions are not 
based on scientific evidence. In fact, it was clearly marked in this thesis that randomly 
promoting drug substitution is a controversial issue and can negatively impact patients’ 
clinical outcome.  
A series of studies were conducted in this thesis to explore safe and effective drug 
substitution by validating the appropriateness and the potential impact of these 
substitutions on patients’ clinical outcomes and thus, to promote high quality strategic 
logistic planning and effective management of drug formularies in hospitals.  
The aims of this thesis were to:  
1) Explore the ethical issues that may arise in the context of generic and therapeutic 
substitution and the clinical trials that are done to support these substitutions. This 
will be assessed by conducting a literature review study to validate the practice of 
drug substitution from the ethic’s point of view. Based on the outcome of this study, 
other studies can contribute and evaluate patients’ and healthcare professionals’ views 
on drug substitution.   
2) Examine the current patients’ awareness and understanding of generic substitution 
and the influence of healthcare professionals on patients’ acceptance of drug 
substitution. This will be explored by conducting a multicentre surveys to evaluate 
patients’ knowledge, views and understanding of drug substitution. It will also 
explore factors that might affect patients’ views such as the severity of the disease 
and involvement in decision regarding their health.  
3) Assess physicians’ views on generic prescribing and substitution by evaluating their 
prescribing habits. This will be evaluated by conducting a prescription based survey. 
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The outcome of this study will confirm previous findings and will highlight the 
appropriateness in prescribing. These studies may lead to conduct lab or volunteers 
based studies to confirm the obtained results. 
4) Detect the potential lab based differences between the branded medicines and their 
generic counterparts in in-vitro dissolution test. This study will confirm if whether 
there are actual differences in formulations between the branded medicines and their 
generic counterparts. As a consequence, this will verify patients’ and physicians’ 
views on generic substitution. 
5) Detect the potential differences between the branded and generic medicines in an in-
vivo bioequivalence study. This study will give an example of the clinical trial 
required to approve generic drugs. The outcome of this study may investigate the 
strength and weakness of bioequivalent regulations which as a result can contribute 
the findings towards the establishment of high quality strategic logistic planning and 
effective management of drug formularies in hospitals. 
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2 Chapter 2 Ethical issues in generic and therapeutic 
substitutions 
This chapter was published in the Pharmacy World & Science, 2010 (AlAmeri et al., 
2010). A commentary response (Simoens, 2011) and a letter to the editor (Al Ameri et 
al., 2011a) were also published in the International Journal of Clinical Pharmacy, 2011 
(Appendix 19).  
2.1 Introduction 
Cost containment-driven drug substitution is defined as switching to another drug 
because it is cheaper. It has two forms: generic and therapeutic. As defined earlier, 
generic substitution usually refers to switching between a branded medicine and its 
generic counterpart (Suh, 1999). Therapeutic substitution means switching between drugs 
either within the same class or from different classes, the clinical effect of which is 
considered to be broadly equivalent (Kereiakes and Willerson, 2003). Both of these forms 
of substitution may raise some relevant ethical issues. This indicates that they cause 
certain social conflicts that call for a judgment concerning either some compromise 
among the stakeholders or a decision to give one particular stakeholder exclusive 
dominance over the others. Such conflicts are typically resolved in a way that reflects the 
relative power of each stakeholder.  
In this social battle, the ethical discourse plays an important role. It offers the parties a set 
of philosophical justifications from which each could choose the ones that serve its own 
interests best and perhaps help it convince the others that they serve their interests too. 
This point explains the plurality of ethical views regardless of the subject in question. 
Ethics is defined as “the philosophical study of the moral value of human conduct and the 
rules of principles that ought to govern it” (Orme-Smith and Spicer, 2001). In the case of 
cost containment-driven substitution, for example, it explains why some people employ 
the ethics’ principle of justice (having equal access to healthcare resources) to argue that 
in a healthcare system that struggles to meet its ends, cost-effectiveness ought to be the 
imperative, while others use the principles of beneficence (includes all forms of action 
intended to benefit other people), non-maleficence (obligation not to inflict harm on 
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others) and autonomy (the capacity of people to make their own decisions) to argue that 
in an affluent society medical decisions ought to consider the patient’s interests and 
choices only (Orme-Smith and Spicer, 2001).  
One fact remains undisputed, though, such substitutions have drawn their ethical 
legitimacy from the general belief that they would not compromise the clinical interests 
of patients and certainly not violate their right to decline them if they did (Department of 
Health, 2010, Department of Health, 2009, National Health Service, 2009). This study 
does not wish to enter the debate on whether or not substitutions must give exclusive 
priority to individual patients’ clinical interests in order to be ethical. Indeed, it 
acknowledges the plurality of views on this matter (Andersson et al., 2005, Haskins et al., 
2005, Kereiakes and Willerson, 2003, Suh, 1999). It simply argues that substitutions that 
involve a cheaper drug that is known to have different effects and side effects, or even a 
drug whose effects and side effects are unknown, are potentially deleterious to the 
patient, and that no competent and well-informed patient would ever give consent to 
them. Such substitutions are thus unethical in their very own terms.  
2.2 Objective 
The objective of this study was to explore some ethical issues that may arise in the 
context of generic and therapeutic substitution.  
2.3 Method 
A literature review from 1990 onwards was determined to be the most relevant 
considering the fact that the issue of generic and therapeutic substitution is relatively 
new. The literature search was carried out through Athens, Embase, Pubmed, Google and 
Google Scholar to identify relevant publications using the most commonly used terms 
such as generic substitution, therapeutic substitution, ethical issues in drug substitution 
and equivalence/non-inferiority trials. A total of 84 articles generally discussing the issue 
of drug substitution were selected. Out of these, 37 articles discussing the ethical issues 
surrounding drug substitution were carefully selected and reviewed to set the unbiased 
argument presented in this chapter.  
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This chapter is not an exclusive ethics review, but captures some of the key ethical and 
clinical issues that may arise in the perspective of drug substitution. A literature review is 
a systematic survey and interpretation of the research findings of a particular topic or 
field of a study. It is usually conducted to demonstrate an in-depth understanding of 
relevant information and to outline existing knowledge. This enables the identification of 
any gap in the research to position my work in the context of previous research. It helps 
to produce justification for studies included in this thesis and to summarise the current 
knowledge.  
2.4 Debatable practice 
Generic and therapeutic substitutions are debatable practices for patients and the 
stakeholders alike. Since such substitutions can affect the clinical outcomes, it can create 
a conflict between the interests of patients and those of the stakeholders. Patients might 
suspect that substitution that is done only for financial reasons might compromise their 
quality of care. Although there are few studies in the literature evaluating patients’ levels 
of satisfaction with drug substitution, there is some evidence suggesting that a proportion 
of patients are reluctant to switch (Haskins et al., 2005, Andersson et al., 2005).  
For example, a study was conducted in Sweden to investigate the obstacles to generic 
substitution at prescriber, patient and pharmacy level in the first year after the 
introduction of generic substitution. The study showed that 1 to 8% of the prescribers 
opposed substitution. Patients (outside the NHS) declined substitution when the average 
saving per substitution was low (Andersson et al., 2005). Another study in the UK 
reported that over 20% of patients would be enormously concerned if their prescription 
was changed, even with their doctor’s consent. Of these, 40% reported that the new drug 
was less effective than the original drug and 30% experienced more or different side-
effects (Johnston, 2010). These results may be confirmed by conducting surveys to 
evaluate patients’ and physicians’ views towards generic and therapeutic substitution.  
2.5 Promoting Substitution 
Many healthcare providers including the British NHS have been promoting drug 
substitution in an attempt to contain their costs, although it may be difficult to determine 
the extent of any long term savings. (Drug substitution may involve spending or costs in 
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additional to the simple product acquisition costs) (Dombrowski, 2008, Johnston et al., 
2010, National Health Service, 2009). The drug substitution practice is economically 
favoured on the premise that any saving that does not compromise the quality of care is 
essentially ethical. It has been also considered ethical on the basis of the presumption that 
the cheaper drug is equivalent or at least not inferior to the more expensive one. Indeed 
under such circumstances substitution should raise no ethical problem whatsoever. In 
contrast, ethical issues do arise when the specific effects and side effects of the cheaper 
drug are unknown, let alone when they are known to be different from those of the 
branded drug.  
Healthcare providers believe that financially-driven drug substitution could be ethical and 
appropriate even in the face of therapeutic inferiority/uncertainty as long as it generates 
free resources to be invested in health technologies, even when it leads to a decrease in 
the individual patient’s clinical outcomes (Simoens, 2011). However, currently, a number 
of authors are questioning the cost-effectiveness of promoting drug substitutions 
(Johnston et al., 2010, Lister, 2010, Phillips et al., 2007). They doubt that implementing 
substitutions in favour of drugs with lower acquisition cost will result in savings since the 
total treatment costs are affected by a number of factors and aspects that usually far 
exceed the drug costs. These include, for example, the impact on patient satisfaction of 
switching, adherence and persistence; the cost involved in implementing the switch and 
managing the consequences of switching and the safety and efficacy of the substituted 
drugs relative to the original choice. Indirect costs are also involved such as loosing 
productivity and informal care. Even the DOH in England acknowledge in their 
consultation document on automatic generic substitution of medicines in primary care 
that the “costs of implementation could be disproportionate to the savings” (Department 
of Health, 2010). 
Two cross-sectional telephone-based surveys for patients and physicians were undertaken 
in the UK, Canada, France, Germany and Spain to assess generic antiepileptic drug 
substitution in these five countries. It revealed that patients and physicians have elevated 
concerns about the safety and efficacy of generic antiepileptic drugs as compared with 
drugs for acute care. A total of 70% of physicians believed that epilepsy is an example of 
a medical condition for which universal substitution of branded medications with 
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generics, without direct approval from a physician, is medically unacceptable. Thus, any 
cost savings waged through such substitution may be offset by the perceived long-term 
costs associated with decreased seizure control and adverse events (Haskins et al., 2005). 
In other words “when costing less means costing more” (Gafni and Birch, 2007)  
2.6 Bioequivalence and non-inferiority trials 
As mentioned in the introduction of this thesis, generic and therapeutic drugs are usually 
approved based on bioequivalence and/or non-inferiority trials. A bioequivalence trial is a 
clinical trial that aims at showing that the two treatments are similar in characteristics, 
within defined limits (set by regulations) (European Medicines Agency, 2001, Lesaffre, 
2008). This indicates that bioequivalent should not be seen as semantically equal to 
identical. In non-inferiority trials, the aim is to show that the tested treatment is not worse 
than the standard treatment (Lesaffre, 2008). It is basically showing a treatment is good 
because it is not bad (Blakwelder, 2002).  
The appropriateness of using equivalence and non-inferiority trials to promote drug 
substitutions is controversial (Garattini and Bertele, 2007). On one hand, some 
investigators consider these trials ethical because they can offer useful alternative 
treatments with different profiles of tolerability and increase drug competition which as a 
consequence reduces healthcare costs. On the other hand, other investigators consider 
equivalence and non-inferiority trials unethical because they do not offer any possible 
advantages to patients and they disregard clinical interests in favour of financial or 
commercial ones (Meredith, 2003, Pocock, 2003). They also argue that exposing patients 
to clinical experiments which are primarily driven by economic not clinical motivations 
is essentially unethical (Garattini and Bertele, 2007). 
2.7 Discussion 
Generic and therapeutic substitution raises concerns about whether it serves the interests 
of patients or the target of reducing healthcare related costs. Although the total drug costs 
to the NHS, in 2007, was only 10.3% of the total budget, drug substitution is highly 
favoured within the NHS to reduce healthcare expenditure (Davydova et al., 2010). 
However, many patients and clinicians believe that generic and therapeutic substitution 
can be problematic (Meredith, 2003). Indeed authors are now questioning the quality of 
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generic drugs and the trials supporting their use (Himmel et al., 2005, Garattini and 
Bertele, 2007, Pocock, 2003). 
The NHS Constitution states on the one hand that it is committed to “offer you easily 
accessible, reliable and relevant information to enable you to participate fully in your 
own healthcare decisions and to support you in making choices”. It adds that “you have 
the right to be involved in discussions and decisions about your healthcare and to be 
given information to enable you to do this” (Department of Health, 2009). And yet on the 
other hand, the NHS and other healthcare providers tend to promote substitution without 
a scientific evidence base supporting therapeutic equivalence and also without informing 
patients or getting their consent (Andersson et al., 2005, Department of Health, 2010, 
Phillips et al., 2007).  
For example, the NHS is promoting the widespread therapeutic substitution of statins 
(cholesterol lowering agents) to generic alternatives although only little is currently 
known about the clinical outcomes of the latter (Phillips et al., 2007). Atorvastatin and 
simvastatin are considered to be therapeutically equivalent in terms of their cholesterol–
lowering capacity (Bandolier, 2007). However, switching from atorvastatin to simvastatin 
in primary care is now known to be associated with a significant increase in morbidity 
(major cardiovascular events), mortality and in treatment discontinuation compared with 
patients who did not switch (Phillips et al., 2007).  
Similar study evaluated the differences between statins in therapeutic substitution. It 
confirmed that there are differences within this class of drugs. Those include the 
cholesterol-lowering efficacy, drug-food interactions, pharmacokinetic properties and 
cost. Therefore, careful monitoring is required when applying therapeutic substitution of 
statin in patients already on stable therapy (Chong et al., 2001). In another study, 
switching from simvastatin to high dose atorvastatin showed no significant differences in 
major clinical events or mortality. However, higher adverse events with atorvastatin led 
to more discontinuation among patients (Pedersen et al., 2005).  
The general acceptance of generic substitution because of evidence that it reduces cost of 
prescription items to healthcare providers has led to the concept of therapeutic 
substitution. However, from a sustainable ethical point of view, therapeutic substitution 
should be regarded as “guilty until proven innocent” (Kereiakes and Willerson, 2003). 
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Some members of a therapeutic class may differ widely in pharmacokinetic and 
pharmacodynamic response, drug-drug interactions, and side effect profile. For example, 
it was stated that the American Academy of Paediatrics Committee strongly opposes 
therapeutic substitution. This was related to that therapeutic toxicity or failure can result 
from substitution of a drug that is chemically different from that prescribed by the 
physician (Committee on Drugs, 1987).  
The potential impact of therapeutic substitution was demonstrated in the Valsartan 
Antihypertensive Long-term Use Evaluation (VALUE) study. It was revealed in this 
study that a significantly lower incidence of heart failure in the valsartan-treated group 
than in amlodipine-treated group, despite similar blood pressure reductions (Julius et al., 
2003). Likewise, in the Blood Pressure-Lowering Arm of the Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT-BPLA), fewer occurrences of cardiovascular outcomes 
was detected when using combination of amlodipine and perindopril compared to the 
combination of beta blocker, atenolol and a diuretic (Fuchs et al., 2006). The Losartan 
Intervention For Endpoint reduction in hypertension (LIFE) study revealed that using 
losartan in patients with essential hypertension and left ventricular hypertrophy prevented 
significantly more cardiovascular morbidity and mortality than atenolol, despite similar 
control and lowering of blood pressure (Dahlof et al., 2002). These studies clearly 
confirm that different classes of drugs should not be considered therapeutically 
equivalent in terms of clinical outcomes. 
Like therapeutic substitution, generic substitution may also affect clinical outcomes. A 
large number of studies were conducted to evaluate the potential effect of generic 
substitution on the clinical outcome. Many have concluded that generic substitution 
caused unexpected and negative effects (Berg et al., 2008b, Olling et al., 1999, Pahkla et 
al., 1999, Richton-Hewett et al., 1988). For example, the increased generic market share 
in Sweden between 1972 and 1996 was found to be associated with the increase in the 
number of reported side effects for 7 of the 15 medicines studied (Hellstrom and 
Rudholm, 2004).  
Other studies showed differences in the pharmacokinetic profile between branded and 
generic drugs, disparities that might affect clinical outcomes,(Kovarik et al., 2006, Olling 
et al., 1999, Qazi et al., 2006, Roza et al., 2002). Differences in formulation have been 
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also noted in generic versions of some drugs (Joshi et al., 2008, Johnston et al., 2010). 
For example, a bioequivalence study comparing a generic ciclosporin with its branded 
counterpart drug Neoral® found that the extent and rate of absorption of the former were 
significantly lower than those of Neoral® (Hibberd et al., 2006). Since generic and 
therapeutic substitution can be faced with uncertain risks, a precautionary principle 
should be adapted (Andorno, 2004). 
Since generic and therapeutic substitution can affect patients’ clinical outcomes, 
healthcare providers must understand that the additional monitoring may offset the 
potential cost savings of the generic drugs. Some patients consider the use of generic 
drugs as being risky especially in treating chronic conditions. They are distrustful of 
generics because they consider these drugs as being less effective and associated with 
increased adverse events (Andersson et al., 2005, Haskins et al., 2005).  
In general switching patients to alternative drugs would require additional clinician time 
in providing reassurance to patients. This may result in compromising patients’ adherence 
and may also result in further switches back to the original branded drugs. Therefore, 
healthcare providers should not support random substitution with the aim of reducing 
costs; especially when there is no scientific data to conclude that all drugs are generically 
and therapeutically substitutable. Yet, we all agree that healthcare providers/payers 
cannot pay for everybody everything regarding their health all the time. Nevertheless, the 
decisions on allocating resources must be made based on the ethics’ principles. 
Some health economists may argue that ethics merely focuses on the individual patient's 
perspective to the detriment of the societal perspective. Their argument is based on that 
health economics perceives to be the 'societal perspective'. Resting on the premise of 
limited resources, they advocate ranking health technologies according to their cost-
effectiveness. This entails that, in principle, substitution could maximise health outcomes 
in a given budget, even if the generic medicine were less effective than the reference 
medicine. They might indicate that prescribing the more expensive reference medicine, 
which may perhaps improve the outcomes in the individual case, could result in overall 
decrease in population health (Simoens, 2011). 
However, according to the ethics’ point of view presented in this review, individual 
patient might reject the conception of 'societal perspective' it implies. Working in the 
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assumption of limited resources, in an affluent society that has enough wealth to provide 
the best medical care for all, has nothing to do with good medicine or with any genuine 
'societal perspective'. It seems that the social role of health economics is to ensure that the 
distribution and redistribution of resources in our society will benefit the few at the 
expense of the many, with respect to the determination of the minority to take good care 
of its interests. But patients have other values; they believe that medicine ought to have 
no role other than taking care of their interest and health. If there are not enough 
resources for that, it should insist that more are brought in. This is the ideal notion of 
'societal perspective' (Al Ameri et al., 2011a). 
Overall, in the case of generic and therapeutic substitution the absence of evidence of 
differences is not tantamount to evidence of no differences. Studies have shown that 
similar treatments can have different clinical outcomes (Kovarik et al., 2006, Qazi et al., 
2006, Roza et al., 2002, Taber et al., 2005). Promoting generic and therapeutic 
substitution on economic grounds alone is potentially harmful to patients, and unethical. 
Attempting to obtain the patients’ consent would not solve any problems here, since the 
options before the patients are not equally defensible. In other words, autonomous 
patients would never consent to substitutions that were likely to compromise their health. 
Ethically, generic and therapeutic substitution should always take place with the interest 
of individual patients in mind and not solely to reduce costs.  
2.8 Main limitation of the study 
Limitations of this literature review include that small study groups are usually used. Bias 
in the data provided can occur and influence of interests can direct the literature flow. 
Furthermore, literature review usually relies on previously published research which 
might have inappropriate criteria of the inclusion/exclusion procedure. Findings from 
literature reviews are not always in harmony with the findings from a large-scale high 
quality single trial. Therefore, further surveys are suggested to evaluate current patients’ 
and physicians’ views on drug substitution. 
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3 Chapter 3 A survey to determine the views of renal 
transplant patients on generic substitution in the UK  
This chapter was published as an original article in the Transplant International, 2011 (Al 
Ameri et al., 2011b) (Appendix 19). 
3.1 Introduction 
Rising healthcare costs have received significant attention from many healthcare 
providers and political arenas (Bloor and Freemantle, 1996, Department of Health, 2010). 
In many countries health authorities are supporting the practice of drug substitution to 
provide a cheaper alternative to the branded medicines. Most policy makers are looking 
to limit their healthcare expenditure while, optimistically, maintaining or improving the 
quality of care. Reducing healthcare costs is often easier when intervening on the 
expenditure of medications because their identifiable costs. This is supported by many 
proofs that substitution of cheaper medicines can result in substantial savings (Andersson 
et al., 2005, Haas, 2005, Tilson et al., 2005). As a consequence, the preference for 
promoting generic substitution among patients has been reported in many countries 
(Barton et al., 2004, Decullier and Chapuis, 2006).  
In the UK and other European countries, the cost-saving benefits from promoting generic 
substitution are attained and considerable (Andersson et al., 2005, Polsky and Glick, 
2009, Tilson et al., 2005). However, as mentioned earlier in this thesis, the quality of 
some cheaper medicines is now questioned. It was indicated that generic and therapeutic 
substitutions have raised concerns about whether they serve the interests of patients or 
simply the target of reducing healthcare related costs (Duerden and Hughes, 2010, 
Garattini and Bertele, 2007, Himmel et al., 2005, Kereiakes and Willerson, 2003, Phillips 
et al., 2007, Pocock, 2003, Snow et al., 2003). Without consulting patients, and thus 
obtaining their consent to treatment, many healthcare providers, including the British 
NHS, have been promoting generic and therapeutic substitution in an attempt to contain 
their costs (American Cancer Society, 2010, National Health Service, 2009). Despite the 
UK’s National Health Service espousing “evidence based medicine”, this has been done 
without any attempt to determine the extent, if any, of long term savings. It has also been 
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done without any consideration of the potential for adverse consequences which may 
arise (Duh et al., 2009). 
Although there are few published articles to evaluate patients’ views on drug substitution, 
some have shown that drug substitution can be problematic (Doshi et al., 2009, Himmel 
et al., 2005, Krska et al., 2012, Meredith, 2003). A survey of patients in the UK has 
shown that 46% of patients stated that they were dissatisfied when faced with generic 
substitution (Patel and Taylor, 2002). Another survey has shown that at least 20-30% of 
patients believe that generic drugs are less safe and effective (Ganther and Kreling, 
2000). Many other studies have shown that people’s beliefs about the use of generic 
drugs are usually associated with the nature of the illness for which they are being 
prescribed (Figueiras et al., 2008, Ganther and Kreling, 2000). This was also confirmed in 
the literature by other studies where patients with more serious or risky medical condition 
were found less likely to accept generic products (Ganther and Kreling, 2000, Hassali et 
al., 2009).   
Another study assessing patients’ attitudes towards generic substitution revealed that 
about one third of patients care to know about the drugs they are taking and many patients 
who pay for their medicine (in countries outside the NHS) preferred a drug with a lower 
co-payment. It was concluded that patients’ lack of knowledge about generic medicines 
directed them to avoid the use of these drugs (Michaela and Lassanova, 2008). This was 
also confirmed in other studies where authors found a strong correlation between 
patients’ medication adherence and both remembering that information had been 
provided by their physicians and the dose frequency as well as the duration of treatment. 
(Kjonniksen et al., 2005, Mould, 2002).  
As a result, this survey was designed to evaluate the current renal transplant patients’ 
views and attitudes towards generic substitution in the UK and the role of healthcare 
professionals on patients’ acceptance of generic substitution. This study is not against 
generic prescribing or substitution, but it is concerned with the effective prescribing, and 
public (patients) engagement, in the process and its perceived transparency. These are 
important factors in the acceptance of generic substitution and in obtaining valid and 
legal consent from patients. 
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3.2 Objective 
The objective of this study was to evaluate the renal transplant patients’ current 
understanding, opinions and experiences concerning generic medicines and substitution 
and how they consider this may be better managed by healthcare professionals.  
3.3 Methods 
This study was conducted in the Renal Clinic of the Royal London Hospital, UK. It was 
approved by the Ethics Committee of the East London and The City REC Alpha (REC 
No. 10/H0704/16). The protocol, ethic’s approval and the questionnaire of this study are 
included in Appendix 1, Appendix 2, Appendix 3 and Appendix 4. It is worth noting 
that it  required seven months to obtain the ethic’s approval for this study.  
According to the study protocol, a minimum of 100 patients were intended to be 
surveyed. However, nurses and receptionists in the participating clinic were able to 
recruit a total of 163 transplant recipients treated at Barts and The London Renal 
Transplant Clinic, in the UK. It was difficult to enrol a higher number of patients during 
the regular clinic hours because of time constraints. This study was conducted to evaluate 
the attitudes of a specific group of patients, renal transplant recipients who should be well 
informed about their medications and may be particularly affected by generic 
substitution. Any small changes in the medicinal effect of this group of patients can 
negatively impact their clinical outcome.  
A questionnaire consisted of 36 multiple-choice closed questions (Table 1) was used as a 
tool to obtain the required information. Before commencing the study, the questionnaire 
was piloted and validated in the Renal Clinic, Royal London Hospital in the UK 
including 30 patients (18 males and 12 females) aged from 18 to 75 years (Figure 8). No 
additions or deletions were required; therefore, the study commenced directly after the 
validation and these patients were included in the main analysis. The aim and the 
protocol of the study were explained and discussed with the medical professionals in a 
weekly Renal Clinic Meeting. Patients were recruited by reception and nursing staff as 
patients booked in for a clinic visit over a period of 6 months (from May 1st until 
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November 1st, 2010). The inclusion criteria of this study were all adult patients over 18 
years, able to read and write English, and willing to fill in the questionnaire.  
After reviewing the information sheet which contained a short introduction about generic 
medicines and substitution, patients consented by choosing to fill in the questionnaire. 
This survey was related to all medication and not immunosuppressant agents alone.  
Table 1: The content of the questionnaire used in the survey to determine the views 
of renal transplant patients in the UK. 
No. Questions Multiple choices 
1. Sex [  ] Male     [  ] Female 
2. Age ___________ Years 
3. Number of different medications taken each 
day? 
[  ] 1 – 3      [  ] 4 - 6  
[  ] 7 - 9      [  ] > 9  
4. What is the highest level of education 
you have completed? 
[  ] Secondary school (GCSE)   
[  ] Vocational Training (e.g. Apprenticeship) 
[  ] Sixth form (A-level or equivalent) 
[  ] College  
[  ] University (First degree) 
[  ] Postgraduate  
5. If you have had an organ transplant, when 
did the transplant taken place? 
[  ] Less than a year ago  
[  ] More than a year ago 
[  ] I haven’t had transplantation 
6. Were you aware in general that there 
may be different forms of the same 
medicine available, produced by 
different manufacturers? 
[  ] Yes 
[  ] No 
[  ] Don’t know 
7. Do you understand the terms “generic” and 
“branded” in relation to medicines? 
[  ] Yes – go to question 8 
[  ] No – go to question 9 
[  ] Uncertain – go to question 8 
8. Does it matter to you if the medicines 
that you are taking are generic or 
original branded forms? 
 
[  ] Yes 
[  ] No 
[  ] Uncertain 
[  ] It depends (please specify) 
9. Are you aware of the practice of generic 
substitution? 
[  ] Yes, I am  
[  ] No, I am not  
[  ] Don’t know  
10. Were you aware that the practice of 
generic substitution involves 
switching between a branded product 
and a generic version of the same 
medicine? 
[  ] Yes, I am 
[  ] No, I am not 
[  ] Don’t know 
11. Do you know if you are currently taking 
any generic prescription medications? 
[  ] Yes, I am – go to question 12 
[  ] No, I am not – go to question 16 
[  ] Don’t know – go to question 16 
12. How satisfied are you with the generic 
alternative that you are taking? 
 
[  ] Very satisfied 
[  ] Dissatisfied 
[  ] Neither very satisfied nor dissatisfied  
13. Have you experienced any differences 
in terms of the effectiveness or side 
effects between the branded and 
[  ] Yes – go to question 14 
[  ] No – go to question 16 
[  ] Uncertain 
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No. Questions Multiple choices 
generic medicine? 
14. What were the differences between the 
branded and generic medicines that you 
have experienced? (Mark all that apply) 
[  ] Packaging  
[  ] Shape, colour or taste 
[  ] The brand is more effective 
[  ] The generic is more effective 
[  ] The brand has more side-effect 
[  ] The generic has more side-effects  
[  ] Others, please describe 
15. Do you think adapting to these 
differences was a concern? 
[  ] Agree  
[  ] Disagree 
[  ] Uncertain 
16. Do you think that receiving a generic 
medicine might affect how regularly you 
take your medicines? 
[  ] Agree  
[  ] Disagree 
[  ] Uncertain 
17. Do you think that generic medicines 
are equivalent and have the same 
quality as the branded medicines?  
[  ] Agree- always  
[  ] Disagree- always 
[  ] Yes- Sometimes 
[  ] Uncertain 
18. If you have a mild condition such as flu or 
headache, would you consider taking 
generic medicines? 
[  ] Yes 
[  ] No 
[  ] Uncertain 
[  ] It depends (please specify) 
19. If you have a chronic condition such 
as high blood pressure or diabetes, 
would you consider taking generic 
medicines? 
[  ] Yes 
[  ] No 
[  ] Uncertain 
[  ] It depends (please specify) 
20. Were you aware that a generic form of 
ciclosporin (sometimes spelt 
cyclosporine) will be available very 
soon in the UK? 
[  ] Yes 
[  ] No 
[  ] Uncertain 
21. Would you agree to switch your current 
branded ciclosporin to a generic form to 
save the NHS (National Health Service) 
money? 
[  ] Agree 
[  ] Disagree 
[  ] Uncertain 
22. In general, how far do you feel that 
your doctor involves you in decisions 
regarding your medications? 
[  ] A lot 
[  ] A bit 
[  ] Not at all 
[  ] Don’t know 
23. Do you think that you should be 
consulted about being given generic 
medications? 
[  ] Yes- only by GP 
[  ] Yes – only by hospital specialists 
[  ] Agreement of both GP and hospital specialist 
[  ] Do not think that this is necessary. 
24. Has your doctor ever told you to make sure 
that you always receive the same brand of 
any medicine? 
[  ] Yes 
[  ] No 
[  ] Don’t know 
25. Has your doctor ever changed your 
medicine to a generic form? 
[  ] Yes – go to question 26 
[  ] No – go to question 35 
[  ] Don’t know – go to question 35 
26. Would you agree to switch your 
medicine to a generic alternative if 
your doctor felt that the two 
medications were interchangeable?  
[  ] Agree 
[  ] Disagree 
[  ] Uncertain 
27. Did anyone discuss the reasons for 
switching your medicine to the generic 
[  ] Yes — go to question 28 
[  ] No — go to question 29 
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No. Questions Multiple choices 
form?  [  ] Don’t know — go to question 29 
28. Who discussed the reasons for 
switching your medicine to the generic 
form? (Mark all that apply) 
[  ] Specialists 
[  ] Hospital Doctor 
[  ] General Practitioner (GP) 
[  ] Pharmacist 
[  ] Nurse 
[  ] Others, please describe 
29. Which of the following do you think 
may be potential reasons for switching 
your medicine from a brand to a 
generic? (Mark all that apply) 
[  ] Save money for the NHS (National Health                          
Services) 
[  ] The generic medicine is more effective. 
[  ] The generic medicine has same effectiveness 
and less costs. 
[  ] The branded medicine was not available                       
anymore. 
[  ] Others, please describe 
30. Did your doctor monitor the effect of 
your medicine after switching you to a 
generic form? 
[  ] Yes 
[  ] No 
[  ] Don’t know 
31. Did anyone provide you with 
background information about your 
generic medicine? 
[  ] Yes – go to question 32 
[  ] No – go to question 35 
[  ] Don’t know 
32. Who provided you with background 
information about your generic 
medicine? (Mark all that apply) 
[  ] Specialist 
[  ] Hospital Doctor 
[  ] General Practitioner (GP)  
[  ] Pharmacist 
[  ] Nurse 
[  ] Others, please describe. 
33. If you got information on your generic 
medicine, how did you get the 
information? (Mark all that apply) 
 
[  ] Verbally  
[  ] Written  
[  ] Web/ internet 
[  ] Other, please describe 
[  ] Not applicable as no information received 
34. Did you consider the information 
provided about your generic medicine 
to be sufficient? 
[  ] Yes 
[  ] No 
[  ] Uncertain 
35. How much would you favour or 
oppose a requirement that patients 
always be notified if their medicine is 
changed to a generic form? 
[  ] Favour 
[  ] Oppose 
[  ] Neither favour nor oppose 
36. Would you agree to switch to a 
generic if initiated by your hospital 
consultant/doctor, general practitioner, 
pharmacist or nurse i.e. NOT by your 
specialist? 
Hospital Consultant/ Doctor: 
[  ] Agree [  ] Disagree [ ] Uncertain 
General Practitioner (GP): 
[  ] Agree [  ] Disagree [  ] Uncertain 
Pharmacist: 
[  ] Agree [  ] Disagree [  ] Uncertain 
Nurse: 
[  ] Agree [  ] Disagree [  ] Uncertain 
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Figure 8: The age distribution of patients (n=30) who participated in the pilot study 
to validate the method of the survey to determine the views of renal 
transplant patients on generic substitution in the UK. 
3.4 Results 
The data from the questionnaire were collected and analysed using Microsoft Office 
Excel 2007 and Minitab 16 Statistical Software (Made by “Minitab Inc”, Pennsylvania, 
USA). Results of all questions put to patients in the survey are reported and expressed as 
% [95% Confidence intervals (CI)]. The missing values were not included in the 
calculations of percentages; the total number (n) of respondents for each question is given 
in parentheses after each question (Table 2).  
According to the result of this study, a total of 163 [87 (53%) male and 76 (47%) female] 
patients (Figure 9) with an average age of 48 years [range (18-81), median (47)] 
participated in this study (Figure 10). The majority of participating patients [96% (95% 
CI 91-98)] confirmed that they had undergone a kidney transplant more than a year ago, 
Figure 11. In addition, more than two thirds were taking more than seven medications 
[44%, (95% CI 36-52) were taking between 7-9 medications and 27% (95% CI 20-35) 
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were taking more than 9 medications] (Figure 12). In addition, A total of 74/147 
participants [50.34% (95% CI 42-59)] were highly educated (graduated from college, 
university or postgraduate), and 73/147 participants [49.66% (95% CI 41-58)] were less 
educated (graduated from secondary school, vocational training or sixth forms) (Figure 
13 and Table 2).  
Table 2: Demographics of the participating patients (n=163). 
Demographics Number of responders Percentages of 
responders 
95% Confidence 
Intervals 
Gender (n*=163) 
         Male 
         Female  
 
87 
76 
 
53 
47 
 
(45-61) 
(39-55) 
Age distribution (n*=163) 
        39 years or less 
        40-49 years 
        50-59 years 
        60 years or more 
 
44 
46 
47 
26 
 
27 
28 
29 
16 
 
(20-34) 
(21-36) 
(22-36) 
(11-22) 
Number of medications 
taken daily (n*=154): 
        1-3 medications 
        4-6 medications 
        7-9 medications 
        > 9 medications 
 
 
1 
43 
68 
42 
 
 
1 
28 
44 
27 
 
 
(0.02-4) 
(21-36) 
(36-52) 
(20-35) 
The time of organ 
transplant (n*=154) 
        Less than a year ago 
        More than a year ago 
        No transplantation 
 
 
5 
147 
2 
 
 
3 
96 
1 
 
 
(1-7) 
(91-98) 
(0.02-4) 
The level of education 
(n*=147) 
       Secondary School 
       Vocational training 
       Sixth form 
       College 
       University 
       Postgraduate 
 
 
60 
4 
9 
39 
22 
13 
 
 
41 
3 
6 
26 
15 
9 
 
 
(33-49) 
(1-7) 
(3-11) 
(20-34) 
(10-22) 
(5-15) 
*The total number of patients who responded to the question. 
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Figure 9: The percentage of male and female participating patients (n=163). 
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Figure 10: The age distribution of the participating patients (n=163). 
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Figure 11: The time of organ transplant of the participating patients (n=154). 
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Figure 12: The number of medications taken by the participating patients (n=154). 
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Figure 13: The level of education of the participating patients (n=147). 
The questionnaire was divided into three sections as follows: 
3.4.1 Patients’ general knowledge of generic medicines and substitution 
Although many participating patients [75% (95% CI 67-82)] did not know and were 
unsure of taking generic medicines, 84% (95% CI 76-89) felt that generics were not 
equivalent or only equivalent sometimes, and they were uncertain that generics had the 
same quality as branded medicines (Figure 18). Nevertheless, 81% (95% CI 74-87) of 
patients were unaware and uncertain that a generic form of ciclosporin 
(immunosuppressant agent) was available in the UK and only 23% (95% CI 16-31) 
admitted that they would accept the generic substitution of ciclosporin when it became 
available (Table 3 and Figure 20).  
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Table 3: Questions and responses evaluating renal patients’ general knowledge of 
generic medicines and substitution. 
Questions Answers Number  
of 
responders  
Percentages 
of 
responders 
95%  
Confidence 
Intervals 
Were you aware that there are 
different forms of the same 
medicine available, produced by 
different manufacturers? (n*=160) 
(Figure 14) 
 
Yes 
No 
Uncertain 
 
134 
13 
13 
 
84 
8 
8 
 
(77-89) 
(4-13) 
(4-13) 
Do you understand the terms 
“generic” and “branded” in relation 
to medicines? (n*=142)  
Figure 15) 
Yes 
No 
Uncertain 
99 
33 
10 
70 
23 
7 
(61-77) 
(17-31) 
(3-13) 
Are you aware of the practice of 
generic substitution? (n*=146) 
(Figure 16) 
Yes 
No 
Uncertain 
79 
50 
17 
54 
34 
12 
(46-62) 
(27-43) 
(7-18) 
Do you know if you are currently 
taking any generic prescription 
medications? (n*=147) (Figure 17) 
Yes 
No 
Uncertain 
37 
52 
58 
25 
35 
40 
(18-33) 
(28-44) 
(32-48) 
Do you think that generic medicines 
are equivalent and have the same 
quality as the branded medicines? 
(n*=146) (Figure 18) 
Agree-always 
Disagree-always 
Yes- sometimes 
Uncertain 
24 
10 
50 
62 
16 
7 
34 
43 
(11-23) 
(3-12) 
(27-43) 
(34-51) 
Were you aware that a generic form 
of ciclosporin is available in the 
UK? (n*=150) (Figure 19) 
Yes 
No 
Uncertain 
28 
108 
14 
19 
72 
9 
(13-26) 
(64-79) 
(5-15) 
Would you agree to switch your 
current branded ciclosporin to a 
generic form to save the NHS 
money? (n*=135) (Figure 20) 
Agree 
Disagree 
Uncertain 
31 
50 
54 
23 
37 
40 
(16-31) 
(29-46) 
(32-49) 
*The total number of patients who responded to the question. 
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Figure 14: Answers of patients when asked if they were aware that there are different 
forms of the same medicine available, produced by different 
manufacturers? (n=160). 
69.7%
23.2%
7.0%
0
10
20
30
40
50
60
70
80
Yes No Uncertain
%
 o
f 
p
a
ti
e
n
ts
 
Figure 15: The answers of patients when asked if they understand the terms “generic” 
and “branded” in relation to medicines? (n=142). 
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Figure 16: The answers of patients when asked if they were aware of the generic 
substitution practice (n=146). 
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Figure 17: The answers of patients when asked if they were currently taking any 
generic prescription medications (n=147). 
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Figure 18: The answers of patients when they were asked if they thought that generic 
medicines were equivalent and had the same quality as the branded 
medicines (n=146). 
18.7%
72.0%
9.3%
0
10
20
30
40
50
60
70
80
Yes No Uncertain
%
 o
f 
p
a
ti
e
n
ts
 
Figure 19: The answers of patients when asked if they were conscious that a generic 
form of ciclosporin is available in the UK (n=150). 
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Figure 20: The answers of patients when asked if they would agree to switch their 
current branded ciclosporin to a generic form to save the NHS money 
(n=135). 
Findings in this survey also marked the influence of educational attainment on patients’ 
acceptance of generic substitution. A total of 69 highly educated patients (graduated from 
college, university or postgraduate) responded to a question evaluating their awareness of 
generic substitution practice. Of these 51 [74% (95% CI 62-84)] had reported that they 
were aware of the substitution practice. On the other hand, from a total of 67 less 
educated patients (graduated from secondary school, vocational training or sixth forms) 
who responded to the same question, only 39 [58% (95% CI 46-70)] reported that they 
were aware of the generic substitution practice (p = 0.013) (Figure 21). 
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Figure 21: The answers of educated and less educated patients when asked if they 
were aware of the generic substitution practice (n=136).  
Moreover, a total of 64 highly educated renal patients responded to a question evaluating 
their potential acceptance of generic substitution of ciclosporin. Of these 18 [28% (95% 
CI 18-41)] confirmed that they would refuse the substitution of ciclosporin. On the other 
hand, from a total of 60 less educated renal patients who responded to the same question, 
29 [48% (95% CI 35-62)] confirmed that they would refuse generic substitution of 
ciclosporin (p = 0.056) (Figure 22). 
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* graduated from college, university or postgraduate, ** graduated from secondary school, vocational 
training or sixth form. 
Figure 22: The answers of educated and less educated patients when asked if they 
would accept the generic substitution of ciclosporin (n=124).  
3.4.2 Patients’ attitudes towards generic medicines and substitution 
According to the survey, most patients (67%, 95% CI 53-79) receiving generic medicines 
were dissatisfied or uncertain about their satisfaction concerning generic medicines 
(Figure 23) and more than half (55%, 95% CI 41-67) were uncertain and had 
experienced noticeable differences between the branded and the generic medicines and 
were uncertain about these differences (Figure 24). Of these, 94% (95% CI 84-99) 
reported that the main differences they noticed were in the packaging, shape and the more 
effectiveness of the branded medicines (Figure 25). Of these, 76% (95% CI 62-86) were 
uncertain about the consequence of these differences and admitted that adapting to these 
differences was a problem (Figure 26). In addition, 55% (95% CI 41-67) of participants 
felt that the generic medicines might affect their medication regime adherence (Figure 
27). Nevertheless, 79% (95% CI 71-85) wished to be always notified when switching 
their medicines (Table 4 and Figure 28). 
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Table 4: Questions and responses evaluating renal patients’ attitudes towards 
generic medicine and substitution. 
Questions Choices Number 
of 
responders 
Percentages 
of 
responders 
95% 
Confidence 
Intervals 
How satisfied are you with the 
generic alternative that you are 
taking? (n*=55) 
Very satisfied 
Dissatisfied 
Neither very 
satisfied nor 
dissatisfied 
18 
8 
 
29 
33 
14 
 
53 
(21-47) 
(6.5-27) 
 
(39-66) 
Have you experienced any 
differences in terms of the 
effectiveness or side effects 
between the branded and 
generic medicine? (n*=56) 
Yes 
No 
Uncertain 
8 
25 
23 
14 
45 
41 
(6.4-26) 
(31-59) 
(28-55) 
What were the differences 
between the branded and 
generic medicines that you 
have experienced? (n*=52)  
Packaging 
Shape, colour or 
taste 
The brand is more 
effective 
The generic is 
more effective 
The brand has 
more side-effect 
The generic has 
more side-effect 
Others 
30 
 
16 
 
3 
 
1 
 
0 
 
1 
1 
57 
 
31 
 
6 
 
2 
 
0 
 
2 
2 
(43-71) 
 
(19-45) 
 
(1-16) 
 
(0.5-10) 
 
(0-6) 
 
(0.5-10) 
(0.5-10) 
Do you think adapting to these 
differences was a concern? 
(n*=57) 
Agree 
Disagree 
Uncertain 
18 
14 
25 
32 
24 
44 
(20- 45) 
(14- 38) 
(31- 58) 
Do you think that receiving a 
generic medicine might affect 
how regularly you take your 
medicines? (n*=148) 
Agree 
Disagree 
Uncertain 
21 
66 
61 
14 
45 
41 
(9-21) 
(36-53) 
(33-50) 
How much would you favour 
or oppose a requirement that 
patients always be notified if 
their medicine is changed to a 
generic form? (n*=144) 
Favour 
Oppose 
Neither favour nor 
oppose 
113 
6 
 
25 
79 
4 
 
17 
(71-85) 
(2-9) 
 
(12-25) 
*The total number of patients who responded to the question. 
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Figure 23: The answers of patients when asked about their satisfaction with the 
generic alternative that they were taking (n=55). 
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Figure 24: The answers of patients when asked about if they had experienced any 
differences in terms of the effectiveness or side effects between the 
branded and generic medicine (n=56). 
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Figure 25: The answers of patients when asked about the differences between the 
branded and generic medicines that they have experienced (n*=52). 
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Figure 26: The answers of patients when asked if they thought adapting to these 
differences was a concern (n=57). 
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Figure 27: The answers of patients when asked if they thought that receiving a 
generic medicine might affect how regularly they took their medicines 
(n=148). 
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Figure 28: The answers of patients when asked about how much they would favour or 
oppose a requirement that they always be notified if their medicine was 
changed to a generic form (n=144). 
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The severity of the disease was also affecting patients’ acceptance of generic substitution. 
Patients were asked about their potential acceptance of generic substitution if they were 
diagnosed with mild versus chronic disease, irrespective of their renal transplant. 
According to the survey, more than half of the participating patients [55% (95% CI 47-
63)] admitted that they would accept generic substitution if they had mild disease 
compared to 35% (95% CI 27-43) who would do so if they had a chronic disease (Figure 
29). 
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Figure 29: The responses of patients when asked about their potential acceptance of 
generic substitution if they were diagnosed with mild versus chronic 
disease, irrespective of their renal transplant.  
3.4.3 Professionals’ roles on generic substitution 
According to the result of this survey, a number of patients (34%, 95% CI 26-42) were 
uncertain if their doctor had changed their medicine to a generic form (Figure 30). In 
addition, many patients [79% (95% CI 67-88)] declared that no background information 
regarding generic medicines and substitution was provided (Figure 31) and more than 
half [51% (95% CI 42-59)] felt that they had been involved to a small degree or not at all 
in decisions regarding their health (Figure 32). Moreover, 85% (95% CI 73-93) of 
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patients stated that they were not monitored or were uncertain of being monitored after 
switching to a generic medicine (Figure 33). According to 32% (95% CI 17-51) of 
patients reported that pharmacists were the main source of information (Figure 34) and 
35% (95% CI 20-53) of them reported that information was mainly given in verbal form 
(Figure 35).  
A total of 48% (95% CI 29-67) of patients were uncertain about the information provided 
and considered it insufficient (Figure 36). Moreover, the reasons for switching medicines 
were not discussed with 69% (95% CI 57-80) of patients (Figure 37) and a total of 38% 
(95% CI 21-58) of patients believed that general practitioners (GPs) were the 
professionals who most often discussed the reasons for switching their medicines (Figure 
38).  
When patients were asked about the potential reasons for promoting generic substitution, 
many of them (81%, 95% CI 72-88) believed that substitution was promoted mainly to 
save the NHS money or because the similar effectiveness between the branded and 
generic medicines. In addition, 14% (95% CI 07-22) of patients believe that substitution 
was promoted because of the unavailability of the branded medicine at the time of 
dispensing (Figure 39). When patients were asked about their communication with 
healthcare professionals regarding generic medicines, 53% (95% CI 44-61) reported that 
their doctors never informed them about whether they should always receive branded or 
generic medicine (Figure 40).  
However, 60% (95% CI 47-71) of patients admitted that they would agree to switch their 
medicine to a generic alternative if their doctor agrees that the two medications were 
interchangeable (Figure 41). Almost half of participating patients (49%, 95% CI 41-58), 
believed that they should be consulted about being given generic medicines by their 
general practitioner (GP) and the hospital specialist (Figure 42). Nevertheless, about 
75% (95% CI 68-82) of the participating patients agreed to accept generic substitution if 
it was initiated by a hospital consultant or doctor (Figure 43). 
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Table 5: Questions and responses evaluating healthcare professionals’ roles on 
renal patients’ acceptance of generic substitution. 
Questions Choices Number  
of  
responders 
Percentages  
of  
responders 
95%  
Confidence  
Intervals 
Has your doctor ever 
changed your medicine to a 
generic form? (n*=141) 
Yes 
No 
Uncertain 
25 
68 
48 
18 
48 
34 
(12-25) 
(40-57) 
(26-42) 
Did anyone provide you 
with background 
information about your 
generic medicine? (n*=67) 
Yes 
No 
Uncertain 
9 
53 
5 
13 
79 
8 
(6.3-24) 
(67-88) 
(2.4-17) 
Who provided you with 
background information 
about your generic 
medicine? (n*=31) 
Specialist 
Hospital doctor 
General practitioner  
Pharmacist 
Nurse 
Others 
5 
8 
5 
10 
3 
0 
16 
26 
16 
32 
10 
0 
(24-17) 
(12-45) 
(24-17) 
(17-51) 
(20-26) 
(0.0-9.2) 
If you got the information 
on your generic medicine, 
how did you get the 
information? (n*= 37) 
Verbally 
Written 
No information received 
Web/ internet 
Other 
13 
11 
5 
7 
1 
35 
30 
13 
19 
3 
(20-53) 
(16-47) 
(5-29) 
(8-35) 
(0-14) 
Did you consider the 
information provided about 
your generic medicine to be 
sufficient? (n*=29) 
Yes 
No 
Uncertain 
15 
3 
11 
52 
10 
38 
(33-70) 
(22-27) 
(21-58) 
In general, how far do you 
feel that your doctor 
involves you in decisions 
regarding your medications? 
(n*=152) 
A lot 
A bit 
Not at all 
Uncertain 
75 
45 
27 
5 
49 
30 
18 
3 
(41-58) 
(22-38) 
(12-25) 
(1.0-8) 
Did your doctor monitor the 
effect of your medicine after 
switching you to a generic 
medicine? (n*=58) 
Yes 
No 
Uncertain 
9 
23 
26 
15 
40 
45 
(7.3-27) 
(27-53) 
(32-58) 
Did anyone discuss the 
reasons for switching your 
medicine to the generic 
form? (n*=65) 
Yes 
No 
Uncertain 
12 
45 
8 
19 
69 
12 
(10-30) 
(57-80) 
(5.4-23) 
Who discussed the reasons 
for switching your medicine 
to the generic form? (n*=29) 
Specialist 
Hospital doctor 
General practitioner 
Pharmacist 
Nurse 
Others 
6 
8 
11 
4 
0 
0 
21 
27 
38 
14 
0 
0 
(8-40) 
(13-47) 
(21-58) 
(4-32) 
(0-10) 
(0-10) 
Chapter 3 UK patient survey 
Page 97 of 446 
Questions Choices Number  
of  
responders 
Percentages  
of  
responders 
95%  
Confidence  
Intervals 
Which of the following do 
you think may be potential 
reasons for switching your 
medicine to the generic 
form? (n*=96) 
Save the NHS money 
Generics are more 
effective 
Generics have the same 
effectiveness and less 
costs 
The branded medicine 
was not available 
44 
 
5 
 
 
34 
 
13 
46 
 
5 
 
 
35 
 
14 
(36-56) 
 
(2-12) 
 
 
(26-46) 
 
(7-22) 
Has your doctor ever told 
you to make sure that you 
always receive the same 
brand of any medicine? 
(n*=142) 
Yes 
No 
Uncertain 
60 
75 
7 
42 
53 
5 
(34-51) 
(44-61) 
(2-10) 
Would you agree to switch 
your medicine to a generic 
alternative if your doctor 
felt that the two medications 
were interchangeable? 
(n*=72) 
Agree 
Disagree 
Uncertain 
43 
8 
21 
60 
11 
29 
(47-71) 
(5-21) 
(19-41) 
Do you think that you 
should be consulted about 
being given generic 
medicines?(n*=142) 
Yes- only by GP 
Yes- only by hospital 
specialist 
Agreement of both GP 
and hospital specialist 
Do not think that this is 
necessary 
15 
 
45 
 
70 
 
12 
11 
 
32 
 
49 
 
8 
(6-17) 
 
(24-40) 
 
(41-58) 
 
(4-14) 
*The total number of patients who responded to the question. 
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Figure 30: The responses of patients when asked if their doctors ever had changed 
their medicine to a generic form (n=141). 
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Figure 31: The responses of patients when asked if anyone had provided them with 
background information about their generic medicine (n=67). 
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Figure 32: The responses of patients when asked about how far they felt that their 
doctor involved them in decisions regarding their medications (n=152). 
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Figure 33: The responses of patients when asked if their doctors monitored the effect 
of their medicine after switching them to a generic medicine (n=58). 
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Figure 34: The responses of patients when asked about the main professional who had 
provided them with background information about their generic medicine 
(n=31). 
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Figure 35: The responses of patients when asked in what form they got the 
information on their generic medicine (n= 37). 
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Figure 36: The responses of patients when asked if they considered the information 
provided about their generic medicine was sufficient (n=29). 
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Figure 37: The responses of patients when asked if anyone discussed the reasons for 
switching their medicine to the generic form (n=65). 
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Figure 38: The responses of patients when asked about the main professional who 
discussed the reasons for switching their medicine to the generic form 
(n=29). 
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Figure 39: The responses of patients when asked about their opinion of the potential 
reasons for switching their medicine to the generic form (n=96). 
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Figure 40: The responses of patients when asked if their doctor had ever told them to 
make sure that they always receive the same brand of any medicine 
(n=142). 
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Figure 41: The responses of patients when asked if they would agree to switch their 
medicine to a generic alternative if their doctor felt that the two 
medications were interchangeable (n=72). 
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Figure 42: The responses of patients when asked if they thought that they should be 
consulted about being given generic medicines (n=142). 
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Figure 43: The responses of patients when asked about the most healthcare 
professional that they would agree with to initiate their generic 
substitution. 
3.5 Discussion 
Although the majority of the participating renal transplant patients in this survey reported 
that they were aware of the term generic medicine and substitution, three quarters of them 
did not know if they were taking generic medicines and one-third did not know if their 
medicine was substituted. Most of these patients were uncertain that generics had the 
same quality as branded medicines. Therefore many patients in the survey were 
suspicious about their satisfaction concerning generic medicines and, furthermore, they 
claimed that they would not accept the generic substitution of ciclosporin. These beliefs 
were highly marked in patients with chronic disease, less education, less communication 
with healthcare professionals and who suspected that the cheaper drug substitution was 
implemented only to save costs.  
This indicates that the level of education, knowledge, severity of the disease and 
involving patients in decisions concerning their health played major roles in framing 
patients’ views and acceptance of generic substitution. For example, patients with a high 
Chapter 3 UK patient survey 
Page 105 of 446 
level of education were more knowledgeable about their generic medicines and 
substitution; as a result they were more likely to accept generic substitution of ciclosporin 
than those with a lower level of education. However, according to the results of this 
study, some educated patients were still suspicious about generic medicine and 
substitution. This suspicion mostly occurred among patients who were not assured, by 
their healthcare professionals, about the safety and the effectiveness of the prescribed 
generic medicine (Melchior, 2009).  
In addition, most patients in this study reported that they were not provided with 
background information regarding their generic medicine upon substitution and very few 
reported that they were monitored after substitution. However, a study in the literature 
assessing patients’ attitudes towards generic drugs revealed that about 79% of patients 
who were educated considered generics as equivalent to their counterpart branded drug 
and accepted generic substitution. In addition, patients who were informed by physicians 
or pharmacist about generic substitution were more susceptible to accept generic 
substitution (Michaela and Lassanova, 2008). 
Severity of the disease was also found to play a major role in patients’ acceptance of 
generic substitution. For example, many patients in this study reported that they would be 
more reluctant to accept generic substitution if they were diagnosed with chronic disease. 
This was also confirmed by other studies in the literature (Decollogny et al., 2011). The 
majority of patients favoured being informed upon switching their medicines and many 
reported that they would agree to accept generic substitution and adhere to the treatment 
if they were informed and educated by their healthcare professionals. This explores the 
clear need for educating patients about generic medicine and substitution, particularly in 
terms of clarifying the prevalence and processes by which generic substitution occurs and 
the potential roles of healthcare professionals in successfully introducing generic 
substitution.  
Findings in this study are compatible with those in the existing literature (Berg et al., 
2008a, Decollogny et al., 2011, Gossell-Williams, 2007, Michaela and Lassanova, 2008). 
Some studies explored that there is a lack of confidence among healthcare professionals 
in the therapeutic equivalence of all available generic substitutions (Berg et al., 2008a, 
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Gossell-Williams, 2007). Small differences in some particular medicines during 
manufacturing could theoretically result in a risk of significant adverse effects or loss of 
efficacy (Himmel et al., 2005, Garattini and Bertele, 2007, Pocock, 2003). Many other 
studies have shown that patients need to be educated and informed adequately about the 
equivalence of the branded and the generic medicines otherwise generic substitution will 
be challenging (Decollogny et al., 2011, Himmel et al., 2005, Meredith, 1996, Meredith, 
2003, Simoens, 2011).  
Moreover, many studies have shown differences in the pharmacokinetic profile between 
branded and generic medicines, disparities that might affect clinical outcomes (Kovarik et 
al., 2006, Qazi et al., 2006, Roza et al., 2002). The results of this survey show that the 
research into therapeutic and generic substitution may be problematic. Healthcare 
providers and payers including health insurance companies, in countries outside the NHS 
system, are promoting generic substitution and are not prepared to consider that there 
may be a problem in that patient outcomes could be detrimentally affected. To do so 
would reduce the potential savings from these substitutions (Cox et al., 1978, Kingma et 
al., 1997, Helderman et al., 2010) and might lay the providers open to legal redress from 
patients adversely affected by the substitution policies. They also fail to get patients’ 
valid and legal consent to treatment when they switch treatments without explaining their 
reasons to the patients.  
Overall, according to the results of this chapter, patients’ decisions about and acceptance 
of generic substitution are likely to be multi-faceted. A number of factors such as 
patients’ education, knowledge, severity of the disease, efficacy of the generic medicines 
and patients’ involvement in decisions regarding their health appear to drive patients’ 
attitudes towards generic medicines and substitution. A lack of transparency around 
generic medicines and substitution was clearly marked in this survey and other surveys in 
the literature (Michaela and Lassanova, 2008). Many patients, with or without experience 
in generic substitution, were sceptical about generic medicines. Therefore, generic 
substitution necessitates patient education and additional time to provide more 
information and reassurance.  
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3.6 Main limitations of the study 
Limitations of this study include that the view of generic substitution was mainly 
assessed from the renal patients’ point of view and not that of healthcare professionals. It 
is not clear if the healthcare professionals were already giving the necessary information 
about generic medicines and substitution. Another limitation include that this study was 
conducted to evaluate the attitudes of a specific group of patients, renal transplant 
recipients, who should be well informed about their medications and may be particularly 
affected by generic substitution; therefore, generalising the results to a wider patient 
population as whole is not appropriate. A similar study is required to evaluate the 
healthcare professionals’ and a more general patient population views towards generic 
medicines and substitution. 
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4 Chapter 4 Patients’ and physicians’ views on generic 
prescribing and substitution: Example from the United 
Arab Emirates (UAE)  
4.1 A multicentre study to determine renal patients’ views on 
generic substitution in the United Arab Emirates (UAE) 
This chapter was accepted for publication as an original article in the Eastern 
Mediterranean Health Journal (EMHJ) by the World Health Organisation (WHO) on 
November, 2011, manuscript number 11/112 (Appendix 19) 
4.1.1 Introduction 
In the last two decades healthcare costs have been increasing globally. For example, the 
UK spending on drugs represents over 10% of its total budget and has increased steadily 
over recent decades (Nabholtz et al., 1999). In 2010, in the UAE, it was reported that the 
consumption of medicine has reached £700 Million (Alittihad Newspaper, March 5th, 
2011). As result, there is an urgent move in the UAE to reduce inefficiency in the 
healthcare and pharmaceutical sectors. Therefore, the Health Authority in Abu-Dhabi has 
announced that there is a need to adopt more cost-effective drug procurement strategies, 
including the use of generic substitution (Pharma and Healthcare, 2010).  
The free healthcare system in the UAE has resulted in an increase in the total medical 
expenditure. In addition, UAE has a large expatriate population and for their healthcare 
needs they used to depend upon government hospitals until the health insurance scheme 
was introduced (Nambiar, 2005). Therefore, encouraging effective generic substitution 
via involving patients’ in their health decisions is becoming essential. About 85% of the 
UAE pharmaceutical market consists of branded products. Therefore, the present rule of 
drug substitution in the UAE is branded based. In the past few years, the private health 
insurance scheme has grown dramatically in the UAE. This, as a consequence, 
empowered the regulators’ ability to coordinate healthcare development in a direction 
that is beneficial to both the consumer and the pharmaceutical industry (Datamonitor, 
2009). In addition to prohibiting direct to consumer marketing, a new rule has been 
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implemented in the UAE requiring physicians to prescribe using chemical names and by 
choosing from a list of medicines, drug formularies, to overcome the influence of 
pharmaceutical companies (Datamonitor, 2009).  
There are many articles in the literature exploring the medical views on generic and 
therapeutic substitution (Bandolier, 2007, Kereiakes and Willerson, 2003, Phillips et al., 
2007, Snow et al., 2003). Other articles explored that drug substitution and prescribability 
can easily mislead patients and physicians by supporting misconceptions about generic 
drugs and substitution (Christians et al., 2010, Heisterberg, 2011). For example, some 
articles would state that once bioequivalence is established, patients can be freely 
switched from one version of an immunosuppressant to another without experiencing 
clinical relevant loss of efficacy or exposure to an increase risk of toxicity (Christians et 
al., 2010, Heisterberg, 2011). However, this is considered a misconception (Johnston et 
al., 2004, Meredith, 2003).  
Cost is a very important factor in drug substitution and prescribability—the physician’s 
first choice for prescribing between a branded and its generic counterpart medicine for a 
new patient (Chow, 1999). Drug substitution can be considered more critical than drug 
prescribability for patients who have been on a branded medicine for a period of time. As 
mentioned earlier in this thesis, there are some safety and ethical issues surrounding 
switching patients from a drug to another (AlAmeri et al., 2010, Duerden and Hughes, 
2010). However, it is proven globally that promoting generic substitution will save 
money. For example, generic substitution could lower the NHS’s brand medicine bill by 
£80 million based on a peak yearly spend of £8 billion (American Cancer Society, 2010). 
Likewise, in Germany, health insurance could save €1.5 billion if prescriptions were fully 
generically dispensed (Mannion, 2011). In the US, 11% ($9 billion) of the total 
prescription costs was also saved by promoting generic substitution (Haas, 2005). Similar 
savings have occurred in healthcare systems around the world, including developing 
countries (Andersson et al., 2005, Haas, 2005, Tilson et al., 2005).  
In general, there are some challenging factors affecting the promotion of generic 
substitution. Those include, for example, that most pharmacies in the government 
hospitals in the UAE do not promote generic substitution which became a huge burden of 
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the cost of treatment. Physicians are also prescribing medicines by their trade names 
(Datamonitor, 2009). Despite the availability of numerous generics for some outside 
patent brands, physicians still prescribe the branded form. For example, the branded 
prescribing of Augmentin®, Glucophage®, Voltaren® and Zocor® is still growing despite 
generic competition (Datamonitor, 2009). Therefore, the two studies in this chapter will 
evaluate patients’ and physicians’ views on generic prescribing and substitution in the 
UAE. 
4.1.2 Objective 
The objective of this study was to examine the current renal patients’ awareness and 
understanding of generic drugs and substitution in the United Arab Emirates.  
4.1.3  Method 
This is a multicentre survey conducted in two hospitals in the United Arab Emirates (the 
UAE General Hospital and the UAE University Hospital). The original names of both 
hospitals were kept anonymous to comply with their rules. This survey was approved by 
the administration of the UAE General Hospital and by Al Ain Medical District Human 
Research Ethics Committee- Protocol No. 10/64. The ethics approval, protocols, and the 
questionnaires of this chapter are shown in Appendix 5, Appendix 6, Appendix 7 and 
Appendix 8. The ethics approval of this study required six months. 
According to the study protocol, a minimum of 100 patients were intended to be included 
in the survey. However, clinical pharmacists and nurses in the participating hospitals 
were able to recruit a total of 188 renal patients (101 patients treated at the UAE General 
Hospital and 87 patients treated at the UAE University Hospital). It was difficult to 
recruit more patients during the regular clinic hours because of time constraints. The aim 
and the protocol of the survey were explained and discussed with the medical 
professionals involved in the study in both hospitals. Renal patients over 18 years, able to 
read and write Arabic and/or English, and willing to fill in the questionnaire were 
targeted.  
This specific group of patients were selected in this survey because they are considered 
more general group than the renal transplant patients in the previous UK study (Al Ameri 
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et al., 2011b). In addition, any small changes in the medicinal effect of this group of 
patients can still negatively impact their clinical outcome. This survey was related to all 
medication and not only immunosuppressant agents. A questionnaire translated into 
Arabic and consisting of 36 (in the UAE General Hospital) and 37 (in the UAE 
University Hospital) multiple choice closed questions was used as the tool to obtain the 
required information (Table 6). The UAE University Hospital requested an additional 
question about whether the participant was a UAE citizen at the time of filling in the 
questionnaire for the hospital internal use.  
The questionnaire was piloted and validated in the Renal Clinic, Royal London Hospital 
in the UK (Al Ameri et al., 2011b). No additions or deletions were required; therefore, 
the study started directly after the validation. Patients were recruited by clinical 
pharmacists and nursing staff as patients booked in for a clinic visit over a period of six 
months (from 01/07/2010 to 01/01/2011 in the UAE General Hospital and from 
01/03/2011 to 01/09/2011 in the UAE University Hospital). After reviewing the 
information sheet which contained a short introduction in English or Arabic about generic 
medicines and substitution, patients consented by choosing to fill in the questionnaire.  
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Table 6: The content of the questionnaire used in the survey to determine the views 
of renal transplant patients in the UAE. 
No. Questions Multiple choices 
1. Sex [  ] Male     [  ] Female 
2. Age ___________ Years 
3. Are you a UAE citizen?iii [  ] Yes        [  ] No 
4. Number of different medications taken 
each day? 
[  ] 1 – 3      [  ] 4 - 6  
[  ] 7 - 9      [  ] > 9  
5. What is the highest level of 
education you have completed? 
[  ] Secondary school (GCSE)   
[  ] Vocational Training (e.g. Apprenticeship) 
[  ] Sixth form (A-level or equivalent) 
[  ] College  
[  ] University (First degree) 
[  ] Postgraduate  
6. If you have had an organ transplant, when 
was the transplant taken place? 
[  ] Less than a year ago  
[  ] More than a year ago 
[  ] I haven’t had transplantation 
7. Were you aware in general that 
there may be different forms of the 
same medicine available, produced 
by different manufacturers? 
[  ] Yes 
[  ] No 
[  ] Don’t know 
8. Do you understand the terms “generic” 
and “branded” in relation to medicines? 
[  ] Yes – go to question 9 
[  ] No – go to question 10 
[  ] Uncertain – go to question 9 
9. Does it matter to you if the 
medicines that you are taking are 
generic or original branded forms? 
 
[  ] Yes 
[  ] No 
[  ] Uncertain 
[  ] It depends (please specify) 
10. Are you aware of the practice of generic 
substitution? 
[  ] Yes, I am  
[  ] No, I am not  
[  ] Don’t know  
11. Were you aware that the practice of 
generic substitution involves 
switching between a branded 
product and a generic version of the 
same medicine? 
[  ] Yes, I am 
[  ] No, I am not 
[  ] Don’t know 
12. Do you know if you are currently taking 
any generic prescription medications? 
[  ] Yes, I am – go to question 13 
[  ] No, I am not – go to question 17 
[  ] Don’t know – go to question 17 
13. How satisfied are you with the 
generic alternative that you are 
taking? 
 
[  ] Very satisfied 
[  ] Dissatisfied 
[  ] Neither very satisfied nor dissatisfied 
14. Have you experienced any 
differences in terms of the 
effectiveness or side effects between 
the branded and generic medicine? 
[  ] Yes – go to question 15 
[  ] No – go to question 17 
[  ] Uncertain 
15. What were the differences between the 
branded and generic medicines that you 
have experienced? (Mark all that apply) 
[  ] Packaging  
[  ] Shape, colour or taste 
[  ] The brand is more effective 
                                                 
iii
 This question was only asked to participants from the UAE University Hospital for their internal use. 
Chapter 4 UAE patient survey 
Page 113 of 446 
No. Questions Multiple choices 
[  ] The generic is more effective 
[  ] The brand has more side-effects 
[  ] The generic has more side-effects  
[  ] Others, please describe 
16. Do you think adapting to these 
differences was a concern? 
[  ] Agree  
[  ] Disagree 
[  ] Uncertain 
17. Do you think that receiving a generic 
medicine might affect how regularly you 
take your medicines? 
[  ] Agree  
[  ] Disagree 
[  ] Uncertain 
18. Do you think that generic medicines 
are equivalent and have the same 
quality as the branded medicines?  
[  ] Agree- always  
[  ] Disagree- always 
[  ] Yes- Sometimes 
[  ] Uncertain 
19. If you have a mild condition such as flu 
or headache, would you consider taking 
generic medicines? 
[  ] Yes 
[  ] No 
[  ] Uncertain 
[  ] It depends (please specify) 
20. If you have a chronic condition such 
as high blood pressure or diabetes, 
would you consider taking generic 
medicines? 
[  ] Yes 
[  ] No 
[  ] Uncertain 
[  ] It depends (please specify) 
21. Were you aware that a generic form 
of ciclosporin (sometimes spelt 
cyclosporine) will be available very 
soon in the UAE? 
[  ] Yes     
[  ] No 
[  ] Uncertain 
22. Would you agree to switch your current 
branded ciclosporin to a generic form to 
save the NHS (National Health Service) 
money? 
[  ] Agree  
[  ] Disagree 
[  ] Uncertain 
23. In general, how far do you feel that 
your doctor involves you in 
decisions regarding your 
medications? 
[  ] A lot 
[  ] A bit 
[  ] Not at all 
[  ] Don’t know 
24. Do you think that you should be 
consulted about being given generic 
medications? 
[  ] Yes- only by GP 
[  ] Yes – only by hospital specialists 
[  ] Agreement of both GP and hospital specialist 
[  ] Do not think that this is necessary. 
25. Has your doctor ever told you to make 
sure that you always receive the same 
brand of any medicine? 
[  ] Yes 
[  ] No 
[  ] Don’t know 
26. Has your doctor ever changed your 
medicine to a generic form? 
[  ] Yes – go to question 27 
[  ] No – go to question 36 
[  ] Don’t know – go to question 36 
27. Would you agree to switch your 
medicine to a generic alternative if 
your doctor felt that the two 
medications were interchangeable?  
[  ] Agree  
[  ] Disagree 
[  ] Uncertain 
28. Did anyone discuss the reasons for 
switching your medicine to the 
generic form?  
[  ] Yes — go to question 29 
[  ] No — go to question 30 
[  ] Don’t know — go to question 30 
29. Who discussed the reasons for 
switching your medicine to the 
generic form? (Mark all that apply) 
[  ] Specialists 
[  ] Hospital Doctor 
[  ] General Practitioner (GP) 
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No. Questions Multiple choices 
[  ] Pharmacist 
[  ] Nurse 
[  ] Others, please describe 
30. Which of the following do you 
think may be potential reasons for 
switching your medicine from a 
brand to a generic? (Mark all that 
apply) 
[  ] Save money for the NHS (National Health 
Services) 
[  ] The generic medicine is more effective. 
[  ] The generic medicine has same effectiveness and 
less costs. 
[  ] The branded medicine was not available anymore. 
[  ] Others, please describe 
31. Did your doctor monitor the effect 
of your medicine after switching 
you to a generic form? 
[  ] Yes 
[  ] No 
[  ] Don’t know 
32. Did anyone provide you with 
background information about your 
generic medicine? 
[  ] Yes – go to question 33 
[  ] No – go to question 36 
[  ] Don’t know 
33. Who provided you with background 
information about your generic 
medicine? (Mark all that apply) 
[  ] Specialist 
[  ] Hospital Doctor 
[  ] General Practitioner (GP)  
[  ] Pharmacist 
[  ] Nurse 
[  ] Others, please describe. 
34. If you got information on your 
generic medicine, how did you get 
the information? (Mark all that 
apply) 
 
[  ] Verbally  
[  ] Written  
[  ] Web/ internet 
[  ] Other, please describe 
[  ] Not applicable as no information received 
35. Did you consider the information 
provided about your generic 
medicine to be sufficient? 
[  ] Yes 
[  ] No 
[  ] Uncertain 
36. How much would you favour or 
oppose a requirement that patients 
always be notified if their medicine 
is changed to a generic form? 
[  ] Favour 
[  ] Oppose 
[  ] Neither favour nor oppose 
37. Would you agree to switch to a 
generic if initiated by your hospital 
consultant/doctor, general 
practitioner, pharmacist or nurse i.e. 
NOT by your specialist? 
Hospital Consultant/ Doctor: 
[  ] Agree [  ] Disagree [ ] Uncertain 
General Practitioner (GP): 
[  ] Agree [  ] Disagree [  ] Uncertain 
Pharmacist: 
[  ] Agree [  ] Disagree [  ] Uncertain 
Nurse: 
[  ] Agree [  ] Disagree [  ] Uncertain 
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4.1.4 Results 
The data from the questionnaire were collected and analysed using Microsoft Office 
Excel 2007 and Minitab 16 Statistical Software (made by “Minitab Inc”, Pennsylvania, 
USA). Results of all questions put to patients in the survey were reported and expressed 
as % [95% Confidence Intervals (CI)]. The missing values were not included in the 
calculations of percentages; the total number (n) of respondents for each question is given 
in parentheses after each question.  
According to the survey, a total of 188 [122 (65%) male and 66 (35%) female] patients 
with an average age of 49.5 years [range (18-86), median (50)] were included in this 
study (Figure 44). About half 42/86 [49% (95% CI 38-60)] of the participated patients in 
the UAE University Hospitals were UAE citizens (Figure 45). The majority [80% (95% 
CI 74-86)] of the participating patients confirmed that they did not have kidney 
transplantation but were on kidney dialysis at the time of filling in the survey (Figure 
46). In addition, more than three quarters [78%, (95% CI 72-84)] of the patients were 
taking between 1 and 6 medications [34% (95% CI 27-41) were taking between 1-3 
medications and 44% (95% CI 37-52) were taking between 4 and 6 medications] (Figure 
47). Moreover, a total of 95/161 participants [59% (95% CI 51-67)] were considered 
highly educated (graduated from college, university or postgraduate), and 66/161 
participants [41% (95% CI 33-49)] were considered less educated (graduated from 
secondary school, vocational training or sixth forms) (Figure 48 and Table 7). 
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Table 7: Demographics of the participating patients (n=67). 
Demographics Number of responders Percentages (%) of 
responders 
95% Confidence 
Intervals 
Gender (n*=188) 
        Male 
        Female  
 
122 
66 
 
65 
35 
 
(58-72) 
(28-42) 
Age distribution (n*=186) 
        39 years or less 
        40-49 years 
        50-59 years 
        60 years or more 
 
41 
48 
59 
38 
 
22 
26 
32 
20 
 
(16-29) 
(20-33) 
(25-39) 
(15-27) 
Number of medications 
taken daily (n*=184): 
        1-3 medications 
        4-6 medications 
        7-9 medications 
        > 9 medications 
 
 
62 
82 
18 
22 
 
 
34 
44 
10 
12 
 
 
(27-41) 
(37-52) 
(6-15) 
(8-18) 
The time of organ 
transplant (n*=186) 
        Less than a year ago 
        More than a year ago 
        Only dialysis 
 
 
8 
29 
149 
 
 
4 
16 
80 
 
 
(2-8) 
(11-22) 
(74-86) 
The level of education 
(n*=161) 
        Secondary School 
        Vocational training 
        Sixth form, Diploma 
        College 
        University 
        Postgraduate 
 
 
46 
20 
0 
29 
53 
13 
 
 
29 
12 
0 
18 
33 
8 
 
 
(22-36) 
(8-19) 
(0-2) 
(12-25) 
(26-41) 
(4-13) 
*The total number of patients who responded to the question. 
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Figure 44: The age distribution of the participating patients (n=186). 
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Figure 45: The percentage of the UAE citizens who participated in the UAE 
University Hospital (n=86). 
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Figure 46: The time of organ transplant of the participating patients (n=186). 
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Figure 47: The number of medications taken by the participating patients (n=148).  
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Figure 48: The level of education of the participating patients (n=161). 
The questionnaire was divided into three sections as follows: 
4.1.4.1 Patients’ general knowledge about generic medicines and 
substitution 
On one hand, many patients [70%, (95% CI 64-77)] admitted that they were aware of the 
availability of different forms of the same medicine in the pharmacy (Figure 49). Others 
[60% (95% CI 53-67)] claimed that they understood the term “generic” and “branded” in 
relation to medicines (Figure 50). Moreover, 64% (95% CI 57-71) of patients reported 
that they were aware of generic substitution practice (Figure 51) and more than half 
[51% (95% CI 43-58)] were able to define generic substitution practice (Figure 52). On 
the other hand, 72% (95% CI 64-78) were not sure and did not know if they were taking 
generic medicines (Figure 53). In addition, 68% (95% CI 60-74) of patients felt that 
generics were not equivalent or only equivalent sometimes, and they were uncertain that 
generics had the same quality as branded medicines (Figure 54). Many patients [85% 
(95% CI 78-90)] were unaware and uncertain about the availability of the generic form of 
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ciclosporin in the global market (Figure 55) and 47% (95% CI 40-55) admitted that they 
would refuse generic substitution of ciclosporin when it became available in hospitals 
(Figure 56). In addition 24% (95% CI 18-31) were confused and unsure if they will 
accept the generic substitution of ciclosporin (Figure 56 and Table 8). 
Table 8: Questions and responses evaluating renal patients’ general knowledge of 
generic medicines and substitution. 
Questions Answers 
 
Number  
of 
responders 
Percentages 
of 
responders 
95% of 
Confidenc
e Intervals 
Were you aware that there are 
different forms of the same 
medicine available, produced by 
different manufacturers? (n*= 85) 
Yes 
No 
Uncertain 
130 
32 
23 
70 
17 
13 
(63-77) 
(12-24) 
(8-18) 
Do you understand the terms 
“generic” and “branded” in relation 
to medicines? (n*=185) 
Yes 
No 
Uncertain 
111 
61 
13 
60 
33 
7 
(53-67) 
(26-40) 
(4-12) 
Are you aware of the generic 
substitution practice? (n*=185) 
Yes 
No 
Uncertain 
119 
18 
48 
64 
10 
26 
(57-71) 
(6-15) 
(20-33) 
Were you aware that generic 
substitution involves switching 
between brand and generic 
medicines? (n*=182) 
 
Yes 
No 
Don’t Know 
 
92 
31 
59 
 
51 
17 
32 
 
(43-58) 
(12-23) 
(26-40) 
Do you know if you are currently 
taking any generic prescription 
medications? (n*=183) 
Yes 
No 
Uncertain 
52 
72 
59 
29 
39 
32 
(22-36) 
(32-47) 
(26-40) 
Were you aware that a generic form 
of ciclosporin is available in most of 
the hospitals abroad? (n*=138) 
Yes 
No 
Uncertain 
21 
110 
7 
15 
80 
5 
(10-22) 
(72-86) 
(2-10) 
Would you agree to switch your 
current branded ciclosporin to a 
generic form to save the local health 
authority money? (n*=178) 
Agree 
Disagree 
Uncertain 
51 
84 
43 
29 
47 
24 
(22-36) 
(40-55) 
(18-31) 
Do you think that generic medicines 
are equivalent and have the same 
quality as the branded medicines? 
(n*=182) 
Agree-always 
Disagree-always 
Yes- sometimes 
Uncertain 
59 
53 
4 
66 
33 
29 
2 
36 
(26-40) 
(23-36) 
(0-6) 
(29-44) 
*The total number of patients who responded to the question. 
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Figure 49: The responses of patients when asked if they were aware of the 
availability of different forms of the same medicine, produced by different 
manufacturers (n=185). 
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Figure 50: The responses of patients when asked if they understood the terms 
“generic” and “branded” in relation to medicines (n=185). 
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Figure 51: The responses of patients when asked if they were aware of the generic 
substitution practice (n=185). 
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Figure 52: The responses of patients when asked if they were aware that generic 
substitution involves switching between brand and generic medicines 
(n=182). 
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Figure 53: The responses of patients when asked if they knew whether they were 
taking any generic prescription medications (n=183). 
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Figure 54: The responses of patients when asked if they thought that generic 
medicines were equivalent and had the same quality as the branded 
medicines (n=182). 
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Figure 55: The responses of patients when asked if they were aware of the 
availability of the generic form of ciclosporin in most of the hospitals 
abroad (n=138). 
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Figure 56: The responses of patients when they were asked if they would agree to 
switch their current branded ciclosporin to a generic form to save the local 
health authority money (n=178). 
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The effect of education on patients’ acceptance of generic medicines and substitution was 
clearly marked in this survey. A total of 93 highly educated patients (graduated from 
college, university or postgraduate) responded to a question evaluating their awareness of 
generic substitution practice. Of these 78 [84% (95% CI 75-91) had admitted that they 
were aware of the substitution practice. Alternatively, from a total of 64 less educated 
(graduated from secondary school, vocational training or sixth forms) patients who 
responded to the same question, 29 [45% (95% CI 33-58)] were aware of the generic 
substitution practice (Figure 57).  
Furthermore, from a total of 92 highly educated patients who responded to a question 
concerning their acceptance of generic substitution of ciclosporin, 36 [39% (95% CI 29-
50)] confirmed that they would accept generic substitution of ciclosporin. Alternatively, 
from a total of 62 less educated renal patients who responded to the same question, only 
11 patients [18% (95% CI 9-30)] confirmed that they would accept the generic 
substitution of ciclosporin (Figure 58). Another question was asked to evaluate the 
differences between the satisfaction from generic drugs between the highly and less 
educated patients. From a total of 36 highly educated patients who answered this 
question, almost half of patients 17 [47% (95% CI 30-65)] expressed that they were very 
satisfied with generics. In comparison, from a total of 26 less educated patients who 
answered the same question, only 6 patients [23% (95% CI 9-44)] expressed that they 
were very satisfied with generic medicines (Figure 59). 
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Figure 57: The answers of educated and less educated patients when asked if they 
were aware of the generic substitution practice (n=157).  
39.13%
17.74%
0
10
20
30
40
50
60
70
Highly 
educated 
patients* 
(n= 92)
Less 
educated 
patients** 
(n=  62)
%
 o
f 
p
a
ti
e
n
ts
Agree
Disagree
Uncertain
 
*graduated from college, university or postgraduate, **graduated from secondary school, vocational 
training or sixth form. 
Figure 58: The answers of educated and less educated patients when asked if they 
would accept the generic substitution of ciclosporin (n=124). 
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Figure 59: The answers of educated and less educated patients when asked if they 
were satisfied with generic substitution (n= 62).  
4.1.4.2 Patients’ attitudes towards generic medicines and 
substitution 
Most patients [66% (95% CI 53-77)] receiving generic medicines were dissatisfied or 
uncertain about their satisfaction concerning generic medicines (Figure 60). A total of 
44% (95% CI 33-56) had experienced noticeable differences between the branded and the 
generic medicines (Figure 61). Of these, 74% (95% CI 64-82) reported that the main 
differences were noticed in that the branded medicines were more effective than their 
generic counterparts, packaging and shape (Figure 62). Of these 81% (95% CI 67-90) 
were uncertain about the consequence of these differences and admitted that adapting to 
these differences was a problem (Figure 63).  
In addition, 67% (95% CI 59-74) of participants were uncertain and felt that the generic 
medicines might affect their adherence to the medication regime (Figure 64). A total of 
73% (95% CI 65-79) declared that it is matter to them if their medicine was substituted 
by alternative generics (Figure 65). When patients were asked about the potential reasons 
for promoting generic substitution, many (94%, 95% CI 89-97) believed that substitution 
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was mainly promoted to reduce healthcare costs and because the branded medicine was 
not available as well as that generics have the same effectiveness as the branded 
medicines (Figure 66 and Table 9). 
Table 9: Questions and responses evaluating renal patients’ attitudes towards generic 
medicine and substitution. 
Questions Choices Number of 
responders 
Percentages (%) 
of responders 
95% 
Confidence 
Intervals 
How satisfied are you 
with the generic 
alternative that you are 
taking? (n*=70) 
Very satisfied 
Dissatisfied 
Neither very 
satisfied nor 
dissatisfied 
24 
20 
 
 
26 
34 
29 
 
 
37 
(23-47) 
(18-41) 
 
 
(26-50) 
Have you experienced 
any differences in terms 
of the effectiveness or 
side effects between the 
branded and generic 
medicine? (n*=72) 
Yes 
No 
Uncertain 
32 
31 
9 
44 
43 
13 
(33-57) 
(31-55) 
(6-22) 
What were the 
differences between the 
branded and generic 
medicines that you have 
experienced? (n*=107)  
Packaging 
Shape, colour or 
taste 
The brand is more 
effective 
The generic is 
more effective 
The brand has 
more side-effect 
The generic has 
more side-effect 
Others 
26 
 
22 
 
31 
 
3 
 
2 
 
22 
1 
24 
 
20 
 
29 
 
3 
 
2 
 
21 
1 
(17-34) 
 
(13-29) 
 
(21-39) 
 
(0-8) 
 
(0-7) 
 
(13-29) 
(0-5) 
Do you think adapting to 
these differences was a 
concern? (n*=52) 
Agree 
Disagree 
Uncertain 
24 
10 
18 
46 
19 
35 
(32-61) 
(10-33) 
(22-49) 
Do you think that 
receiving a generic 
medicine might affect 
how regularly you take 
your medicines? 
(n*=174) 
Agree 
Disagree 
Uncertain 
48 
58 
68 
28 
33 
39 
(21-35) 
(26-41) 
(32-47) 
Which of the following 
do you think may be 
potential reasons for 
switching your medicine 
to the generic form? 
(n*=153) 
Save the NHS 
money 
Generics are more 
effective 
Generics have the 
same 
effectiveness and 
less costs 
The branded 
medicine was not 
available 
Others 
 
56 
 
8 
 
 
 
43 
 
 
45 
1 
 
37 
 
5 
 
 
 
28 
 
 
29 
1 
 
(29-45) 
 
(2-10) 
 
 
 
(21-36) 
 
 
(22-37) 
(0-4) 
*The total number of patients who responded to the question. 
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The severity of the disease had also shown an influence on patients’ acceptance of 
generic substitution. Patients were asked about their potential acceptance of generic 
substitution if they were diagnosed with mild versus chronic disease, irrespective of their 
renal condition. According to this survey, half 92/183 [50% (95% CI 43-58)] of the 
participating patients who responded to this question admitted that they would accept 
generic substitution if they had mild disease compared to only 43/181 [24% (95% CI 18-
31) who would still do so if they had a chronic disease (Figure 67). 
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Figure 60: The responses of patients when asked about their satisfaction with the 
generic alternative that they were taking (n=70). 
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Figure 61: The responses of patients when asked if they had experienced any 
differences in terms of the effectiveness or side effects between the 
branded and generic medicine (n=72). 
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Figure 62: The responses of patients when asked about the differences between the 
branded and generic medicines that they had experienced (n=107). 
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Figure 63: The responses of patients when asked if they thought adapting to these 
differences was a concern (n=52). 
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Figure 64: The responses of patients when asked if they thought that receiving a 
generic medicine might affect how regularly they took their medicines 
(n=174). 
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Figure 65: The responses of patients when they were asked if it was a concern for 
them to be prescribed generic medicines (n= 153). 
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Figure 66: The responses of patients when asked about the potential reasons for 
switching their medicine to the generic form (n=153). 
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Figure 67: The responses of renal patients when asked about their potential 
acceptance of generic substitution if they were diagnosed with mild versus 
chronic disease, irrespective of their renal transplant. 
4.1.4.3 The influence of professionals on patients’ acceptance of 
generic medicines and substitution. 
According to the survey, half of the participating patients (50%, 95% CI 43-58) reported 
that their doctor had changed their medicine to a generic form (Figure 68). The majority 
of these patients [87% (95% CI 79-93)], however, stated that they were not monitored or 
were uncertain about being monitored after switching their medicine to a generic (Figure 
69). Moreover, 53% (95% CI 45-61) of patients did not know and felt that they had been 
involved to a small degree or not at all in decisions regarding their health (Figure 70) and 
more than half [54% (95% CI 45-64)] declared that no background information regarding 
generics and substitution was provided (Figure 71).  
According to 26% (95% CI 20-33) of patients, pharmacist was the main source of 
information, if given, regarding generic substitution (Figure 72). Of these, 74% (95% CI 
64-84) admitted that most information was given in a verbal form (Figure 73). Yet, 52% 
(95% CI 39-65) of patients were uncertain about the information provided and considered 
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it to be insufficient (Figure 74). According to the survey, the reasons for switching their 
medicines were not discussed, at all, with 35/100 [35% (95% CI 26-45)] (Figure 75). In 
addition, 26% (95% CI 20-33) admitted that specialists were the most professional who 
discussed the reasons for switching their medicine to the generic form (Figure 76).  
A total of 81% (95% CI 75-87) of patients declared that their doctors never informed 
them about whether they should always receive branded or generic medicine (Figure 77). 
Nevertheless, 88% (95% CI 83-92) wished to be always notified when switching their 
medicines (Figure 78). Nevertheless, 71% (95% CI 61-80) of patients admitted that they 
would agree to switch their medicine to a generic alternative if their doctor felt that the 
two medications were interchangeable (Figure 79).  
More than half of participating patients (59%, 95% CI 51-66), believed that they should 
be consulted only by the hospital specialists or by both the general practitioner (GP) and 
the hospital specialist before switching their medicine (Figure 80). Nevertheless, about 
69% (95% CI 63-76) of patients admitted that they would be more likely to accept 
generic substitution, if it was initiated by a hospital consultant (Figure 81).  
Table 10: Questions and responses evaluating healthcare professionals’ roles on 
renal patients’ acceptance of generic substitution. 
Questions Choices Number  
of 
responders 
Percentages 
of 
responders 
95% 
Confidence 
Intervals 
Has your doctor ever changed 
your medicine to a generic 
form? (n*=179) 
Yes 
No 
Uncertain 
90 
47 
42 
50 
26 
24 
(43-58) 
(20-33) 
(17-30) 
Did your doctor monitor the 
effect of your medicine after 
switching you to a generic 
medicine? (n*=106) 
Yes 
No 
Uncertain 
14 
50 
42 
13 
47 
40 
(7-21) 
(37-57) 
(30-50) 
In general, how far do you feel 
that your doctor involves you in 
decisions regarding your 
medications? (n*=175) 
A lot 
A bit 
Not at all 
Uncertain 
82 
71 
18 
4 
47 
41 
10 
2 
(39-54) 
(33-48) 
(6-16) 
(0-6) 
Did anyone provide you with 
background information about 
your generic medicine? 
(n*=105) 
Yes 
No 
Uncertain 
40 
57 
8 
38 
54 
8 
(29-48) 
(44-64) 
(3-14) 
Who provided you with 
background information about 
your generic medicine? 
(n*=168) 
Specialist 
Hospital doctor 
General practitioner 
Pharmacist 
Nurse 
Others 
38 
39 
39 
44 
6 
2 
23 
23 
23 
26 
4 
1 
(17-30) 
(17-30) 
(17-30) 
(20-34) 
(1-8) 
(0-4) 
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Questions Choices Number  
of 
responders 
Percentages 
of 
responders 
95% 
Confidence 
Intervals 
If you got the information on 
your generic medicine, how did 
you get the information? (n*= 
76) 
Verbally 
Written 
No information 
received 
Web/ internet 
Other 
56 
8 
 
5 
7 
0 
74 
10 
 
7 
9 
0 
(62- 83) 
(5- 20) 
 
(2- 15) 
(4- 18) 
(0- 4) 
Did you consider the 
information provided about 
your generic medicine 
sufficient? (n*=63) 
Yes 
No 
Uncertain 
30 
12 
21 
48 
19 
33 
(35-61) 
(10-31) 
(22-46) 
Did anyone discuss the reasons 
for switching your medicine to 
the generic form? (n*=100) 
Yes 
No 
Uncertain 
65 
33 
2 
65 
33 
2 
(55-74) 
(24-43) 
(0-7) 
Who discussed the reasons for 
switching your medicine to the 
generic form? Choose all 
applicable (n*=194) 
Specialist 
Hospital doctor 
General practitioner 
Pharmacist 
Nurse 
Others 
51 
45 
41 
49 
8 
0 
26 
23 
22 
25 
4 
0 
(20-33) 
(17-30) 
(16-28) 
(19-32) 
(2-8) 
(0-2) 
Has your doctor ever told you 
to make sure that you always 
receive the same brand of any 
medicine? (n*=175) 
Yes 
No 
Uncertain 
29 
142 
4 
17 
81 
2 
(11-23) 
(75-87) 
(0-6) 
Would you agree to switch your 
medicine to a generic 
alternative if your doctor felt 
that the two medicines were 
interchangeable? (n*=104) 
Agree 
Disagree 
Uncertain 
74 
17 
13 
71 
16 
13 
(61-80) 
(10-25) 
(7-20) 
How much would you favour or 
oppose a requirement that 
patients always be notified if 
their medicine is changed to a 
generic form? (n*=178) 
Favour 
Oppose 
Neither favour nor 
oppose 
156 
12 
 
10 
88 
7 
 
5 
(82-92) 
(4-11) 
 
(3-10) 
Do you think that you should 
be consulted about being given 
generic medicines? (n*=189) 
Yes- only by GP 
Yes- only by hospital 
specialist 
Agreement of both GP 
and hospital specialist 
Do not think that this is 
necessary 
26 
 
56 
 
55 
 
52 
14 
 
30 
 
29 
 
27 
(9-20) 
 
(23-37) 
 
(23-36) 
 
(21-34) 
*The total number of patients who responded to the question. 
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Figure 68: The responses of patients when asked if their doctors had ever changed 
their medicine to a generic form (n=179). 
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Figure 69: The responses of patients when asked if their doctors monitored the effect 
of their medicine after switching them to a generic medicine (n=106). 
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Figure 70: The responses of patients when asked about how far they felt that their 
doctor involved them in decisions regarding their medications (n=175). 
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Figure 71: The responses of patients when asked about if anyone provided them with 
background information about their generic medicine (n=105). 
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Figure 72: The responses of patients when asked about the main professional who 
had provided them with background information about their generic 
medicine (n=168). 
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Figure 73: The responses of patients when asked about the main form in which they 
had received their information (n=76). 
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Figure 74: The responses of patients when asked if they considered the information 
provided about their generic medicine sufficient (n=63). 
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Figure 75: The responses of patients when asked if anyone discussed the reasons for 
switching their medicine to the generic form (n=100). 
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Figure 76: The responses of patients when asked about the main professional who 
had discussed the reasons for switching their medicine to the generic form 
(n=194). 
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Figure 77: The responses of patients when asked if their doctors had ever told them to 
make sure that they always receive the same brand of any medicine 
(n=175). 
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Figure 78: The responses of patients when asked if they would favour or oppose a 
requirement that patients always be notified if their medicine was changed 
to a generic form (n=178). 
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Figure 79: The responses of patients when asked if they would agree to switch their 
medicine to a generic alternative if their doctor felt that the two medicines 
were interchangeable (n=104). 
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Figure 80: The responses of patients when asked if they thought that they should be 
consulted about being given generic medicines (n=189). 
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Figure 81: The responses of patients when asked about the most healthcare 
professional that they would agree with to initiate their generic 
substitution.  
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4.1.5 Discussion 
According to the results of this chapter, many patients admitted that they were familiar 
with the availability of different formulations of the same medicine and understood the 
term generic versus branded medications. In addition, many patients were able to define 
the generic substitution practice. However, about three quarters of patients did not know 
whether their medicine had been substituted to a generic or if they were currently taking 
generic medicines. Several others were doubtful that generics have the same quality as 
the branded medicines. Therefore, they were not convinced and dissatisfied with generic 
medicines and substitution. It was clearly marked that these attitudes were mainly found 
in patients with less education, not involved in healthcare decisions and believed that 
substitution is mostly performed because of a shortage in healthcare budgets and in the 
availability of the branded medicine. These attitudes might also be related to the belief 
that the cheaper medicine must be inferior to the more expensive branded medicines 
(Meredith, 2003).  
Factors such as the level of education, knowledge, severity of the disease, effectiveness 
of generics and involving patients in decisions concerning their health played major roles 
in framing patients’ views and acceptance of generic substitution. For example, patients 
with a high level of education were more knowledgeable about their generic medicines 
and substitution; as a result they were more likely to accept generic substitution of 
ciclosporin than those with less level of education. However, this study explored that 
there are still some educated patients suspicious about the efficiency of generic medicine 
and substitution. This suspicion mostly occurred among patients who were not assured, 
by their healthcare professionals, about the safety and the effectiveness of the prescribed 
generic medicine.  
The severity of the disease was also found to be a factor framing the patients’ views and 
acceptance of generic substitution. For instance, many patients in this survey reported 
that they would be reluctant to accept generic substitution if they were diagnosed with 
chronic disease. This is also confirmed by other studies in the literature (Decollogny et 
al., 2011). For example, a study has shown that people’s beliefs and acceptance of 
generic drugs and substitution is associated with the nature of their illness (Figueiras et 
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al., 2008). Most renal patients, in this study, favoured to be always notified when 
switching their medicines. Many others admitted that they would agree to accept generic 
substitution, if they were directly informed and educated by their healthcare providers. 
This shows the clear need for educating patients, particularly in terms of clarifying the 
prevalence and processes by which generic substitution occurs and the potential roles of 
healthcare professionals in successfully introducing generic substitution.  
Patients also reported that most information given to them was by pharmacists in a verbal 
form. Yet, it is recommended that patients should be given information in a written form 
to allow reviewing and remembering the complex medical information whenever needed 
(Weinman, 1990). A survey in the literature evaluating the level of interaction between 
physicians and community pharmacists in the UAE revealed that 60% of physicians 
rarely or never discussed patients’ drug therapy with pharmacists (Abduelkarem and 
Sharif, 2008). Another survey conducted in the nearby Iraqi universities showed a lack of 
understanding among medical students on issues related to generic medicines (Sharrad 
and Hassali, 2011).  
The guidelines for approving bioequivalence of generic medicines in the UAE are mostly 
produced by the WHO, EMA, FDA and ICH. For example, to approve interchangeability 
between two medicines, they should be equivalent to one another through bioequivalence 
study, comparative clinical trials and/or in-vitro dissolution tests (Ministry of Health of 
the United Arab Emirates). However, findings in this survey clearly proposes tightening 
the regulations of accepting generic medicines and substitution in the UAE and 
encouraging patient monitoring after switching their medicines.  
The results obtained in this study are compatible with those in the existing literature. 
Although there are few published articles evaluating patients’ views on generic 
substitution in the UAE, most studies have shown that drug substitution can be 
problematic (Johnston et al., 2010, Meredith, 2003, Simoens, 2011). A large number of 
studies were also conducted to evaluate the potential effect of generic substitution on the 
clinical outcome (Cox et al., 1978, Johnston et al., 2010). Many other studies showed that 
there are differences in the pharmacokinetic profile between branded and generic drugs, 
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disparities that might affect clinical outcomes (Food and Drug Administration, 2009, 
Kovarik et al., 2006, Qazi et al., 2006, Roza et al., 2002, Taber et al., 2005).  
Overall, many patients were still sceptical of accepting generic medicines and 
substitution. They might consider cheaper drugs as being less effective and associated 
with increased adverse events. As a result, this can negatively affect patients’ adherence 
to their medication regime. In addition, the role and regulation surrounding generic 
bioequivalence and substitution should be strengthened to maintain high quality of care. 
Random generic substitution should not be implemented because there is uncertainty and 
lack of knowledge on the patients’ side. Thereby, proper patient education, monitoring 
and involving patients in decisions regarding their health would improve transparency 
around the generic substitution practice, enhance patients’ assurance and promote 
efficient prescribing.  
4.1.6 Main limitations of the study 
Limitations of this study include that the attitudes toward generic substitution were 
mainly assessed from the patients’ point of view and not from that of the healthcare 
professionals. It was not clear if the healthcare professionals were already giving the 
necessary information about generic medicines and substitution. This survey was done in 
selected patients in two hospitals in the United Arab Emirates; therefore, the results 
cannot generalise to the whole country or region. Further studies are needed to evaluate 
physicians’ views on generic prescribing and substitution. 
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4.2  Physicians’ attitudes towards generic prescribing and 
substitution: Example from the United Arab Emirates (UAE) 
4.2.1 Introduction 
The Ministry of Health (MOH) in the UAE is the main medicinal regulator. It regulates 
all clinical studies, approval reviews and post-marketing safety measures, licensing and 
various regulations applying to the development, manufacture, import, marketing, and 
proper use of drugs and medical devices. The current health system in the UAE for 
citizens is mainly based on a national insurance scheme in which patients would visit 
their physicians and get medications without paying fees. Among the responsibilities of 
the UAE MOH are supplying medications to all general practitioners (GPs), clinics and 
hospitals, maintaining and storing medications, and hiring healthcare professionals.  
Therefore, the government has to provide payments for all health services and all medical 
supplies without charging its citizens. As the result, the people of the UAE have access to 
a high standard of medical care and this has been applauded by the World Health 
Organisation (WHO) (Thomas et al., 2005). However, like other healthcare services, this 
forces the local health authority to consider all plausible options such as drug substitution 
to reduce costs to medication while maintaining high quality standards to use the 
financial savings to empower other medical fields. The MOH defines pharmaceutical 
equivalence as any pharmaceutical product that contains the same active ingredient, 
formulation, dosage form, route of administration, and sometimes the same excipients. 
All bioequivalence trials should be conducted according to the applicable principles of 
Good Laboratory Practice (GLP) and produced according to Good Manufacture Practice 
(GMP) (Thomas et al., 2005).  
In order for pharmaceutical companies to get approval to market generic drugs in the 
UAE, documents have to be submitted to the MOH. These include the name of the drug, 
the active ingredient(s), the formulation and route of administration, information about 
the formulation of the drug, laboratory data, indications, contraindication, side effects, 
bioequivalence study, the doses and the storage of the drug. If the drug is approved in an 
overseas country, the sponsor should provide all documents regarding the overseas’ 
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approval. As mentioned earlier in this thesis, drug substitution has been introduced in 
many countries to control pharmaceutical expenditure (Heikkila et al., 2007, Tilson et al., 
2005). In order to evaluate the success of drug substitution, physicians and patients’ 
attitudes toward drug substitution should be assessed. Patients’ views and attitudes 
towards generic substitution were evaluated in the current and previous chapters in this 
thesis. This study will mainly assess physicians’ views on generic prescribing and 
substitution. Physicians’ views are considered essential because they have the 
commitment to write prescriptions in which they choose the appropriate drugs to treat 
their patients. A prescription is defined as a physician’s first choice for an appropriate 
drug for a new patient between a branded and a number of its generic counterparts, which 
are considered bioequivalent (Chow, 1999).  
According to the literature, there are many factors influencing physicians’ acceptance of 
generic substitution. These include the physician’s concerns about pharmacists’ ability to 
substitute safely, and about the therapeutic equivalence of interchangeable medicines and 
they are also concerned about control over losing the medicines ultimately taken by 
patients (Brust et al., 1990). Therefore, many other studies have suggested that physicians 
should consider more intensive monitoring of high risk patients given generic medicines 
(Johnston et al., 2004, Masri, 2003). The British NHS has continuously stressed its 
determination to reduce costs and volume of prescription drugs and improve prescribing 
quality (Buetow et al., 1996).  
A systematic literature review conducted to determine the prevalence of potentially 
inappropriate long term prescribing in general practice in the UK from 1980 to 1995. In 
this review, it was found that prevalence of potentially inappropriate prescribing varied 
by indicators (such as indication, choice of drug, drug administration, communication and 
review) and chronic condition. The occurrence of inappropriate prescribing was 
confirmed in this study (Buetow et al., 1996). There were several potential factors that 
can be related to inappropriate prescribing. These include patient pressure on physicians 
to write unnecessary prescriptions, the tendency to continue patients, especially the 
elderly, on medications for a long time without proper review of their medication. In 
addition, while physicians are inundated with information about the availability and 
efficacy of drugs, they receive little information about actual drug costs in medical 
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school, in residency training, or once in practice. This shows that there is insufficient 
training in clinical pharmacology and failure of physicians to keep-up-to-date. 
In addition, many of the drugs on the market may not have been available when a general 
practitioner was at medical school. For example, a study was conducted to evaluate the 
knowledge and perceptions of recent pharmacy graduates about generic medicines. It 
revealed that more than 80% of participating young pharmacists believed that generics 
are inferior and less effective with more side effects than their branded counterpart 
medicines (Hassali et al., 2007). This clearly translates the general opinion of healthcare 
professionals on generic medicines and substitution. As a consequence, physician 
frequently prescribes branded drugs rather than cheaper generic equivalents, even if there 
was no conceivable therapeutic advantage (Andersson et al., 2006, Sharrad and Hassali, 
2011). 
4.2.2 Objective 
The objective of this study was to evaluate the physicians’ attitudes towards generic 
prescribing and substitution in the UAE. 
4.2.3 Method  
This was a quantitative retrospective survey based on analyzing written prescriptions 
written between 02/04/2010 and 01/07/2010 at the UAE General Hospital, United Arab 
Emirates. The name of the hospital was kept anonymous to comply with the hospital’s 
wishes. The ethics approval of this study was obtained from the administration of the 
UAE General Hospital (Appendix 6).  
A random 1,000 written prescriptions containing an average of seven medications was 
collected from the Pharmacy Department at the UAE General Hospital. Each prescription 
was written for an average of two month supply for patients with chronic disease. Only 
medicines used to treat chronic conditions were selected to be analysed (Table 11). These 
specific chronic medications were selected to clearly highlight the physicians’ attitudes 
towards generic and therapeutic substitution and to allocate factors that may affect 
physicians’ prescribing habits such as the disease state (chronic or mild). The results were 
collected and analysed using Microsoft Office Excel 2007 and Minitab 16 Statistical 
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Software (Minitab Inc”, Pennsylvania, USA). Results of all prescriptions in the survey 
were reported and expressed as % [95% Confidence Intervals (CI)]. 
Table 11: A list of medicines included in the study to evaluate physicians’ attitudes 
towards generic prescribing and substitution. 
Medication Indication 
Antihypertensive agents Treat high blood pressure 
Aspirin Antiplatelet to prevent heart attack, stroke and blood clot 
Digoxin Cardiac glycoside to treat heart conditions 
Immunosuppressant agents Prevent activity of the immune system to prevent the 
rejection of transplanted organs and tissues 
Anticholesterolamics Anticholesteremic agents to control elevated cholesterol 
Metformin Antidiabetic agent to treat type 2 diabetes 
Tenormin The most common antihypertensive agent to treat high 
blood pressure in the UAE General Hospital 
Warfarin Anticoagulant agent to prevent formation of blood clots 
4.2.4 Results  
A total of 1,000 written prescriptions collected in this study contained a total of 7,516 
medications mostly intended for chronic conditions. Of these, 5,912 [79% (95% CI 78-
80)] were written to be dispensed as branded medicines and 1,604 [21% (95% CI 20-22)] 
were written to be dispensed as generic medicines (Figure 82). This result clearly 
confirms that the system of prescribing in the UAE is branded based. The calculated 
percentage of the prescribed branded and generic items of the selected medicines is listed 
in Table 12. 
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Figure 82: The volume of branded and generic prescribing in Abu-Dhabi General 
Hospital, United Arab Emirates (UAE). 
Table 12: The total prescribed medicines in the sampled prescriptions collected from 
the UAE General Hospital.  
Parameters Medicines per 1000 prescriptions 
% from the total 
prescribed 
medicines* 
95% Confidence 
Intervals 
Number of medicines 7516 100  
Number of prescribed by 
brand-name 5912 78.66 (78-80) 
Number of prescribed by 
generic name 1604 21.34 (20-22) 
Total prescribed 
immunosuppressants 163 2.17 (1.8-2.5) 
Immunosuppressant 
prescribed by brand-name 93 1.24 (0.9-1.5) 
Immunosuppressant 
prescribed by generic 
name 
70 0.93 (0.7-1.1) 
Total prescribed aspirin 601 8.00 (7.3-8.6) 
Aspirin prescribed by 
brand-name 595 7.92 (7.3-8.5) 
Aspirin prescribed by 
generic name 6 0.08 (0-0.1) 
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Parameters Medicines per 1000 prescriptions 
% from the total 
prescribed 
medicines* 
95% Confidence 
Intervals 
Total prescribed 
metformin 289 3.85 (3.4-4.3) 
Metformin prescribed by 
brand-name 225 3.00 (2.6-3.4) 
Metformin prescribed by 
generic name 64 0.85 (0.65-1.0) 
Total antihypertensive 2370 31.53 (30.4-32.5) 
Antihypertensive 
prescribed by brand-name 2216 29.48 (28.4-30.5) 
Antihypertensive 
prescribed by generic 
name 
154 2.05 (1.7-2.3) 
Total prescribed warfarin 53 0.71 (0.52-0.92) 
Warfarin prescribed by 
brand-name 3 0.04 (0-0.1) 
Warfarin prescribed by 
generic name 50 0.67 (0.49-0.87) 
Total prescribed Tenormin 64 0.85 (0.65-1.1) 
Tenormin prescribed by 
brand-name 30 0.40 (0.26-0.56) 
Tenormin prescribed by 
generic name 34 0.45 (0.31-0.63) 
Total prescribed 
anticholesterolamic 794 10.56 (9.8-11.2) 
Anticholesterolamic 
prescribed by brand-name 775 10.31 (9.6-11.0) 
Anticholesterolamic 
prescribed by generic 
name 
19 0.25 (0.15-0.39) 
Total prescribed digoxin 31 0.41 (0.28-0.58) 
Digoxin prescribed by 
brand-name 31 0.41 (0.28-0.58) 
Digoxin prescribed by 
generic name 0 0 (0-0.03) 
Other prescribed by 
generic name brand-name 1944 25.86 (24.8-26.8) 
Other medicines 
prescribed by generic 
name 
1207 16.06 (15.2-16.9) 
*Calculated by dividing the total number of prescribed medicines over the total number of all items (7516). 
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According to the results of this study, most medicines were prescribed in their branded 
forms (Figure 83 and Table 13). For example, 100% of digoxin (cardiac glycoside) was 
prescribed in its brand form. A total of 99% (95% CI 98-100) of aspirin (antiplatelet to 
prevent heart attack, stroke and blood clot) was prescribed in its branded form and a total 
of 98% (95% CI 96-99) of anticholesterolaemic agents was prescribed in their branded 
forms. Moreover, a total of 93% (95% CI 92-94) of most antihypertensive agents were 
prescribed in their branded forms.  
In contrast, some medicines used to treat chronic conditions were prescribed in their 
generic forms more than in their branded form. For example, a total of 94% (95% CI 84-
99) of warfarin (anticoagulant agent) was prescribed in its generic form. Moreover, a 
total of 53% (95% CI 40-66) of Tenormin (beta blocker) was prescribed in its generic 
form (Table 13). Moreover, some medicines treating chronic conditions were prescribed 
in their generic form in a higher volume compared to other chronic condition medicines. 
For example, a total of 43% (95% CI 35-51) of immunosuppressant agents were 
prescribed in their generic forms and 22% (95% CI 171-27) of metformin (antidiabetic 
agent) was prescribed in its generic form (Table 13). 
57 99 78 93 6 47 98 100
43 1 22 7 94 53 2 0
% of branded prescribed medicines % of generically prescribed medicines
 
Figure 83: A comparison of the level of branded prescribed medicines to the 
generically prescribed medicines in the UAE General Hospital. 
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Table 13: A comparison of the level of prescriptions written in the branded form to 
that in the generic form at the UAE General Hospital.  
Parameters 
Medicines per 
1000 
prescriptions 
% from the total 
prescribed medicines 
(brand or generic)* 
95% Confidence 
Intervals 
Total prescribed 
immunosuppressants 163 100%  
Immunosuppressant 
prescribed by brand-name 93 57% (49-65) 
Immunosuppressant 
prescribed by generic 
name 
70 43% (35-51) 
Total prescribed aspirin 601 100%  
Aspirin prescribed by 
brand-name 595 99% (98-100) 
Aspirin prescribed by 
generic name 6 1% (0.4-2) 
Total prescribed 
metformin 289 100%  
Metformin prescribed by 
brand-name 225 78% (73-83) 
Metformin prescribed by 
generic name 64 22% (17-27) 
Total antihypertensive 2370 100%  
Antihypertensive 
prescribed by brand-name 2216 93% (92-94) 
Antihypertensive 
prescribed by generic 
name 
154 7% (6-8) 
Total prescribed warfarin 53 100%  
Warfarin prescribed by 
brand-name 3 6% (1-16) 
Warfarin prescribed by 
generic name 50 94% (84-99) 
Total prescribed 
Tenormin 64 100%  
Tenormin prescribed by 
brand-name 30 47% (34-60) 
Tenormin prescribed by 
generic name 34 53% (40-66) 
Total prescribed 
anticholesterolamic 794 100%  
Anticholesterolamic 
prescribed by brand-name 775 98% (96-99) 
Anticholesterolamic 
generics 19 2% (1-4) 
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Parameters 
Medicines per 
1000 
prescriptions 
% from the total 
prescribed medicines 
(brand or generic)* 
95% Confidence 
Intervals 
Total prescribed digoxin 31 100%  
Digoxin prescribed by 
brand-name 31 100%  
Digoxin prescribed by 
generic name 0 0% (0-9) 
*Calculated by dividing the number of prescribed brand or generic medicines on the total prescribed items 
of each medicine. 
4.2.5 Discussion  
Comparing the percentage of generic prescribing in the UAE (21%) in 2010 to the UK 
(83%) in 2008, shows that generic prescribing in the UAE is still far from that in the UK 
(National Health Service, 2009) and prescriptions in the UAE are branded based. For 
example, prescribers are found more willing to prescribe branded medicines than 
generics, especially for patients with chronic conditions. For example, the results of this 
study showed that medicines such as digoxin, anticholesterolamic and antihypertensive 
agents were prescribed in their branded forms in considerably high volumes. This was 
also confirmed in other studies in the literature (Johnston et al., 2010, Haas, 2005).  
However, almost half [43% (95% CI 35-51)] of the immunosuppressant agents included 
in the study were prescribed in their generic forms. It is strongly recommended for 
narrow therapeutic index drugs that they are prescribed in their branded form because any 
small changes in absorption rates of these drugs can cause major problems 
(Dokoumetzidis and Macheras, 2006, Johnston et al., 2004). For example, the generic 
prescribing of immunosuppressant agents without patient monitoring can lead to organ 
rejection and, as a result, to re-transplantation (Kovarik et al., 2006, Qazi et al., 2006, 
Taber et al., 2005). Moreover, the volume of branded prescriptions of metformin (anti-
diabetic) was also in the lower range compared to other medicines used to treat chronic 
conditions. This can be acceptable as long as the generic alternative was therapeutically 
equivalent, safe and effective and patients are monitored (Johnston et al., 2011). 
Additionally, physicians were still prescribing high volume of generic medicines on 
occasions where health complications may be more susceptible to occur as well as 
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increase health expenditure. For example, there was a high volume of generic prescribing 
of medicines such as warfarin (anticoagulant) and Tenormin (the most prescribed 
antihypertensive agent in the UAE Hospital). The generic prescribing of these agents is 
not recommended to avoid health complications (Snow et al., 2003, Wandel et al., 2003); 
especially if they were prescribed for a long period of time when patients cannot be 
monitored. In another study, for example, a significant increase in morbidity and overall 
healthcare costs was allocated in a hospital in the US by substituting branded warfarin in 
an attempt to reduce costs (Richton-Hewett et al., 1988). Authors also suggested that any 
switching of antihypertensive agents such as Tenormin should be implemented after 
careful consideration of the suitability of a specific drug for a particular individual 
(Johnston et al., 2010). 
In general, in the case of chronic diseases, physicians should provide close supervision 
and monitoring if they decide to switch patients from a branded to a generic drug. Patient 
monitoring can be accomplished by supplying medicines for a shorter period of time. 
This would enable patients to take their medicine, evaluate its effectiveness and side 
effects and participate efficiently in the switching decision. Nevertheless, it is worth 
noting that attempting to reduce costs on treating chronic conditions might lead to an 
increase in the overall health expenditure (Andersson et al., 2005, Gafni and Birch, 2007, 
Richton-Hewett et al., 1988).  
There are many factors that may speculate the reasons for physician’s high brand 
prescribing. These might include that physicians are not yet ready to prescribe generic 
medicine or to promote generic substitution (Berg et al., 2008a, Gossell-Williams, 2007). 
Another factor include the physicians’ lack of knowledge of drug costs may contribute to 
the inefficient use of societal resources and rising pharmaceutical spending (Zaoui et al., 
2011 ). As some patients have to pay for the full cost of their medications (countries 
outside the NHS), expensive prescriptions may go unfilled or may be used less frequently 
than directed resulting in compromised patient health. In general, healthcare providers 
should oppose prescribing to become cash limited because physicians’ performance 
might be affected and forced to focus on reducing costs rather than increasing quality.  
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For example, a study was conducted to evaluate the importance of the physician in the 
generic versus branded prescription decision revealed that physicians are the key 
decision-making agent to determine whether patients receive either branded or generic 
drugs. It added that almost all physicians prescribed both types of drugs to their patients, 
but some physicians are more likely to prescribe branded drugs while others are more 
likely to prescribe generics; reasons behind these choices were unknown (Hellerstein, 
1998). Generally, the results of this study were compatible with those in the literature. 
For example, a US survey was conducted to measure attitudes about prescribing and 
knowledge of drug costs among physicians and internal medicine residents. It revealed 
that 80% of participating physicians often felt unaware of the actual costs, and 71% of 
them were willing to sacrifice some degree of efficacy to make drugs more affordable for 
their patients. This shows that physicians were predisposed to being cost-conscious in 
their prescribing habits, but lacked the accurate knowledge about the actual costs of drugs 
(Baugniet et al., 2000).  
Another study, conducted to evaluate physicians’ opinions and experiences of drug 
substitution in Sweden, declared that although many physicians were positive about 
implementing generic substitution to reduce pharmaceutical expenditure (Andersson et 
al., 2005, Haas, 2005), still there are some physicians reporting health problems with 
their patients caused by generic substitution (Andersson et al., 2006). In addition, a US 
survey of therapeutic substitution programs in ten hospitals revealed that 56% (93/166) of 
physicians stated that they were unaware or uncertain if the therapeutic substitution was 
being practiced in their work setting (Shulman et al., 1992).  
It was also reported in the literature that many physicians are still doubtful about whether 
bioequivalence of a generic is similar to therapeutic equivalence of the branded drug 
(Berg et al., 2008a, Gossell-Williams, 2007). For example, in New Zealand, 52% of 
physicians opposed the proposal to allow automatic generic substitution (Tilyard et al., 
1990). Another example is in Mississippi, in the USA, where 57% of physicians opposed 
generic substitution and generic drugs (Banahan and Kolassa, 1997). Furthermore, 61% 
of physicians in Denmark were dissatisfied with the generic substitution system after it 
was introduced (Rubak et al., 2000). As a result, the Danish Medicines Agency has 
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terminated the generic substitution for oral medicines containing ciclosporin or 
tacrolimus (Heisterberg, 2011).  
A survey in Morocco found that 68% of physicians stated that they are against generic 
substitution because generic medicines are not always effective compared to their 
branded counterparts and generic substitution presents an obstacle to their freedom of 
prescription (Zaoui et al., 2011 ). In addition, a survey conducted on Italian Family 
Pediatricians declared that 66% of physicians believed that efficacy of generic medicines 
was considered insufficient compared to their branded counterparts (National Institute for 
Clinical Excellence, 2001). This indicates that to promote effective generic prescribing 
and substitution, educating and providing physicians with better information about 
generic medicines is essential (Simoens, 2011, Zaoui et al., 2011 ). 
It should be clarified that the appropriateness of physician prescribing habits does not 
only require the use of cheaper medicines, but it also requires the use of more costly 
drugs, in some circumstances. Only by giving appropriateness high priority, will the 
healthcare providers be able to achieve their aim of ensuring patients’ clinical needs. 
Overall, this study has confirmed that prescribers are reluctant to prescribe generic 
medicines. They are more willing to prescribe branded medicines. However, appropriate 
generic prescribing and substitution may be implemented by improving awareness and 
education among physicians and pharmacists as well as encouraging patient monitoring. 
This should also result in lowering the overall healthcare expenditure.  
4.2.6 Main limitations of the study 
The limitations of this study are associated with selection of a standard and uncertainty 
about the context of prescribing and/or dispensing decisions. Another limitation is that 
the physicians’ habits of prescribing were mainly assessed from retrospective collected 
prescriptions and not by direct interview. Therefore, the actual reasons behind these 
habits of prescribing and the patient-physician relationship were unclear. This survey was 
done in one hospital in the UAE; therefore, results cannot be generalised to the whole 
country or region. Further studies to assess the potential differences in the actual 
formulations between branded and generic medicines are required. 
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5 Chapter 5 The differences between the branded and 
generic medicines using solid dosage forms—in-vitro 
dissolution testing 
This chapter was published as an original article in the Results in Pharma Sciences, 2012 
(Al Ameri et al., 2012) (Appendix 19). 
5.1 Introduction 
Generic drugs prescribing and substitution has currently increased and promoted globally 
(Dombrowski, 2008, National Health Service, 2009). In order to gain market approval, 
generic products must be shown bioequivalent and be identical in quality (strength, 
purity, content uniformity, disintegration and dissolution rates) to the innovator’s product 
(Adegbolagun et al., 2007). As a consequence, this has given many healthcare providers 
the confident to promote generic substitution. For example, in the US, increasingly, 
generic drugs represented 18.6% of all prescriptions dispensed in 1984 compared to 63% 
in 2007, 70% in 2010 and 79% in 2011 (Cook et al., 2010, Frank, 2007, Partners 
Healthcare, 2011). Approving generic medicines in the US has resulted in average 
savings of 77% of the product cost within one year (Kozlowski et al., 2011). Similarly, 
for the UK’s generic substitution, which has been largely successful, 83% of all 
prescriptions dispensed are written generically (Kamerow, 2011).  
However, drug substitution has been accompanied by a variety of problems of which the 
most critical is the widespread distribution of substandard generics and fake drug 
products. As a consequence, healthcare providers and patients are usually concerned 
when selecting one drug from among several bioequivalent ones during the treatment 
regime (Al Ameri et al., 2011b, Adegbolagun et al., 2007). In order to maintain a quality 
control procedure in research and development, dissolution testing has been employed 
over the past 50 years to detect the influence of critical manufacturing variables and in 
comparative studies of in-vitro-in-vivo correlation (IVIVC). It is considered one of the 
most important tools to predict in-vivo bioavailability, in some cases replacing clinical 
studies to determine bioequivalence. Dissolution testing in-vitro is also considered 
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critical because drug release from the solid dosage form after oral administration is a 
prerequisite for drug absorption and bioavailability (Savaser et al., 2005).  
Dissolution is an important test for a drug quality assurance includes the ability to 
confirm that the correct manufacturing procedures have been followed for a given batch, 
that the product performs effectively throughout its shelf life and that batch-to-batch 
reproducibility of the product meets regulatory requirements (Dressman et al., 1998). 
Dissolution refers to the amount of substance that goes into solution per unit time under 
standardised conditions of liquid/solid interface, solvent composition and temperature 
(Pharmainfo.net, 2008). Although dissolution cannot be used as a predictor of therapeutic 
efficiency, it can be used as a qualitative and a quantitative tool which can provide 
important information about biological availability of a drug as well as batch-to-batch 
consistency (Singla et al., 2009). In the cases when the in-vitro results fail to predict the 
in-vivo performance of a drug product, larger clinical studies are needed to assess the 
product bioavailability and additional costs will be added to the drug development 
expenses (Dressman et al., 1998).  
It is very common that any report in the literature on formulation and development of any 
solid dosage form starts with dissolution testing. Drug dissolution can play an important 
role in both the development process of a new formulation and as a means of production 
control. Therefore, the FDA guidance for industry indicates that for highly soluble drugs 
a single point dissolution test specification of 85% in 60 minutes or less is sufficient as a 
routine quality control test for batch-to-batch uniformity (Food and Drug Administration, 
1997). Similarly the EMA guidance states that “In cases where more than 85% of the 
active substances are dissolved within 15 minutes, the similarity of dissolution profiles 
may be accepted as demonstrated” (European Medicines Agency, 2001). 
This test is mainly designed to obtain correlation with in-vivo performance of the 
formulation. If a good correlation is obtained with an in-vitro test, the test may serve as a 
routine quality control or may be useful in screening new drug formulations (Savaser et 
al., 2005). Historically, dissolution testing has been a key tool to measure product 
performance during the development stage and to characterise the drug release 
mechanism. Commercially, dissolution testing is used to confirm manufacturing and 
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product consistency and to evaluate the quality of the product during its shelf life and to 
assess post approval changes and the need for bioequivalence studies (Vangani et al., 
2009). 
There are many known errors that may occur in the process of the dissolution test. These 
include the sample preparation (filtration), the use of a graduated-cylinder, temperature 
and the pH of the medium (Guo et al., 2000, Joshi et al., 2008). Following dissolution 
testing, filtration can be a key sample preparation step to separate the dissolved drug from 
the un-dissolved dosage components before sample analysis. The choice of filtration pore 
size can lead to inaccurate and irreproducible results (Joshi et al., 2008). Using UV 
Spectrophotometer as an analytical technique following dissolution also warrants 
filtration before analysis because particulate impurities can affect the analysis.  
Other errors arise from using a graduated-cylinder to dispense the medium into 
dissolution vessel. This error has been estimated to be 0.5 to 1.0% for 750-900 ml when 
measured in 1000 ml graduated-cylinder (Cox et al., 1978). Also, if the volume 
measurement is made at 37 ºC, the expansion of water will cause an additional error 
which is estimated to be 0.4% (Cox et al., 1978). The pH of the medium can also play a 
role in the rate of dissolution. For example, the dissolution rate of the hydrochloride salt 
decreases at low pH whereas the dissolution rate of the base increases (Serajuddin and 
Jarowski, 1985). In addition, it has been reported in the literature that a statistically 
significant difference was detected when using the same drug in different vessels (Cox et 
al., 1978). 
5.2 Objective 
The objective of this study was to compare the differences in dissolution behaviour of 
solid dosage forms between the branded medicines (reference products) and their generic 
counterparts (test products). 
5.3 Material and Methods 
The development of a dissolution procedure involves selecting the dissolution tester, 
media, apparatus type (paddle or basket) and hydrodynamic (agitation rate) appropriate 
for the product. The Low-Head Tablet Dissolution Test Apparatus (model PT-DT70) 
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equipped with six dissolution vessels from Pharma Test Company was used to conduct 
this study (Figure 84). A total of 58 medicines (tablets and capsules) were originally 
selected across different therapeutic categories and were obtained locally and 
internationally. However, the selection criteria of this study included all medicines that 
have wavelengths above 230 nm. This wavelength was selected to avoid detecting the 
absorbance of the impurities and to ensure detecting the absorbance of the active 
ingredient. A total of 37 medicines (13 innovator medicines and 24 generic counterparts) 
fulfilled this requirement by having wavelengths over 230 nm (Table 14).  
The original names of all generic medicines were kept anonymous to comply with the 
objective of this study and to avoid any purification or corruption of any pharmaceutical 
company’s reputation. This study was intended to detect any differences in dissolution 
behaviour between the branded and their generic counterparts to encourage safe and 
effective generic prescribing and substitution. The following names were used for generic 
medicines instead of their original names:  
• Generic A: The generic counterpart of the branded medicine.  
• Generic A1: The generic medicine from the same manufacturer with different batch 
number from generic A. 
• Generic B: The second generic counterpart of the same branded medicine. 
 
Figure 84: Low-head tablet dissolution test apparatus (model PT-DT70) from Pharma 
Test Company. 
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Table 14: Characteristics of the branded medicines (reference products) used in the 
dissolution study. 
Formulation Brand Name® 
Strength 
(mg) 
Type 
(Tablet/
Capsule) 
Indication Batch No. Manufacturer 
Nifedipine Adalat® 10 Capsule Antihyper-tensive agent 
ITA07
KZ 
Bayer Schering 
Pharma 
(Germany) 
Amoxicillin Amoxil® 500 Capsule 
Antibiotic to 
treat bacterial 
infections 
44963
0 
GlaxoSmithKlin 
(UK) 
Amoxicillin 
and 
Clavulanate 
Potassium 
Augmentin® 375 Tablet 
Antibiotic to 
treat bacterial 
infections 
50079
1 
GlaxoSmithKlin 
(UK) 
Amoxicillin 
and 
Clavulanate 
Potassium 
Augmentin® 1000 Tablet 
Antibiotic to 
treat bacterial 
infections 
47150
4 
GlaxoSmithKlin 
(UK) 
Loratadine Claritine® 10 Tablet 
H1 histamine 
antagonist used 
to treat allergies 
ORXF
A1400
5 
Shering-Plough 
Labo N.V. 
(Belgium) 
Ciprofloxacin Ciproxin® 250 Tablet 
Antibiotic to 
treat bacterial 
infections 
ITA09
24 
Bayer Schering 
Pharma (UK) 
Omeprazole Losec® 20 Capsule 
Proton pump 
inhibitor to 
treat peptic 
ulcer disease 
MK74
22 AstraZeneca (UK) 
Meloxicam Mobic® 7.5 Tablet 
Nonsteroidal 
anti-
inflammatory to 
treat arthritis 
04415
5 
Boehringer 
Ingelheim (UK) 
Meloxicam Mobic® 15 Tablet 
Nonsteroidal 
anti-
inflammatory to 
treat arthritis 
90534
1 
Boehringer 
Ingelheim 
(Germany)) 
Mefenamic 
Acid Ponstan
®
 500 Tablet 
Analgesic and 
anti-
inflammatory 
15249 Chemidex Pharma Ltd (UK) 
Diclofenac 
Sodium Voltaren
®
 50 Tablet 
Analgesic and 
anti-
inflammatory 
TO418 Novartis (Italy) 
Capecitabine Xeloda® 500 Tablet 
Chemotherapeu
tic agent to treat 
metastatic 
breast and 
colorectal 
cancers 
X0115
B01 Roche (Mexico) 
Simvastatin Zocor® 20 Tablet Anticholesterol
a-emic agent 
30543
5 MSD (UK) 
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All tested tablets and capsules were stored according to conditions described in their 
labels and were weighed individually before performing the dissolution test using a 
Sartorius AZ64 Research Analytical Weighing Balance. The average weight of the 
obtained tablets and capsules was calculated using Microsoft Office Excel 2007. The 
temperature was maintained at 37 ± 0.5 ºC throughout the dissolution test for two hours 
(120 minutes). The sizes of tablets and capsules were measured using Electronic Digital 
Calliper.  
The dissolution test was performed by manually pipetting out 5 ml samples of the 
dissolution medium at 5, 15, 30, 60, 90 and 120 minutes and transferring to tubes. In this 
study standardised procedures from pharmacopoeias were included (European Medicines 
Agency, 1995). The medium, apparatus type and agitation rate for each drug were 
prepared according to the British Pharmacopoeia (Commission on Human Medicines), 
European Pharmacopoeia (Council of Europe-Strasbourg) and the US Pharmacopoeia 
(The United states Pharmacopoeia Convention) (Table 15 and Table 16). 
Table 15: In-vitro dissolution procedures for different medicines. 
Drug Dissolution medium Volume (mL) 
Agitation rate 
(revolutions per 
minute) 
UV Analysis 
(wavelength, 
nm) 
Adalat 10 mg 0.1M hydrochloric acid 900 50 340 
Amoxil 500 mg Water 900 75 272 
Augmentin 
1000 mg Water 900 75 272 
Augmentin 375 
mg Water 900 75 272 
Claritine 10 mg 0.1M hydrochloric acid 900 50 280 
Ciproxin 250 mg 0.1MN hydrochloric acid 900 50 276 
Losec 20 mg Phosphate buffer, pH 7.4 900 75 302 
Mobic 7.5 mg Phosphate buffer, pH 7.5 1000 50 362 
Mobic 15 mg Phosphate buffer, pH 7.5 1000 50 362 
Ponstan 500 mg 0.05 M Tris buffer 900 100 285* 
Voltaren 50 mg 0.1 M hydrochloric acid 900 50 276 
Xeloda 500 mg Water 900 50 304 
Zocor 20 mg 
0.01M sodium dihydrogen 
orthophosphate containing 0.5% w/v 
of sodium dodecyl sulphate, pH 7.0 
900 50 238 
*The wavelength of Ponstan 500 mg in the British Pharmacopoeia is 254 nm but in this study it was found 
to be 285 nm. 
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Table 16: The preparations of different dissolution medium. 
Dissolution medium Preparation 
Water 
Deionised water at a purity of 18.2 MΩ-cm was obtained from ultra water 
system (Model Purelab®). 
0.1M hydrochloric acid 
(M1) (V1) = (M2) (V2) 
(12M HCL) (V1) = (0.1N HCL) (2000mL) 
(12) (V1) = 200mL 
V1= 200/12 = 16.66mL of original 12 M HCL 
Use 16.6 mL of 12 M into each 2 L Buffer 
Phosphate buffer 
Dissolve 6.81 g of potassium dihydrogen phosphate in 800 mL of water, 
adjusting the pH to 7.5 or 7.4 with 0.5 N sodium hydroxide, and diluting 
with water to 1 L. 
To prepare 400 mL of NAOH (MW of NAOH X Molar X Volume/1000) 
= 40X 0.5 X 400/1000= 8 g of NAOH, since the NAOH is tablets form I 
follow the following formula to find the exact volume 
Exact weight X (100 mL/4g) 25 = V mL of H2O. 
0.05 M Tris buffer 
Dissolve 60.5 g of tris (hydroxymethyl) aminomethane in 6 L of water, 
and dilute with water to 10 L. Adjust with phosphoric acid to a pH of 9.0 
± 0.05. To a second container, transfer about 6 litres of this solution; add 
100 g of sodium lauryl sulfate, and mix to dissolve the solid material. 
Transfer this solution back into the first container, and mix.  
Or in another simpler way: 
Add 1.52 g of Trizma HCL and 10.94 g of Trizma base to 2 L of water 
and then mix with 20 g of sodium lauryl sulphate 
0.01M sodium dihydrogen 
orthophosphate containing 
0.5% w/v of sodium 
dodecyl sulphate and adjust 
to pH 7.0 with 1M NAOH 
Add 2.8 g of Sodium Dihydrogen orthophosphate to 2 liters of deionised 
water. (MW sodium dihydrogen orthophosphateX MolarX Volume/1000) 
= 137.99 X 0.01 X 1000/1000= 1.3799 = 1.4 g of sodium dihydrogen 
orthophosphate in each liter. Then add 9 g of sodium dodecyl sulphate to 
same 2 L. Mix and adjust the pH to 7.0 with 1 M NAOH 
The dissolution test was carried out on four replicates for each batch using the paddle 
method (apparatus type 2) (Figure 85). Deionised water at a purity of 18.2 MΩ-cm was 
used for the preparation of dissolution media and was obtained from ultra water system 
(Model Purelab®). Samples were filtered appropriately through 20 micron filters before 
measuring the absorbance using ultra-violet/visible Spectrophotometer (model 6715 
UV/Vis. Spectrophotometer, Jenway).  
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Figure 85: The paddle method (apparatus type 2) (Brief, 2010). 
Method validation 
In order to demonstrate whether the method was suitable for its intended purpose, it was 
validated through precision (repeatability and reproducibility) parameters (European 
Medicines Agency, 1995, Rossi et al., 2007). Validation of dissolution methods was 
necessary for the formulation research and development. The precision of an analytical 
procedure was determined by repeated analysis (n=3) to express the closeness between a 
series of measurements obtained from multiple sampling of the same homogeneous 
sample under the same conditions. Repeatability expresses the precision under the same 
operating conditions over a short interval of time (Figure 86). Reproducibility expresses 
the precision between laboratories by repeating the analysis of the series of measurements 
obtained from multiple sampling of the same homogenous sample under the same 
conditions in separate days (Figure 87).  
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Figure 86: Validation of the dissolution method using repeatability procedure by 
testing the same drug in three replicates on the same day. 
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Figure 87: Validation of the dissolution method using repeatability procedure by 
testing the same drug in three replicates on different days (0, 15 and 30 
days). 
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Calibration of the UV Spectrophotometer: 
Before starting the analysis of the collected samples, calibration of the UV 
Spectrophotometer was necessary. Spectrophotometer UV cuvettes were filled with a 
total of 3 mL of the prepared medium for each medicine to zero the UV 
Spectrophotometer. Then, each sample was diluted with its medium until the appearance 
of a clear peak of the active ingredient in the UV spectrum. The same dilution was 
carried out to the rest of the collected samples of each medicine. It should be noted that 
the specified wavelength of Ponstan 500 mg in the British Pharmacopoeia 2011 is 254 
nm (Commission on Human Medicines); however, in this study, after using 0.1 mL of the 
dissolved sample and 2.9 mL of the medium (0.05 M Tris buffer) in the UV 
Spectrophotometer, the correct wavelength was found to be 285 nm as shown in Figure 
88.  
The following are the UV calibrations for each medicine. 
 
Figure 88: The UV Spectrum of Ponstan 500 mg at 285 nm after using 0.1 mL of the 
dissolved sample and 2.9 mL of the medium (0.05 M Tris buffer). 
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Figure 89: The UV Spectrum of Adalat 10 mg at 340 nm after using 3 mL of the 
dissolved sample.  
 
Figure 90: The UV Spectrum of Amoxil 500 mg at 272 nm after using 1 mL of the 
dissolved sample and 2 mL of the medium (water).  
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Figure 91: The UV Spectrum of Losec 20 mg at 302 nm after using 3 mL of the 
dissolved sample. 
 
Figure 92: The UV Spectrum of Voltaren 50 mg at 276 nm after using 1 mL of the 
dissolved sample and 2 mL of the medium (0.1 N hydrochloric acid).  
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Figure 93: The UV Spectrum of Mobic 7.5 and 15 mg at 362 nm after using 3 mL of 
the dissolved sample. 
 
Figure 94: The UV Spectrum of Ciproxin 250 mg at 276 nm after using 0.6 mL of the 
dissolved sample and 2.94 mL of the medium (0.1 N hydrochloric acid). 
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Figure 95: The UV Spectrum of Xeloda 500 mg at 304 nm after using 0.3 mL of the 
dissolved sample and 2.7 mL of the medium (water). 
 
Figure 96: The UV Spectrum of Zocor 20 mg at 238 nm after using 1 mL of the 
dissolved sample and 2 mL of the medium (0.01M sodium dihydrogen 
orthophosphate containing 0.5% w/v of sodium dodecyl sulphate, pH 7.0). 
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Figure 97: The UV Spectrum of Claritine 10 mg at 280 nm after using 3 mL of the 
dissolved sample.  
5.4 Results 
Dissolution testing involves dissolving the solid dosage form of a drug under controlled 
conditions, followed by collection and analysis of the sample to determine the percentage 
of drug dissolved at a certain time point. The results of this study were expressed as % 
[95% Confidence intervals (CI)], using Microsoft Office Excel 2007 and Minitab 16 
(Minitab Inc, Pennsylvania, PA, USA). Variations were evaluated using one-way analysis 
of variance (ANOVA) and P≤0.05 was considered statistically significant. The 
concentration of dissolved drug was calculated using Microsoft Office Excel 2007. The 
dissolution profile compares the percentage of a drug substances dissolved relating to 
time and represents an alternative to assessment of solid forms before clinical tests 
(Oliveira et al., 2009) (Table 17). To comply with the EMA and the FDA guidelines for 
dissolution and to cover the wide range of medications collected for this study, two time 
intervals (60 and 120 minutes) were selected to compare the dissolution rate between the 
branded medicines and their generic counterparts (European Medicines Agency, 2001, 
Food and Drug Administration, 1997).  
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Table 17: The average percentage of the dissolution rate comparing the branded 
(reference products) medicines to their generic counterparts (test 
products). 
Drug Name Expiry date 
Average 
weight of 
the 4 
tablets or 
capsules 
(g)  
Sampling time (min) and Average % dissolved 
5 min 15 min 30 min 60 min 90 min 120 min* 
Adalat® 10 
mg 
12/201
1 0.59875 13.8% 93.7% 106.3% 102.3% 105% 100% 
Generic 
A** 
11/201
3 0.61532 7.2% 75.7% 87% 88.8% 87.6% 86% 
Amoxil® 
500 mg 
09/201
4 0.691810 40.1% 83.7% 95.4% 101.1% 
104.9
% 100% 
Generic A 04/2015 0.68846 16.2% 70.8% 89.9% 100% 
102.4
% 105.3% 
Generic 
A1** 
05/201
2 0.698708 11% 76.1% 91.1% 105.2% 
105.2
% 104.4% 
Generic B** 01/2013 0.698363 39.8% 71.8% 90.1% 104.8% 
112.8
% 112.7% 
Augmentin
®
 375 mg 
10/201
2 0.67019 28.9% 93.3% 103.7% 104.6% 98.8% 100% 
Generic A 12/2012 0.66545 25.5% 
103.7
% 90.7% 85.5% 86.8% 85.8% 
Augmentin
®
 1000 mg 
03/201
5 1.48098 32.3% 81.3% 98.2% 100.9% 
101.4
% 100% 
Generic A 04/2013 1.44494 30.4% 78.2% 94.8% 96% 
100.3
% 94.3% 
Claritine® 
10 mg 
04/201
3 0.10000 45.8% 94.4% 101.5% 102.9% 102% 100% 
Generic A 01/2013 0.09970 58.6% 97.1% 102.6% 103.7% 
103.1
% 103.3% 
Generic B 11/2011 0.11713 83.5% 98.5% 100.8% 102.1% 
101.6
% 101.2% 
Ciproxin® 
250 mg 
09/201
4 0.38277 71% 96.3% 100.1% 100.1% 98.1% 100% 
Generic A 07/2012 0.39973 24.6% 88.4% 97.6% 100.9% 
100.6
% 99.9% 
Generic B 04/2014 0.40445 61% 96.2% 100.3% 103% 103% 100.6% 
Losec® 20 
mg 
09/201
3 0.29163 3.5% 65.7% 93.3% 102% 
101.4
% 100% 
Generic A 09/2012 0.29875 3.8% 21.5% 69.7% 95.4% 
102.8
% 105.5% 
Generic B 03/2013 0.28517 3.4% 16.2% 70.8% 102.9% 
109.8
% 109.5% 
Mobic® 7.5 
mg 
01/201
3 0.18218 23% 65.3% 85.8% 96.7% 98.5% 100% 
Generic A 04/2014 0.11150 23.9% 60.4% 83.9% 97.5% 
100.1
% 101.2% 
Generic A1 12/2013 0.11150 20.7% 52.4% 73.6% 85.8% 92% 93.7% 
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Drug Name Expiry date 
Average 
weight of 
the 4 
tablets or 
capsules 
(g)  
Sampling time (min) and Average % dissolved 
5 min 15 min 30 min 60 min 90 min 120 min* 
Mobic® 15 
mg 
06/201
2 0.18217 17.4% 58% 84.1% 96% 99% 100% 
Generic A 04/2014 0.182165 19.1% 50.8% 72.8% 87.7% 95.3% 98% 
Generic A1 07/2014 0.22036 14.9% 48.6% 78.9% 96.2% 
101.9
% 104.2% 
Generic B 07/2012 0.22170 6.8% 82.7% 106.1% 109.6% 109% 108.5% 
Ponstan® 
500 mg 
02/201
4 0.69577 55.7% 94.2% 95.8% 98.7% 98.9% 100% 
Generic A 09/2013 0.74245 28.4% 84.3% 97.9% 98.9% 
100.6
% 99.8% 
Generic B 04/2013 0.82695 66.4% 98.1% 104.3% 104% 
101.1
% 97.4% 
Voltaren® 
50 mg 
10/201
3 0.21431 8.4% 45.4% 88.8% 98.6% 99.7% 100% 
Generic A 03/2012 0.20725 13.6% 63.4% 96.1% 101.5% 
101.5
% 101.2% 
Generic B 03/2012 0.22830 17.9% 53.2% 72.7% 76.4% 77.6% 76.2% 
Xeloda® 
500 mg 
10/201
2 0.63751 22.8% 72.7% 97.3% 102.3% 
101.1
% 100% 
Generic A 12/2012 0.98755 64% 85% 86.3% 88.3% 89.5% 90.1% 
Zocor® 20 
mg 
07/201
2 0.20649 17% 85.1% 103.1% 103.1% 
103.4
% 100% 
Generic A 02/2012 0.20322 66.8% 98.8% 102.3% 102.5% 
107.9
% 105.9% 
Generic B 06/2012 0.20330 23.2% 54.4% 77.3% 93.6% 92.7% 96.9% 
* The branded medicine was taken as a reference product at 100% of the expected dissolution rate at 120 minutes. 
**Brand: The innovator product. Generic A: The generic counterpart of the branded medicine, Generic A1: Generic 
drug from the same manufacturer with different batch number from generic A, Generic B: The second generic 
counterpart of the same branded medicine. 
5.4.1 The dissolution rate of generic medicines compared to their branded 
counterpart at 60 minutes 
When comparing the branded medicines with their generic counterparts at 60 minutes, 
21% (5/24) of the generic medicines showed statistically significantly differences in the 
dissolution rate compared to their branded counterpart (Table 18 and Table 19). Some 
generics showed a slower dissolution rate compared to their branded counterparts. For 
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example, the generic version of capecitabine 500 mg (Xeloda® 500 mg) showed a much 
slower and different dissolution rate than its branded counterpart (P= 0.003) (Figure 98). 
Another example is meloxicam 15 mg (Mobic® 15 mg) where its generic A showed a 
significantly slower dissolution rate than its branded counterpart (P= 0.001) (Figure 99).  
In addition, the generic form (Generic A1) of meloxicam 7.5 mg (Mobic® 7.5 mg) had 
also shown a slower dissolution rate than its branded counterpart (P= 0.032) (Figure 
100). Another example is that the dissolution rate of the generic form (Generic A) of 
omeprazole 20 mg (Losec® 20 mg) showed a slightly slower dissolution rate than its 
branded counterpart (P= 0.054) (Figure 101). Some generic meedicines showed an 
incomplete dissolution such as the generic forms of nifedipine 10 mg (Adalat® 10 mg, P = 
0.001) (Figure 102) and capecitabine 500 mg (Xeloda® 500 mg, P = 0.003) (Figure 98). 
Other generics showed that they can dissolve faster than their branded counterpart. For 
example, the generic form (Generic B) of meloxicam 15 mg (Mobic® 15 mg) showed a 
faster dissolution rate than its branded counterpart (P= 0.001) (Figure 99).  
Moreover, some generic medicines from different batches of the same manufacturer 
showed significant differences in their dissolution rate. This was clearly shown, for 
instance, in generic A and A1 for meloxicam 15 mg (Mobic® 15 mg) (Figure 99) and 
meloxicam 7.5 mg (Mobic® 7.5 mg) (Figure 100). It is worth noting that the EMA and 
the FDA guidance for industry indicate that for highly soluble drugs, a single point 
dissolution test specification of 85% in 60 minutes or less is sufficient as a routine quality 
control test for batch-to-batch uniformity (European Medicines Agency, 2001, Food and 
Drug Administration, 1997). However, some generic medicines failed to comply with the 
85% in 60 minutes guidance. For example, only 72% (95% CI 42-122) of generic B in 
diclofenac sodium 50 mg (Voltaren® 50 mg) had dissolved at 60 minutes compared to 
100% dissolution of its branded counterpart (Figure 103). 
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Table 18: The average percentage of the dissolution rate of the generic medicines 
(test products) compared to their branded counterparts (reference 
products) at 60 minutes. 
Drug name % of drug dissolved at 60 
minutes* 
95% Confidence 
Interval P value 
Adalat® 10 mg 100  0.001 Generic A 87 (82-92) 
Amoxil® 500 mg 100  
0.263 Generic A 99 (91-107) Generic A1 104 (96-113) 
Generic B 104 (96-113) 
Augmentin® 375 mg 100  0.132 Generic A 83 (64-108) 
Augmentin® 1000 mg 100  0.145 Generic A 95 (88-102) 
Claritine® 10 mg 100  
0.449 Generic A 101 (98-104) 
Generic B 99 (96-102) 
Ciproxin® 250 mg 100  
0.613 Generic A 101 (93-109) 
Generic B 103 (95-111) 
Losec® 20 mg 100  
0.054 Generic A 94 (87-101) 
Generic B 101 (94-109) 
Mobic® 7.5 mg 100  
0.032 Generic A 101 (90-113) 
Generic A1 89 (79-100) 
Mobic® 15 mg 100  
0.001 Generic A 91 (83-100) Generic A1 100 (91-110) 
Generic B 114 (104-126) 
Ponstan® 500 mg 100  
0.063 Generic A 92 (82-104) 
Generic B 97 (86-109) 
Voltaren® 50 mg 100  
0.200 Generic A 103 (60-176) 
Generic B 72 (42-122) 
Xeloda® 500 mg 100  0.003 Generic A 86 (80-93) 
Zocor® 20 mg 100  
0.738 Generic A 98 (66-146) 
Generic B 90 (60-133) 
* The branded medicine was taken as the reference product at 100% of the expected dissolution rate at 60 minutes 
**Brand: The innovator product. Generic A: The generic counterpart of the branded medicine, Generic A1: Generic 
drug from the same manufacturer with different batch number from generic A, Generic B: The second generic 
counterpart of the same branded medicine. 
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Table 19: The mean, standard deviation and the coefficient of variation for the 
dissolution percentage of the tested medicines at 60 minutes. 
Drug name Mean of stated 
concentration (%) 
% of standard 
deviation 
% of the coefficient 
of variation 
Adalat® 10 mg 102 3.2 3.1 
Generic A 89 2.8 3.1 
Amoxil® 500 mg 101 3.8 3.7 
Generic A 100 6.5 6.5 
Generic A1 105 3.3 3.2 
Generic B 105 2.1 2.0 
Augmentin® 375 mg 105 24.0 23.0 
Generic A 85 1.6 1.9 
Augmentin® 1000 mg 101 1.52 1.51 
Generic A 96 5.6 5.9 
Claritine® 10 mg 103 0.36 0.35 
Generic A 104 1.7 1.6 
Generic B 102 2.5 2.4 
Ciproxin® 250 mg 100 6.6 6.6 
Generic A 101 1.58 1.57 
Generic B 103 3.2 3.1 
Losec® 20 mg 102 1.5 1.47 
Generic A 95 4.2 4.4 
Generic B 103 5.3 5.2 
Mobic® 7.5 mg 97 8.7 9.0 
Generic A 97 5.1 5.2 
Generic A1 86 2.2 2.6 
Mobic® 15 mg 96 4.0 4.2 
Generic A 88 8.0 9.2 
Generic A1 96 0.91 0.94 
Generic B 110 0.73 0.67 
Ponstan® 500 mg 99 5.9 6.0 
Generic A 99 2.02 2.04 
Generic B 104 6.0 5. 8 
Voltaren® 50 mg 99 1.19 1.21 
Generic A 101 1.67 1.65 
Generic B 76 29 38 
Xeloda® 500 mg 102 0.97 0.94 
Generic A 88 5.2 5.8 
Zocor® 20 mg 103 15.1 14.6 
Generic A 102 23.3 22.7 
Generic B 94 22.7 24.3 
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Generic A: The generic counterpart of the branded medicine. 
Figure 98: The differences in dissolution rate between branded Xeloda® 500 mg and 
its generic counterparts. 
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Generic A: The generic counterpart of the branded medicine, Generic A1: generic drug with the same 
manufacturer and different batch number from generic A, Generic B: The second generic counterpart of the 
same branded medicine (capsule form). 
Figure 99: The differences in dissolution rate between branded Mobic® 15 mg and its 
generic counterparts. 
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Generic A: The generic counterpart of the branded medicine, Generic A1: generic drug from the same 
manufacturer with different batch number from generic A. 
Figure 100: The differences in dissolution rate between branded Mobic® 7.5 mg and its 
generic counterparts. 
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Generic A: The generic counterpart of the branded medicine, Generic B: The second generic counterpart of 
the same branded medicine. 
Figure 101: The differences in dissolution rate between branded Losec® 20 mg and its 
generic counterparts. 
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Generic A: The generic counterpart of the branded medicine. 
Figure 102: The differences in dissolution rate between branded Adalat® 10 mg and its 
generic counterpart. 
0%
20%
40%
60%
80%
100%
120%
5 15 30 60 90 120
%
 d
ru
g
 d
is
so
lv
e
d
Dissolution time (minutes)
Dissolution between different formulations of diclofenac 
sodium 50 mg (n=4)
Voltaren 50 mg Generic A Generic B
 
Generic A: The generic counterpart of the branded medicine, Generic B: The second generic counterpart of 
the same branded medicine. 
Figure 103: The differences in dissolution rate between branded Voltaren® 50 mg and 
its generic counterparts. 
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5.4.2 The dissolution rate of generic medicines compared to their branded 
counterpart at 120 minutes 
When comparing the branded medicines with their generic counterparts at 120 minutes, 
54% (13/24) of the studied generic medicines were found significantly different (p≤ 0.05) 
than their branded counterpart (Table 20 and Table 21). Some generic medicines showed 
a slower dissolution rates compared to their branded counterpart. For example, the 
generic form of capecitabine 500 mg (Xeloda® 500 mg) (Figure 98) and nifedipine 10 
mg (Adalat® 10 mg) (Figure 102) showed a much slower and different dissolution rate 
than their branded counterpart (P=0.008 and 0.003, respectively).  
The generic form of amoxicillin and clavulanate potassium 1000 mg (Augmentin® 1000 
mg) also showed a slower dissolution rate than its branded counterpart (P=0.019) (Figure 
104). In addition, the generic form (Generic A) of meloxicam 15 mg (Mobic® 15 mg) 
showed a slower dissolution rate than its branded counterpart (P=0.043) (Figure 99). For 
mefenamic acid 500 mg (Ponstan® 500 mg), generic A and B had also shown a 
significantly slower dissolution rates than their branded counterpart (P=0.047) (Figure 
105). In contrast, other generic medicines showed that they can dissolve faster than their 
branded counterpart. For example, generic forms (Generic A, A1 and B) of amoxicillin 
500 mg (Amoxil® 500 mg) dissolved faster than their branded counterpart (P=0.005), 
Figure 106. The generic forms (Generic A and B) of omeprazole 20 mg (Losec® 20 mg) 
also dissolved faster than their branded counterpart (P=0.001), Figure 101.  
Similarly, the generic forms (Generic A1 and B) of meloxicam 15 mg (Mobic® 15 mg) 
had shown a faster dissolution rate than their branded counterpart (P=0.043) (Figure 99). 
Nevertheless, some generic medicines from different batches of the same manufacturer 
showed significant differences in their dissolution rate, for example, generic A and 
generic A1 in meloxicam 15 mg (Mobic® 15 mg) (P=0.043) (Figure 99).  
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Table 20: The average percentage of the dissolution rate of the generic medicines 
(test products) compared to their branded counterparts (reference 
products) at 120 minutes. 
Drug Name % of drug dissolved at 120 minutes* 
95% Confidence 
Interval P value 
Adalat® 10 mg 100  0.003 Generic A** 86 (80-93) 
Amoxil® 500 mg 100  
0.005 Generic A 105 (98-113) Generic A1** 104 (97-112) 
Generic B** 113 (105-121) 
Augmentin® 375 mg 100  0.127 Generic A 87 (71-106) 
Augmentin® 1000 mg 100  0.019 Generic A 94 (90-99) 
Claritine® 10 mg 100  
0.132 Generic A 103 (99-107) 
Generic B 101 (97-105) 
Ciproxin® 250 mg 100  
0.905 Generic A 100 (95-105) 
Generic B 101 (96-106) 
Losec® 20 mg 100  
0.001 Generic A 113 (105-123) 
Generic B 124 (115-135) 
Mobic® 7.5 mg 100  
0.204 Generic A 101 (91-113) 
Generic A1 94 (84-105) 
Mobic® 15 mg 100  
0.043 Generic A 98 (89-107) Generic A1 104 (95-114) 
Generic B 109 (99-119) 
Ponstan® 500 mg 100  
0.047 Generic A 92 (84-101) 
Generic B 90 (82-98) 
Voltaren® 50 mg 100  
0.312 Generic A 101 (44-231) 
Generic B 64 (28-147) 
Xeloda® 500 mg 100  0.008 Generic A 90 (84-96) 
Zocor® 20 mg 100  
0.733 Generic A 106 (77-145) 
Generic B 96 (70-132) 
* The branded medicine was taken as the reference product at 100% of the expected dissolution rate at 120 
minutes **Brand: The innovator product. Generic A: The generic counterpart of the branded medicine, 
Generic A1: Generic drug from the same manufacturer with different batch number from generic A, 
Generic B: The second generic counterpart of the same branded medicine. 
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Table 21: The mean, standard deviation and the coefficient of variation for the tested 
medicines at 120 minutes. 
Drug name Mean of stated 
concentration 
(%) 
% of standard 
deviation 
% of the coefficient of 
variation* 
Adalat® 10 mg 100 5.6 5.6 
Generic A 86 2 2.5 
Amoxil® 500 mg 100 3.2 3.2 
Generic A 105 5.4 5.1 
Generic A1 104 3.1 3.0 
Generic B 113 2.7 2.4 
Augmentin® 375 mg 100 17.0 17.0 
Generic A 86 2.6 3.1 
Augmentin® 1000 mg 100 1.7 1.7 
Generic A 94 3 3.3 
Claritine® 10 mg 100 2.2 2.2 
Generic A 103 2 1.9 
Generic B 101 2.1 2.0 
Ciproxin® 250 mg 100 4.3 4.3 
Generic A 100 1.6 1.6 
Generic B 101 1.23 1.22 
Losec® 20 mg 100 1.3 1.3 
Generic A 105 1.6 1.5 
Generic B 109 2.6 2.4 
Mobic® 7.5 mg 100 7.9 7.9 
Generic A 101 5.2 5.1 
Generic A1 94% 3.7 3.9 
Mobic® 15 mg 100 3.7 3.7 
Generic A 98 8.0 8.3 
Generic A1 104 2.3 2.2 
Generic B 108 1.0 0.92 
Ponstan® 500 mg 100 6.1 6.1 
Generic A 100 3.85 3.85 
Generic B 97 0.48 0.50 
Voltaren® 50 mg 100 0.56 0.56 
Generic A 101 1.32 1.31 
Generic B 76 37 49 
Xeloda® 500 mg 100 0.70 0.70 
Generic A 90 4.8 5.3 
Zocor® 20 mg 100 14 14 
Generic A 106 16.5 15.6 
Generic B 97 20.0 20.7 
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Generic A: The generic counterpart of the branded medicine. 
Figure 104: The differences in dissolution rate between branded Augmentin® 1000 mg 
and its generic counterparts. 
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Figure 105: The differences in dissolution rate between branded Ponstan® 500 mg and 
its generic counterparts. 
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Figure 106: The differences in dissolution rate between branded Amoxil® 500 mg and 
its generic counterparts. 
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The following are the figures for all other tested medicines in this study:  
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Generic A: The generic counterpart of the branded medicine, Generic B: The second generic counterpart of 
the same branded medicine. 
Figure 107: The differences in dissolution rate between branded Claritine® 10 mg and 
its generic counterparts. 
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Generic A: The generic counterpart of the branded medicine, Generic B: The second generic counterpart of 
the same branded medicine. 
Figure 108: The differences in dissolution rate between branded Ciproxin® 250 mg and 
its generic counterparts. 
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Figure 109: The differences in dissolution rate between branded Zocor® 20 mg and its 
generic counterparts. 
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Generic A: The generic counterpart of the branded medicine. 
Figure 110: The differences in dissolution rate between branded Augmentin® 375 mg 
and its generic counterpart. 
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5.4.3 Visually detected differences between the branded medicines and 
their generic counterparts 
In general, there were some visually detected differences between the branded medicines 
and their generic counterparts in this study. There were some differences in the weight 
between the branded and their generic counterparts; this was weighted by Sartorius AZ64 
Research Analytical Weighing Balance. For example, difference in the average weight 
was shown between meloxicam 15 mg (Mobic® 15 mg) (0.18 g) and its generic (B) 
counterpart (0.22 g) (Table 17). There was also difference in weight between 
capecitabine 500 mg (Xeloda® 500 mg) (0.64 g) and its generic (A) counterpart (0.99 g), 
(Table 17). 
Other generics in this study showed differences in tablet or capsule size, this was 
measured by “Electronic Digital Callipers”. For example, the tablets size of the branded 
amoxicillin and clavulanate potassium 375 mg (Augmentin® 375 mg) (14.60 X 6.18 X 
4.80 mm) was much smaller than its generic (A) counterpart (20.12 X 8.62 X 6.05 mm) 
(Figure 111). Another difference in size was detected between capecitabine 500 mg 
(Xeloda® 500 mg) (14.47 X 7.00 X 4.12 mm) and its generic (A) counterpart (18.22 X 
7.87 X 4.71 mm) (Figure 112). Differences in tablet size were also detected between the 
branded diclofenac sodium 50 mg (Voltaren 50 mg) (6.72 X 2.04 mm) and its generic 
counterpart (7.59 X 1.82 mm) (Figure 113). The size of the generic form (A) (5.14 X 
1.03 mm) of meloxicam 15 mg (Mobic® 7.5 mg) was much smaller compared to its 
branded counterpart (7.53 X 1.07 mm) (Figure 114). 
 
Figure 111: The differences in size between the branded Augmentin® 375 mg (B, left), 
14.60 mm (length) X 6.18 mm (width) X 4.80 (depth)and its generic 
counterpart (G, right), 20.12 mm (length) X 8.62 mm (width) X 6.05 mm 
(depth). 
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Figure 112: The differences in size between the branded Xeloda® 500 mg (B, left), 
14.47 mm (length) X 7.00 mm (width) X 4.12 mm (depth) and its generic 
counterpart (G, right), 18.22 mm (length) X 7.87 mm (width) X 4.71 mm 
(depth). 
 
Figure 113: The differences in tablet size between the branded Voltaren 50 mg (B, 
left), 6.72 mm (diameter) X 2.04 mm (depth) and its generic counterpart 
(G, right), 7.59 mm (diameter) X 1.82 mm (depth). 
 
Figure 114: The differences in size between the branded Mobic® 7.5 mg (B, left), 7.53 
mm (diameter) X 1.07 mm (depth)and its generic counterpart (G, right), 
5.14 mm (diameter) X 1.03 mm (depth). 
Moreover, this study detected that there were differences in shapes, colours and 
packaging between the branded medicines and their generic counterparts. For example, 
the differences in shapes and colours between the branded mefenamic acid 500 mg 
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(Ponstan® 500 mg) and its generic (B) counterpart (Figure 115). In addition, there was a 
difference in shape between the branded simvastatin 20 mg (Zocor® 20 mg) and its 
generic (B) counterpart (Figure 116). There was also a difference in colour between the 
branded omeprazole 20 mg (Losec® 20 mg) and its generic counterparts (Figure 117). 
One generic had a different dosage form than its branded counterpart. For example, the 
generic form (B) of Mobic® 15 mg was in capsule dosage form compared to tablet dosage 
form of its branded counterpart (Figure 118). Differences in packaging between the 
branded and generic medicines were also detected in this study as shown in Figure 119 
and Figure 120. 
 
Figure 115: The differences in shape and colour between the branded Ponstan® 500 
mg (B, left) and its generic counterpart (G, right). 
 
Figure 116: The differences in shape between the branded Zocor® 20 mg (B, left) and 
its generic counterpart (G, right). 
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Figure 117: The differences in colours between the branded Losec® 20 mg (B, left) 
and its generic counterpart (G, right). 
 
Figure 118: The differences in shape, colour and dosage form between the branded 
Mobic® 15 mg (B, left) and its generic counterpart (G, right). 
 
Figure 119: The differences in packaging between the branded Augmentin® 375 mg 
(left and top) and its generic counterparts (right and bottom). 
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Figure 120: The differences in packaging between the branded Losec® 20 mg (left) 
and its generic counterpart (right) and between the branded Ciproxin® 250 
mg (top) and its generic counterpart (bottom). 
Moreover, some generic medicines in this study showed poor clarity of solution and 
presence of un-dissolved residue and particles during the dissolution test compared to 
their branded counterparts. For example, the generic forms of Adalat 10 mg, Losec® 20 
mg, Mobic® 15 mg, Ciproxin® 250 mg, Zocor 20 mg, Augmentin® 375 mg, Voltaren® 50 
mg and Xeloda® 500 (Figure 121,Figure 122, Figure 123, Figure 30, Figure 124, 
Figure 125, Figure 126, Figure 127, Figure 128, Figure 129 and Figure 130). 
 
 
Figure 121: The differences between the branded Adalat® 10 mg (left) and its generic 
counterpart (right) after 10 minutes dissolution. 
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Figure 122: The differences between the branded Losec® 20 mg (left) and its generic A 
counterpart (right) after 60 minutes dissolution. 
 
 
Figure 123: The differences between the branded Mobic® 15 mg (left) and its generic 
A counterpart (right) after 60 minutes dissolution. 
 
 
Figure 124: The differences between the branded Ciproxin® 250 mg (left) and its 
generic A counterpart (right) after 120 minutes dissolution. 
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Figure 125: The differences between the branded Zocor® 20 mg (left) vs. generic A 
(middle) and generic B (right) after 120 minutes dissolution. 
 
 
Figure 126: The differences between the branded Zocor® 20 mg (left) vs. generic A 
(middle) and generic B (right) after 300 minutes dissolution. 
 
 
Figure 127: The differences between the branded Augmentin® 375 mg (left) and its 
generic A counterpart (right) after 30 minutes dissolution. 
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Figure 128: The differences between the branded Voltaren® 50 mg (left) and its 
generic A counterpart (right) after 120 minutes dissolution. 
 
 
Figure 129: The differences between the generic A of Voltaren® 50 mg (left) and 
generic B of Voltaren 50 mg (right) after 60 minutes dissolution. 
 
 
Figure 130: The differences between the branded Xeloda® 500 mg (left) and its 
generic A counterpart (right) after 60 minutes dissolution. 
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5.5  Discussion 
According to the result of this study, the dissolution rate profile of many of the studied 
generic medicines complied with the British Pharmacopeia (2011) (Commission on 
Human Medicines), European Pharmacopeia (2007) (Council of Europe-Strasbourg) and 
the US Pharmacopeia (2010) (The United states Pharmacopoeia Convention). Most of 
these medicines achieved 85% dissolution in 60 minutes or less. This is found to be 
compatible with the EMA and the FDA guidance for industry (European Medicines 
Agency, 2001, Food and Drug Administration, 1997). Two-points dissolution 
specification were selected in this study to ensure 85% dissolution in order to characterise 
the quality of all the included products (Food and Drug Administration, 1997). This can 
reflect that the in-vivo bioavailability of these products would be similar to that in-vitro, 
since dissolution testing is commonly used to predict in-vivo behaviour of the oral dosage 
formulation.  
On the other hand, many generic medicines tested in this study showed significant 
differences in dissolution behaviour compared to their branded counterparts. A total of 
21% (5/24) and 54% (13/24) of the generic medicines showed statistically significantly 
differences in their dissolution behaviour compared to their branded counterpart at 60 and 
120 minutes, respectively. In these, for example, some generics showed slower and/or 
faster dissolution rate than their branded counterparts. Other generics from the same 
manufacturer with different batches of the same drug also showed significant differences 
in their dissolution rate. This can confirm that substitution among generic medicines 
themselves can be risky. Nevertheless, some other generics violated the EMA and the 
FDA guidance for industry when they failed to achieve 85% dissolution at 60 minutes. 
This was clearly shown in the dissolution rate of the generic form of diclofenac sodium 
50 mg (Voltaren® 50 mg) (Figure 103).  
Other differences in the weight, size, shape, colour, packaging and dosage forms were 
also detected between the tested branded and their generic counterparts. The relationship 
between the drug weight and its performance is not yet clear. However, depending on the 
cause of these differences, it might elevate the side effects and/or drug interactions. In 
addition, sizes of some generic medicines has reached more than 18 mm; for example, the 
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tablets size of the generic forms of amoxicillin and clavulanate potassium (Augmentin® 
375 mg) and capecitabine 500 mg (Xeloda® 500 mg) were much bigger than their 
branded counterparts.  
However, according to the literature, the easiest size of tablets to swallow is 7-8 mm and 
the easiest size to handle is one larger than 8 mm (Puttalingaiah et al., 2011). A study in 
the literature has confirmed that medicine adherence was greatly influenced by the 
decline of swallowing ability especially for elderly and patients with oesophageal 
diseases (Epstein et al., 2005). Another study, demonstrated that the size and the surface 
form of the tablet were the main reasons causing the difficulty of swallowing (Overgaard 
et al., 2001). This indicates the potential impact of the size of tablet on patients’ 
compliance and adherence as well as clinical outcomes.  
Nevertheless, one generic in this study violated the EMA and the FDA rule of 
bioequivalence when failed to show the same dosage form as its branded counterpart. For 
example, the generic form of Mobic® 15 mg was found in capsule dosage form compared 
to the tablet dosage form of its branded counterpart medicine (Figure 118). According to 
the EMA and the FDA, medicinal product are considered equivalent to the original 
product if they contain the same amount of the same active ingredient (s) in the same 
dosage forms that meet the same or comparable standards (European Medicines Agency, 
2001, Food and Drug Administration, 2003).  
This indicates that bioavailability can differ when switching between tablet and capsule 
and also if used by a healthy person compared to an elderly person. For example, a study 
comparing the serum concentration of digoxin in tablets and capsules revealed that the 
bioavailability of digoxin from the capsules exceeded that from the tablets when used by 
a healthy person. In the elderly, the bioavailability of digoxin from the capsules was 
lower than expected, which can result in lower therapeutic serum concentrations 
(Pouwels et al., 1991). It is well known that digoxin is a narrow therapeutic index drug 
which means that small changes in dissolution rates can cause problems because of too 
many side effects or too little effectiveness (Dokoumetzidis and Macheras, 2006). 
Moreover, some generic medicines in this study showed poor clarity of solution and 
presence of un-dissolved residue and particles compared to their branded counterparts. 
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This, however, might impact patient safety by increasing side effects and drug 
interactions. According to the literature, particles, degradation products and residual 
solvents all pose potential threats to patient safety (Shakweh et al., 2007). For example, a 
study was conducted to compare the pharmaceutical quality of 34 generic formulations of 
ceftriaxone (antibiotic agent) to their branded counterpart Rocephin®. It was found that 
all the 34 tested generic medicines failed to meet Roche specifications for Rocephin®. A 
total of 18 generics tested in this study contained more than five times the number of 
particles found in their branded counterparts and violated the quality standards specified 
in the European and US Pharmacopoeias. The most common failures amongst generic 
medicines were clarity of solution. It concluded that none of the generics tested in this 
study can be considered pharmaceutically equivalent to Rocephin® (Schito and Keenan, 
2005).  
Findings in this chapter are compatible with others in this thesis and in the existing 
literature (Al Ameri et al., 2011b, Angeli and Trezza, 2009, Adegbolagun et al., 2007, 
Bertocchi et al., 2005). For example, a study evaluating the quality and dissolution 
profiles of 22 marketed generic/copy tablet formulations of ramipril 2.5 mg compared 
with its reference Tritace® 2.5 mg showed that only 24% (5/21) of the generic/copies 
were of equivalent quality and similar dissolution profiles to that of the reference product. 
Another study presented in this thesis revealed that a total of 88% of patients surveyed in 
the UK admitted that they detected visual differences in shape, size, colour and 
packaging between the branded and their generic counterparts (Al Ameri et al., 2011b). 
Undoubtedly, these differences might impact patient adherence to the medication regime 
and the side-effects of generic medicines (Berg et al., 2008b, Phillips et al., 2007). 
Therefore, patient education and monitoring is essential when switching their medicine to 
ensure effective and efficient drug substitution. This also confirms that “equivalence does 
not necessary imply bioequivalence as differences in the excipients and/or manufacturing 
process can lead to faster or slower dissolution and/or absorption” (European Medicines 
Agency, 2001).  
There are many potential factors that can explain the differences in dissolution behaviour 
between the branded and their generic counterparts. These include the manufacturer, 
apparatus type, surface area of a drug, surfactants, storage, dosage form and the level and 
Chapter 5 Dissolution 
Page 199 of 446 
type of excipients. The manufacturer of the drug can play a major part in its dissolution 
profile. In the literature, it was reported that there are variable clinical responses to the 
same dosage form of a drug product supplied by different manufacturers. For example, it 
was found that simvastatin tablets and capsules obtained from international 
manufacturers were not comparable to that of the US products’ in the quality assurance 
testing and significant variability was also found among foreign-made tablets (Veronin 
and Nguyen, 2008). Another study compared the dissolution behaviour of six diclofenac 
sodium prolonged release tablets of different brands obtained from the national market. It 
revealed that release characteristics varied considerably among different manufacturers 
and that even identical formulations showed rather dissimilar release profiles. Therefore 
the interchangeability of these drugs was questioned (Bertocchi et al., 2005).  
The choice of apparatus type (paddle vs. basket) can also affect the dissolution test and it 
depends largely on the physiochemical properties of the dosage form (Pharmainfo.net, 
2008). Another possible reason for the dissimilarity in dissolution rate is the difference in 
particle or surface area of the drug particles. For example, a study of an in-vitro 
comparison between the first and second generations of ciclosporin A products to generic 
ciclosporin A formulations revealed that the generic ciclosporin A showed significant 
differences in droplet size and distribution between an aqueous phase and a high fat 
content food (Thomas et al., 2005).  
The use of a surfactant such as sodium lauryl sulphate which is essential for poorly 
soluble drugs such as simvastatin can also affect the dissolution rate (Singla et al., 2009). 
A dissolution medium containing surfactant can better simulate the environment of the 
gastrointestinal tract than a medium containing organic solvents or other 
nonphysiological substances (Singla et al., 2009). Cases where a higher concentration of 
surfactant is used can lead to faster dissolution and any correlation with in-vivo 
performance can be lost. Therefore a low surfactant is a modifier of choice (Singla et al., 
2009).  
The storage of a drug can also affect its dissolution profile. For example, a study 
evaluated the differences between the branded and its generic counterpart of diclofenac 
sodium on the dissolution rate after storing at 40 ºC, 75% relative humidity. It revealed 
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that the dissolution rate of the generic form of diclofinac sodium was reduced 
significantly during storage time compared to its branded counterpart (Risha et al., 2003). 
Another study detected wide variations in in-vitro performance of omeprazole capsules. It 
revealed that the branded medicine was found more resistant to changes caused by the 
packaging material than its generic counterparts (El-Sayed et al., 2007).  
Differences in dissolution rates between the branded and its generic counterpart drugs can 
be also related to the composition of excipients. This can mainly influence the side-effect 
profiles of the generic drugs. Excipients, as mentioned in the introduction of this thesis, 
are substances other than the pharmacologically active drug and include binders, fillers, 
disintegrators, lubricants, sweeteners, preservatives, flavours, colours, printing inks, etc 
(Iheanacho and Blythe, 2009, Wandel et al., 2003). Although excipients are considered 
the inactive ingredients that do not have a therapeutic effect, some studies have revealed 
that excipients can cause various side effects (Wandel et al., 2003). In many cases the 
performance of a drug can greatly depend on the quality of excipients used in 
manufacturing and on the quality of the process (Bertocchi et al., 2005). In the literature, 
for example, it is mentioned that the excipients in one of the generic forms of simvastatin 
caused the rapid release of the drug during the first five minutes of the dissolution test 
(Guzik et al., 2010). 
Drug binding and extractable impurities affect drug dissolution profiles (Joshi et al., 
2008). A study comparing meloxicam 15 mg to its generic counterpart revealed that the 
dissolution profile for the generic product was statistically different from that of the 
branded product regarding the drug release percent of the pharmaceutical form (Oliveira 
et al., 2009). Another study showed that different formulations of digoxin yielded 
tremendous differences in the dissolution profiles. The study indicated that either batch-
to-batch or amongst brands bio-in-equivalence originated from differences in dissolution 
rates (Dokoumetzidis and Macheras, 2006).  
Overall, the dissolution test is a well established, reproducible, reliable and valuable tool 
for characterising a drug at different stages in its lifecycle. Results in this study, like 
others in the thesis, they clearly raise a question about the interchangeability between 
branded medicines and their generic counterparts as well as among generics themselves. 
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Therefore, it is strongly suggested to educate and monitor patients when performing drug 
substitution. Recognition of the scientific concerns explored in this chapter should be 
considered when a clinical choice between two drugs is required. Generic medicines can 
still be recommended especially when the medical or clinical outcomes are easily 
measurable such as pain, headache, and infections and should be avoided when the 
consequences of under-dosing or overdosing are greater such as with critical doses and 
narrow therapeutic index drugs.  
5.6 Main limitations of the study 
The dissolution test is used to forecast the in-vivo behaviour of a drug. However, definite 
conclusions about the bioavailability and bioequivalence of these products should be 
conducted in in-vivo studies. It is critical that the in-vitro test should mimic the in-vivo 
conditions as closely as possible. Given the nature of the human GI tract and various 
factors that affect its activity, the generalisation of dissolution conditions and results of 
this study are not recommended. In-vivo comparison studies are required to demonstrate 
findings in this thesis.  
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6 Chapter 6 Bioequivalence study of two 
clarithromycin 500 mg formulations under fasting 
conditions in healthy subjects. 
6.1  Introduction  
Clarithromycin is a semi-synthetic macrolide antibiotic used to treat tonsillitis, 
pharyngitis, acute bacterial exacerbation of chronic bronchitis, pneumonia and skin 
infections. The mechanism of action of clarithromycin is similar to erythromycin but it is 
more effective against certain gram-negative bacteria, particularly Legionella 
pneumophila. Clarithromycin prevents bacteria from growing by binding to the subunit 
50S of the bacterial ribosome and thus inhibits the translation of peptides and interferes 
with their protein synthesis (Chemical Book, 2010).  
Clarithromycin can be taken orally without being protected from gastric acids because it 
is acid-stable. It is actively transported to the site of infection because of its high 
concentration in phagocytes. The concentration of clarithromycin in the tissues can be 
over 10 times higher than in plasma. Chemically, Clarithromycin is 6-O-
methylerythromycin and is shown as a white crystalline powder soluble in acetone, 
slightly soluble in methanol, ethanol and partially soluble in water. The molecular 
formula is C38H69NO13, and the molecular weight is 747.96 (Chemical Book, 2010) 
(Figure 131). 
 
Figure 131: The structural formula of clarithromycin(Chemical Book, 2010). 
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Taken the drug with food slightly delays the onset of clarithromycin absorption, 
increasing the peak time from approximately 2 to 2.5 hours and the peak plasma 
concentration by about 24% but does not affect the extent of clarithromycin 
bioavailability. Therefore, clarithromycin tablets may be given with disregard of 
food, (Abbott Laboratories Ltd, 2005). The elimination half-life of clarithromycin is 
about 3 to 4 hours with 250 mg administered every 12 hours but increases to 5 to 7 
hours with 500 mg administered every 8 to 12 hours. The nonlinearity of 
clarithromycin pharmacokinetics is slight at the recommended doses of 250 mg and 
500 mg administered every 8 to 12 hours.  
There are many common minor side effects of clarithromycin. These include nausea, 
dyspepsia, diarrhoea, vomiting, abdominal pain and headache. There are also some 
rare major side effect such as hearing loss which is usually reversible upon 
withdrawal of therapy, pseudomembranous colitis which may range in severity 
from mild to life threatening and hypoglycaemia. As with other macrolides, 
hepatic dysfunction (which is usually reversible) including altered liver function 
tests, hepatitis and cholestasis with or without jaundice has been reported (Abbott 
Laboratories Ltd, 2005).  
In order to obtain marketing approval for the generic form of clarithromycin, regulatory 
authorities require the testing of bioequivalence between the generic and innovator 
formulations. Generic drugs, as mentioned in this thesis, are those drugs that contain the 
same active substance, dosage form, strength and route of administration as the original 
product (Suh, 1999). Since generic drugs contain the same active substance, it is not 
necessary to repeat the preclinical tests and the clinical trials done for the original drug. 
Instead, they are replaced by bioequivalence trials (Suh, 1999).  
Bioequivalence studies are considered clinical trials that aim to show that the 
experimental treatment is not different, within defined limits, in characteristics from the 
standard treatment (Lesaffre, 2008). Therefore, generic drugs are usually considered 
bioequivalent to their branded counterparts if they have the same active ingredients, 
dosage form, route of administration, follow good manufacturing practice (GMP) 
guidelines and demonstrate bioequivalence. However, colours, flavours and other 
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inactive ingredients (excipients) of the branded product may still be different from its 
generic counterpart (Iheanacho and Blythe, 2009, Wandel et al., 2003). 
This chapter demonstrates an example of the average bioequivalence trial. Generally, in a 
bioequivalence study, subjects undergo sequences of observation periods in which a 
series blood samples are drawn at various times after administering a single dose of a 
formulation. The commonly computed parameters include the area under the time-
concentration curve (AUC), the maximum plasma concentration (Cmax) and the time to 
maximum concentration (tmax). When the true means of the marginal bioavailability 
distributions of the test and reference formulations in the population of subjects are 
sufficiently close, this is called the ‘average’ bioequivalence.  
According to the EMA and the FDA, sufficiently close means that a 90% confidence 
interval for the ratio of the true mean bioavailability lays entirely between the limits 0.8 
and 1.25 (European Medicines Agency, 2001, Food and Drug Administration, 2009). 
This indicates that the generic medicine should have 80%-125% bioavailability at the site 
of action compared to the original branded drug. For the purpose of meeting the 
requirement of generic approval, the EMA and the FDA state that studies should be 
conducted under fasting conditions to detect potential differences between the tested 
formulations (European Medicines Agency, 2001, Food and Drug Administration, 2009). 
Therefore, this study was conducted in healthy subjects under fasting conditions to 
investigate the bioequivalence between two (branded and generic) clarithromycin 500 mg 
formulations. 
6.2 Objective 
The objective of this study was to demonstrate and investigate the bioequivalence 
between generic Resclar 500 mg tablets (test product, Neopharma, UAE) and its 
innovator Klacid® 500 mg tablet (reference product, Abbott Laboratories Ltd, England) 
in fasting healthy subjects.  
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6.3 Subjects and Method 
6.3.1 Study protocol 
This study was conducted in collaboration with Neopharma Pharmaceutical Company in 
the UAE. This study was a randomised, single dose, open label, two-way crossover 
design. According to the previous bioequivalence studies in IPRC (International 
Pharmaceutical Research Centre, Amman, Jordan) and to many regulatory agencies such 
as the EMA and the FDA, a minimum of 12 subjects is adequate and acceptable to 
conclude bioequivalence between a branded medicine and its generic counterpart 
(Tamboli et al., 2010). However, the protocol of this study called for a minimum of 24 
healthy volunteers to be able to detect any differences between the tested formulations.  
Recruited subjects were to receive one tablet of Resclar 500 mg and one tablet of Klacid® 
500 mg in a randomised trial with a washout period of seven days. The protocol of this 
study was written according to ICH GCP (International Conference on Harmonisation-
Good Clinical Practice guidelines adopted by the EMA and the FDA (European 
Medicines Agency, 1996, Khan et al., 2006). After the Research Ethics Committee of the 
IPRC reviewed the study protocol number: CLA-T023 (Appendix 9); the final approval 
(number: 27/BioNR/09) was granted on 14/04/2009 (Appendix 10). The clinical part of 
the study was initiated at the IPRC clinical site. The first administration of the study drug, 
as well as the first blood collection for drug analysis, took place on 26/04/2009. A 
washout period of seven days was allowed. The last drug administration took place on 
03/05/2009 and the last blood collection took place on 04/05/2009. 
6.3.2 Subjects 
Recruitment was mainly from the communities of Amman, Jordan and surrounding 
regions. Demographic data and sequence of participating volunteers are shown in Table 
22 and Appendix 11. The purpose of the study, the procedures to be carried out and the 
potential hazards were described to all subjects in simple non-technical terms. They were 
required to read, understand, sign and date a consent form summarising the discussion 
prior to enrolment. Subjects were assured that they may withdraw from the study at any 
time without jeopardising their medical care. The study investigators had the right to 
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discontinue any volunteers from the study if they felt it is necessary for any reason 
including side effects or failure to comply with the study protocol. Each subject was 
given a copy of the consent form.  
Table 22: Demographic data and individual values for the eligible 24 subjects for the 
bioequivalence study between Resclar 500 mg (Neopharma, UAE) and 
Klacid® 500 mg (Abbott Laboratories Ltd, England). 
Subject No. Sequence height (cm) weight (kg) Age (years) Sex Race 
1 BA* 181 78 20 Male Caucasian 
3 AB 166 70 39 Male Caucasian 
4 BA 186 70 31 Male Caucasian 
5 AB 170 85 36 Male Caucasian 
6 BA 173 70 21 Male Caucasian 
8 BA 180 65 23 Male Caucasian 
9 BA 174 80 35 Male Caucasian 
10 AB 170 70 40 Male Caucasian 
11 AB 180 85 27 Male Caucasian 
12 BA 170 85 36 Male Caucasian 
13 AB 175 60 22 Male Caucasian 
14 AB 170 80 36 Male Caucasian 
15 AB 172 75 20 Male Caucasian 
16 AB 183 70 25 Male Caucasian 
17 AB 170 60 22 Male Caucasian 
18 BA 170 75 26 Male Caucasian 
19 BA 174 65 28 Male Caucasian 
20 AB 179 90 19 Male Caucasian 
21 BA 180 80 26 Male Caucasian 
22 BA 164 60 26 Male Caucasian 
23 AB 180 65 21 Male Caucasian 
24 BA 178 70 29 Male Caucasian 
25 BA 180 65 22 Male Caucasian 
27 AB 173 80 19 Male Caucasian 
Mean 175 73 27  
SD 5.68 8.76 6.71  
CV% 3.25 11.99 24.83  
Minimum 164 60 19  
Median 174 70 26  
Maximum 186 90 40  
*A: The test drug (Resclar), B: The branded reference drug (Klacid®). 
The demographic characteristics of the participating 24 subjects, who completed 
the study and were involved in the pharmacokinetic analysis were as shown in 
Table 22: 
• Age ranging between 19 and 40 years (Mean ± SD 27 ± 6.71 years).  
• Weight at screening examination between 60 and 90 kg (Mean ± SD 73 ± 8.76 
kg). 
• Height between 164 and 186 cm (Mean ± SD 175 ± 5.68 cm).  
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In this study, subjects received laboratory tests of hepatic function prior to 
admission to Period II and received the same physical assessment and vital signs 
evaluation as well as laboratory tests of hepatic function on follow up examination, 
which was within at least 24 hours from collecting the last sample in Period II. Vital 
signs were taken before dosing and at approximately the following times from the study 
drug’s administration: 0.66, 1, 1.66, 2, 2.50, 3, 4, 6, 11 and 24 hours. A vital sign could 
be taken at other times when deemed necessary (Appendix 11). 
The inclusion criteria: 
• Healthy subjects aged 18 to 45 years.  
• Subjects whose medical demographics were within the normal range (measured 
not longer than two weeks before the initiation of the clinical study).  
• Subjects with results of laboratory tests within the normal range (laboratory tests 
were performed not longer than two weeks before the initiation of the clinical 
study).  
• Subjects who did not have a known allergy to the drug tested or to any of its 
ingredients or any other related drugs (macrolide antibiotics).  
• Subjects with the ability to provide written informed consent.   
The exclusion criteria:  
• Subjects with medical demographics outside the reference ranges.  
• Subjects with results of laboratory tests outside the reference ranges.  
• Subjects with acute infection within one week preceding first study drug 
administration.  
• Subjects with a history of drug or alcohol abuse.  
• Smoker smoking more than 10 cigarettes a day.  
• Subjects who were not welling to stop taking any prescription or non-prescription 
drugs within the two weeks preceding the first study drug administration until the 
end of the trial.  
• Subjects who were on a special diet (for example subject is vegetarian).  
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• Subjects who were not willing to stop consuming any beverages or food 
containing grapefruit seven days prior to the first study drug administration until 
donating the last sample in each respective period.  
• Subjects who had a history of severe disease with a direct impact on the study.  
• Subjects who had participated in a bioequivalence study or in a clinical trial 
within the last two months before first drug study administration.  
• Subjects intending to be hospitalized within three months after first study drug 
administration.  
• Subjects who, through completion of this study, would have donated more than 
500 mL of blood in 14 days, or 750 mL of blood in 30 days, or 1000 mL of blood 
in 90 days, or 1250 mL of blood in 120 days, or 1500 mL of blood in 180 days, or 
2000 mL of blood in 270 days, or 2500 mL of blood in 1 year.  
• Subjects who were pregnant, or had a positive urine or blood pregnancy test, or 
were lactating females.  
• Subjects who had a history or presence of significant asthma, peptic or gastric 
ulcer, sinusitis, pharyngitis, impaired renal function, hepatic disorder, 
cardiovascular disorder, neurological disease, haematological disorders or 
diabetes, psychiatric, dermatologic or immunological disorder.  
• Subjects who had been engaged in strenuous exercise at least one day prior to 
dosing till the last sample of each respective period.  
• Subjects taking theophylline, verapamil, ranitidine bismuth citrate, oral 
anticoagulants, digoxin, colchicine and CYP3A or CYP3A isoform.  
• Subjects who have a history of difficulties in swallowing or any gastrointestinal 
disease. 
A total of 50 healthy subjects were initially recruited according to the selection 
criteria described in the study protocol (Figure 132). All participating subjects were 
treated as a single group. Each subject was examined thoroughly during screening 
procedures as described in the protocol, the screening time being set to be not more 
than two weeks prior to the first study drug administration of study period one.  
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Figure 132: Disposition of subjects. 
After the screening of the enrolled 50 subjects, eight subjects withdrew for 
abnormal laboratory results, 10 subjects withdrew for personal reasons, 2 subjects 
were excluded by IPRC staff due to protocol violation and 2 subjects withdrew for 
medical conditions. A total of 28 subjects were enrolled, 2 subjects withdrew for medical 
conditions after drug administration in study period I but before drug administration in 
period 2 (withdrawal group 2, Table 23), so 26 subjects completed the crossover 
(For details of withdrawals see Appendix 12).  
Table 23: The defined three groups of subjects’ withdrawal. 
Type of withdrawal Definition 
Withdrawal group 1 Withdrawal after screening procedures have been performed but before the study drug administration in study period I. 
Withdrawal group 2: Withdrawal after study drug administration in study period I but before study drug administration in study period II. 
Withdrawal group 3: Withdrawal after study drug administration in study period II. 
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Samples from the first 24 subjects who completed the study was analysed for the drugs’ 
plasma concentrations. Samples from withdrawals were not assayed and were replaced 
with alternate subjects prior to analysis. Alternates were chosen in order to obtain the 
same number of subjects per sequence. Having completed the study, subjects 
underwent thorough physical assessment and vital signs evaluation on follow up 
examination to assure their safety. Clinical assessment for all subjects was carried 
out to evaluate their tolerability to the study’s medications. Study subjects showed 
good tolerance to the two study's drugs. See Appendix 11 for clinical assessment for 
all subjects. 
6.3.3 Randomisation 
The study was a randomised two-way, two sequence crossover design. The order of 
receiving the test or the reference medicine for each subject was determined according to 
the randomisation plan (Table 24). Subjects were sequentially assigned a number as per 
the arrival sequence numbers given on the basis of the subject’s reporting time to the 
facility on the day of check-in for period one and depending on the compliance to the 
requirements of the study protocol.  
All data of the clinical part of the study were documented in case report forms (CRFs) by 
the staff of the IPRC (all forms are in Appendix 14). The principle investigators checked 
correct completion of the case report forms. The study personnel involved in the sample 
analysis were kept blinded to the randomisation code during the study. During this 
study, 28 subjects were dosed. Thus, the risk to a healthy volunteer taking two 
oral doses of Resclar 500 mg and Klacid® 500 mg, with a 7 days washout interval 
was minimal. 
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Table 24: Randomisation plan for the bioequivalence study between Resclar 500 mg 
(Neopharma, UAE) and Klacid® 500 mg (Abbott Laboratories Ltd, 
England). 
Subject Number Treatment 
 Study Period I Study Period II 
1 
2* 
3 
4 
5 
6 
7* 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
B 
A 
A 
B 
A 
B 
B 
B 
B 
A 
A 
B 
A 
A 
A 
A 
A 
B 
B 
A 
B 
B 
A 
B 
B 
B 
A 
A 
A 
B 
B 
A 
B 
A 
A 
A 
A 
B 
B 
A 
B 
B 
B 
B 
B 
A 
A 
B 
A 
A 
B 
A 
A 
A 
B 
B 
A: The test product (Resclar 500 mg tablet, Neopharma, UAE), B: The reference product (Klacid® 500 mg 
tablet, Abbott Laboratories Ltd, England) 
* Withdrawal 
6.3.4 Study treatment 
Bioequivalence evaluation is usually carried out by comparing the in-vivo rate and extent 
of drug absorption of a test and a reference formulation in fasting healthy subjects. The 
sponsor supplied sufficient quantities of the study formulations, Table 25, to allow 
completion of this study. The study was conducted in a pre planned scheme, as described 
in Table 26 and Appendix 11. Drugs were stored in sealed containers in a locked 
cabinet in the pharmacy located on the first floor of the IPRC building. All 
necessary storage conditions were taken into account in handling and dispensing of 
the drugs. Temperature and humidity monitoring were carried out as appropriate.  
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Table 25: Identity of the study medications included the the bioequivalence study 
between Resclar 500 mg (Neopharma, UAE) and Klacid® 500 mg (Abbott 
Laboratories ltd, England). 
Identification Test product- Treatment A Reference product- Treatment B 
Drug name Resclar 500 mg  Klacid® 500 mg 
Dosage form Film coated tablet Film coated tablet 
Strength 500 mg clarithromycin 500 mg clarithromycin 
Manufacturer Neopharma, UAE Abbott Laboratories Ltd, England 
Batch No. CLB8002 66040VA 
Expiry date 12/10 06/11 
Table 26: Study plan and design. 
Study initiation Period I Washout Period II Study completion 
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6.3.5 Dietary restrictions 
No consumption of alcohol was permitted for 48 hours prior to the study drug 
administration until the collection of the last sample of the respective study period. No 
consumption of any beverages or foods containing methyl-xanthines, e.g. caffeine 
(coffee, tea, cola, cocoa, chocolate, etc) was permitted for the subjects 24 hours prior to 
the study drug administration until the end of the confinement in each study period.  
In addition, the consumption of any beverages or foods containing grapefruit was 
prohibited one week before first study drug administration and throughout the entire 
study. Food and fluid intake was identical in both study periods, starting from the dinner 
served 10 hours before study drugs administration on study day one until the end of 
confinement. Meals were standardised in composition and amount in both periods.  
Crossover 
Test product 
Reference product 
Chapter 6 Bioequivalence 
Page 213 of 446 
Subjects were not allowed to consume any additional beverages or food other than those 
provided throughout the period of confinement. The subjects received their standardised 
meals at the times shown in Table 27. 
Table 27: Standardised diets served during the study. 
Study day Standardised diet Time received 
-1 Dinner Finished at least 10 hours before the scheduled time of 
study drug administration in the morning of study day 1 
1 Lunch  4 hours after study drug administration  
1 Snack 8 hours after study administration 
1 Dinner 12 hours after study drug administration 
6.3.6 Blood sample collection and analysis 
Blood samples were collected for the measurement of clarithromycin in each period at 
pre dose and at 0.33, 0.66, 1.00, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 24 and 36 hours, 
(Appendix 11). A nurse was delegated for collecting blood for each sampling time. 
The volunteers were called into the room at the assigned collection time and had 
their blood drawn similarly. Another nurse was delegated for taking the vital signs 
at the assigned time and the volunteers were called in to have their vital signs 
taken. A clock and all equipment necessary for blood collection from the 
volunteers were available in the room, as well as a blood pressure monitor, 
stethoscope and scales. In this room, cannula insertion, administration of study 
drug, as well as blood collection was carried out.  
Blood samples were collected into tubes containing heparin as an anticoagulant, 
slightly shaken and centrifuged for about 10 minutes. After centrifugation, plasma 
samples were transferred directly into 5 mL plastic tube. Samples were 
immediately stored at the study site in a freezer at a nominal temperature of -20°C. 
The label of the collecting tubes had the study code number, subject number, study 
period and the designated sample number. It did not contain information that 
would allow the identification of the given treatment to ensure a blind analysis of 
the samples. The total amount of blood loss during the whole study (including blood 
for laboratory tests) did not exceed 335.5 ml (This volume does not include the blood 
for repeated laboratory tests): [((1x8 mL + 1x8 mL for pre dose samples) + (17x8 mL 
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for subsequent samples)) x 2] plus 13.5 mL for screening examination, 9 mL for liver 
enzyme test prior to admission to period 2 examination and 9 mL for liver enzyme 
test at the follow up examination.  
The bio-analysis of clinical plasma samples for the first 24 subjects was accomplished by 
a LC-MS/MS method for calrithromycin at the IPRC. This method was developed and 
validated in accordance to the FDA and ICH guidance (Eurachem Guide, 1998, Food and 
Drug Administration, 2003, International Conference of Harmonisation of Technical 
Requirements for Registrationof Pharmaceuticals for Human Use, 1996).  
6.4 Results 
The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax and tmax) were calculated 
using Microsoft Office Excel 2007 and Minitab 16 Statistical Software (made by 
“Minitab Inc”, Pennsylvania, USA). A normality test was performed on the data and 
the data appeared normally distributed. The mean of the individual plasma 
concentration for the tested and the reference products are listed in Table 28 and 
Table 29. The mean pharmacokinetics parameters for subjects who completed all 
phases of the study are summarised in Table 30 and Table 31. The ANOVA model 
included “sequence,” “formulation,” and “period” as fixed effects, employing 5% level of 
significance and “subject” (sequence) as a random effect, “sequence” effect was tested 
using “subject” (sequence) as an error term.  
This procedure involved the calculation of 90% confidence intervals for the ratio (or 
differences) between the test and reference products pharmacokinetic variable averages. 
The limits of the observed confidence intervals were within a predetermined range for the 
ratio (or differences) of the product averages. The determination of the confidence 
interval range and the procedures were employed for the analysis of pharmacokinetic data 
derived from in-vivo bioequivalence studies. The bioequivalence of a single dose of 
clarithromycin was assessed by comparing the pharmacokinetic parameters derived from 
the plasma concentration-time profiles. These pharmacokinetic parameters were then 
analysed statistically to determine if the test and reference products yielded comparable 
values. Standard statistical methodology was used based on the two one-sided test 
procedures to determine whether average values for pharmacokinetic parameters 
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measured after administration of the test and reference products were comparable. 
Demographic data and all clinical assessment along with laboratory evaluation 
were performed for all enrolled subjects.  
However, for pharmacokinetic evaluations the data from the first 24 subjects who 
where crossed over and completed the study were included in the calculation. 
Slight variations from the study protocol concerning the clinical laboratory tests were 
observed (a list of these variations can be found in Appendix 13). Yet, these 
variations were considered insignificant. 
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Table 30: Individual pharmacokinetics of clarithromycin after single dose 
administration of Resclar 500 mg (test product). 
Subject No. AUC0-t (ng.h/ml) 
AUC0-∞ 
(ng.h/ml)
  
Cmax (ng/ml) tmax (h) 
1 16103.81 16103.81 1932 1.33 
3 53358.49 55030.73 4839 2 
4 13743.76 13743.76 1590 1.66 
5 33991.56 33991.56 4543 1.66 
6 16816.49 17189.92 2493 2 
8 27866.37 27866.37 3507 0.66 
9 25526.56 25857.17 3429 1.66 
10 25707.98 26445.54 1481 2 
11 26501.62 26501.62 2946 1.66 
12 37635.84 38013.19 3381 2.5 
13 26756.42 26756.42 2681 4 
14 13412.29 13412.29 2568 1.66 
15 15148.56 15148.56 3627 1.33 
16 35871.94 48935.97 4728 1 
17 14716.56 14716.56 2115 2.5 
18 31229.03 31229.03 3697 1.33 
19 13886.37 13886.37 2118 1.33 
20 18852.89 18852.89 2692 1 
21 12107.35 12395.48 1334 0.66 
22 9650.655 9650.655 1513 1.66 
23 22471.59 23003.05 2283 2.5 
24 10692.02 10692.02 1786 2 
25 29673.81 29673.81 4131 1.66 
27 19956.78 19956.78 3459 1.66 
n 24 24 24 24 
Mean 22986.61 23163.71 2869.71 1.73 
SD 10529.80 11114.12 1061.41 0.70 
CV% 45.80 47.98072 36.99 40.54 
Minimum 9650.66 9650.66 1334 0.66 
Median 21471.70 21560.25 3164 1.69 
Maximum 53358.49 55030.73 4839 4.00 
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Table 31: Individual pharmacokinetics of clarithromycin after single dose 
administration of Klacid® 500 mg (reference product). 
Subject No. AUC0-t (ng.h/ml) 
AUC0-∞ 
(ng.h/ml)
  
Cmax (ng/ml) tmax (h) 
1 17411.61 17411.6 2247 2 
3 45883.67 46819.6 4509 3 
4 16200.34 16200.3 2209 1.33 
5 27380.23 27380.2 4102 2.5 
6 18259.87 18259.9 2522 1.66 
8 14467.75 14467.8 1473 1.66 
9 28072.56 28401.4 3823 2 
10 26114.82 26863.0 2098 5 
11 23134.83 23134.8 2624 2.5 
12 39676.67 39966.6 4400 2 
13 40987 40987 3784 1 
14 14108.13 14108.1 1962 2.5 
15 34807.48 35116.6 4901 1.66 
16 22113.51 22113.5 3127 0.66 
17 15197.57 15197.6 3597 0.66 
18 37430.34 37635.6 4267 1.33 
19 16497.32 16497.3 2164 0.66 
20 18713.2 18713.2 2517 1 
21 16220.07 16220.1 3434 1 
22 9959.335 9959.3 1520 1.66 
23 18513.65 18889.5 2301 2.5 
24 10167.67 10167.7 1797 1.33 
25 16587.36 16587.4 2296 2.5 
27 19430.88 19430.9 2989 1.33 
n 24 24 24 24 
Mean 22805.66 22912.01 2944.29 1.81 
SD 10119.92 10380.15 1017.00 0.96 
CV% 44.37 45.3 34.5 52.83 
Minimum 9959.3 9959.3 1473 0.66 
Median 18613.4 18801.3 2573 1.66 
Maximum 45883.7 46819.6 4901 5.00 
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Both tested formulations met the definition of bioequivalence with respect to the 
bioavailability of Resclar 500 mg (test product) compared with that of Klacid® 500 mg 
(reference product). The mean ratio and 90 % confidence intervals of the log-transformed 
values of Cmax and AUC0-t are shown in Table 32 and Table 33. The concentration of 
Cmax, AUC0-t and AUC0-∞ for clarithromycin 500 mg was 96.41% (95% CI 85-110), 
99.98% (95% CI (89-112) and 101.49% (95% CI (90-115), respectively. This clearly 
demonstrates that the 90% confidence interval (CI) for Cmax, AUC0-t and AUC0-∞ were 
within the protocol-defined acceptance limits of 80-125%. In addition, the analysis of the 
mean concentration was not statistically significant, p> 0.05. 
Table 32: Pharmacokinetic parameters (mean ± SD) of Resclar 500 mg (test, 
Neopharma, UAE) tablets and Klacid® 500 mg (reference, Abbott 
Laboratories ltd, England). 
Pharmacokinetic 
parameters 
Treatment (Mean ± SD) 
Resclar (test product) Klacid® (reference product) 
Cmax (ng/mL) 2870 ± 1061 2944 ± 1017 
AUC0-t (ng.h/mL) 22987 ± 10530 22806 ± 10120 
AUC0-∞ (ng.h/mL) 23164 ± 11114 22912 ± 10380 
tmax (h) 1.73 ± 0.70 1.81 ± 0.96 
Table 33: Bioequivalence confidence intervals of Resclar 500 mg (test, Neopharma, 
UAE) tablets and Klacid® 500 mg (reference, Abbott Laboratories ltd, 
England). 
Pharmacokinetic 
parameter Estimated % of concentration 90% Confidence Intervals 
Cmax (ng/ml) 96.41 84.53-109.95 
AUC0-t (ng.h/ml) 99.98 89.56-111.61 
AUC0-∞ (ng.h/ml) 101.49 89.96-114.50 
tmax (h) 0.165 -0.17-0.42 
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6.4.1 Adverse events 
Adverse events (AE) refer to any unfavourable and unintended sign (including an 
abnormal laboratory finding), for example, symptom or disease temporarily associated 
with the use of a medicinal product. The study subjects were asked to inform the clinical 
staff of the occurrence of any AEs immediately when they were experienced. 
However, adverse events encountered during the study were minimal. Both 
formulations were well tolerated in this population and no relevant differences in 
the safety profiles were observed. However, five of the 26 participating subjects 
experienced AEs. Headache and abdominal pain were the most common adverse 
events in both test and reference drug groups. All adverse events which occurred 
during this study are summarised in Table 34 and Appendix 11. 
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6.4.2 The mean blood concentrations of clarithromycin after administering 
Resclar 500 mg (test, Neopharma, UAE) tablets and Klacid® 500 mg 
(reference, Abbott Laboratories ltd, England) tablets in all 
participating subjects. 
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Figure 133: The mean plasma concentrations of clarithromycin 500 mg after a single 
dose of a generic formulation Resclar 500 mg (test) and Klacid® 500 mg 
(reference) in fasting healthy volunteers (n=24). 
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Figure 134: The log mean plasma concentrations of clarithromycin 500 mg after a 
single dose of Resclar 500 mg (test) and Klacid® 500 mg (reference) in 
fasting healthy volunteers (n=24).  
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Figure 135: The mean plasma concentrations of clarithromycin 500 mg after a single 
dose administration of Klacid® 500 mg (test) in fasting healthy volunteers. 
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Figure 136: The mean plasma concentrations of clarithromycin 500 mg after a single 
dose administration of Klacid® 500 mg (test) in fasting healthy volunteers. 
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6.4.3 Concentration and the logarithmic concentration of Resclar 500 mg 
(test, Neopharma, UAE) tablets and Klacid® 500 mg (reference, 
Abbott Laboratories ltd, England) in each participating subjects. 
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Figure 137: Concentration of Resclar compared to Klacid® in subject 1. 
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Figure 138: Logarithmic concentration of Resclar compared to Klacid® in subject 1. 
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Figure 139: Concentration of Resclar compared to Klacid® in subject 3. 
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Figure 140: Logarithmic concentration of Resclar compared to Klacid® in subject 3. 
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Figure 141: Concentration of Resclar compared to Klacid® in subject 4. 
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Figure 142: Logarithmic concentration of Resclar compared to Klacid® in subject 4. 
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Figure 143: Concentration of Resclar compared to Klacid® in subject 5. 
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Figure 144: Logarithmic concentration of Resclar compared to Klacid® in subject 5. 
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Figure 145: Concentration of Resclar compared to Klacid® in subject 6. 
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Figure 146: Logarithmic concentration of Resclar compared to Klacid® in subject 6. 
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Figure 147: Concentration of Resclar compared to Klacid® in subject 8. 
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Figure 148: Logarithmic concentration of Resclar compared to Klacid® in subject 8. 
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Figure 149: Concentration of Resclar compared to Klacid® in subject 9. 
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Figure 150: Logarithmic concentration of Resclar compared to Klacid® in subject 9. 
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Figure 151: Concentration of Resclar compared to Klacid® in subject 10. 
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Figure 152: Logarithmic concentration of Resclar compared to Klacid® in subject 10. 
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Figure 153: Concentration of Resclar compared to Klacid® in subject 11. 
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Figure 154: Logarithmic concentration of Resclar compared to Klacid® in subject 11. 
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Figure 155: Concentration of Resclar compared to Klacid® in subject 12. 
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Figure 156: Logarithmic concentration of Resclar compared to Klacid® in subject 12. 
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Figure 157: Concentration of Resclar compared to Klacid® in subject 13. 
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Figure 158: Logarithmic concentration of Resclar compared to Klacid® in subject 13. 
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Figure 159: Concentration of Resclar compared to Klacid® in subject 14. 
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Figure 160: Logarithmic concentration of Resclar compared to Klacid® in subject 14. 
Chapter 6 Bioequivalence 
Page 241 of 446 
0
1000
2000
3000
4000
5000
0 4 8 12 16 20 24 28 32 36
P
la
sm
a
 c
la
ri
th
ro
m
y
ci
n
, 
µ
g
/L
Time, hours
Resclar 500mg (Test) Klacid® 500mg (Reference)
 
Figure 161: Concentration of Resclar compared to Klacid® in subject 15. 
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Figure 162: Logarithmic concentration of Resclar compared to Klacid® in subject 15. 
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Figure 163: Concentration of Resclar compared to Klacid® in subject 16. 
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Figure 164: Logarithmic concentration of Resclar compared to Klacid® in subject 16. 
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Figure 165: Concentration of Resclar compared to Klacid® in subject 17. 
10
100
1000
10000
0 4 8 12 16 20 24 28 32 36
P
la
sm
a
 c
la
ri
th
ro
m
y
ci
n
, 
µ
g
/L
Time, hours
Resclar 500mg (Test) Klacid® 500mg (Reference)
 
Figure 166: Logarithmic concentration of Resclar compared to Klacid® in subject 17.  
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Figure 167: Concentration of Resclar compared to Klacid® in subject 18. 
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Figure 168: Logarithmic concentration of Resclar compared to Klacid® in subject 18. 
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Figure 169: Concentration of Resclar compared to Klacid® in subject 19. 
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Figure 170: Logarithmic concentration of Resclar compared to Klacid® in subject 19. 
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Figure 171: Concentration of Resclar compared to Klacid® in subject 20. 
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Figure 172: Logarithmic concentration of Resclar compared to Klacid® in subject 20. 
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Figure 173: Concentration of Resclar compared to Klacid® in subject 21. 
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Figure 174: Logarithmic concentration of Resclar compared to Klacid® in subject 21. 
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Figure 175: Concentration of Resclar compared to Klacid® in subject 22. 
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Figure 176: Logarithmic concentration of Resclar compared to Klacid® in subject 22. 
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Figure 177: Concentration of Resclar compared to Klacid® in subject 23. 
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Figure 178: Logarithmic concentration of Resclar compared to Klacid® in subject 23. 
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Figure 179: Concentration of Resclar compared to Klacid® in subject 24. 
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Figure 180: Logarithmic concentration of Resclar compared to Klacid® in subject 24. 
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Figure 181: Concentration of Resclar compared to Klacid® in subject 25. 
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Figure 182: Logarithmic concentration of Resclar compared to Klacid® in subject 25. 
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Figure 183: Concentration of Resclar compared to Klacid® in subject 27. 
10
100
1000
10000
0 4 8 12 16 20 24 28 32 36
P
la
sm
a
 c
la
ri
th
ro
m
y
ci
n
, 
µ
g
/L
Time, hours
Resclar 500mg (Test) Klacid® 500mg (Reference)
 
Figure 184: Logarithmic concentration of Resclar compared to Klacid® in subject 27. 
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6.5 Discussion  
This study demonstrated that the generic Resclar 500 (Neopharma, UAE) attained 
the regulatory definition of bioequivalent to its branded counterpart Klacid® 500 mg 
(Abbott Laboratories Ltd, England). This was accomplished in accordance with all 
parameters in the EMA and the FDA guidelines in a selected population of healthy 
volunteers (European Medicines Agency, 2001, Food and Drug Administration, 2009). 
The 90% confidence interval of all pharmacokinetics parameters of Resclar lays 
entirely between the regulated limits 80-125%. In order to approve new generic 
medicines, the EMA and the FDA rely on the results of bioequivalence trials based on the 
pharmacokinetic parameters tmax, AUC0-t, AUC0-∞ and C max. The FDA requires the 90% 
confidence intervals of the ratio of the branded and its generic counterpart for these three 
parameters, whereas the EMA requires only the AUC0-t, AUC0-∞ and Cmax (van der 
Meersch et al., 2011).  
This study was a randomised, open-label, single dose with a two-way crossover 
design comparing the bioavailability of clarithromycin 500 mg between two 
products, in fasting healthy volunteers. The results have shown that the tested 
generic drug was bioequivalent to its branded reference in terms of the rate and 
extent of absorption. The mean plasma curves of both products were almost super 
imposable suggesting that not only Cmax and AUC but also the time course of 
plasma levels over the whole sampling period were similar. However, there were 
some variations in individual subjects such as subjects 8, 13, 15, 16, 21 and 25. 
This confirms that although both drugs were proved bioequivalent within limits, 
some individual patients might face the less effectiveness and/or the more side 
effects of this drug. In this study, this might not have a major clinical consequence 
on patients’ outcome since the tested drug is antibiotic. However, if the tested 
drug was ciclosporin or any critical dose or narrow therapeutic index drug, major 
side effects such as organ rejection might occur (Johnston et al., 2004, Shah et al., 
1999).   
Since plasma levels are a meaningful surrogate for pharmacodynamic action and 
adverse events, this reveals that an equivalent therapeutic activity and tolerance is 
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to be expected from Resclar 500 mg as compared to its branded counterpart 
Klacid®500 mg. Overall, both formulations were well tolerated in this population 
and no relevant differences in the safety profiles were observed. Headache and 
abdominal pain were the most common adverse events in both test and reference 
drug groups. Although this bioequivalent study achieved the requirement of the 
EMA and FDA to prove that both formulations are similar, some authors are 
questioning the design of this bioequivalence study. They believe that single dose 
studies are generally more sensitive in assessing in-vivo release of the drug 
substance from the drug product. Therefore, they have suggested the use of multiple 
dose bioequivalence studies where differences can be more apparent and this can be 
more useful in investigating bioequivalence (Chen et al., 2001, El-Tahtawy et al., 
1994, El-Tahtawy et al., 1995). As a result, this can assure that both formulations 
are safe and interchangeable. 
Nevertheless, results in this chapter are compatible with others in the literature (Mathew 
et al., 2011, Najib et al., 2002, Najib et al., 2005). For example, a study assessing the 
bioequivalence of two formulations of capecitabine revealed that both formulations were 
bioequivalent and the variables investigated (gender, age, creatinine clearance and body 
surface area) had no clinically significant effect on the pharmacokinetic of the drug or its 
metabolites (Cassidy et al., 1999). Similarly, a systematic review and meta analysis of 
trials comparing seizure outcomes from the use of generic and branded anticonvulsants 
revealed that there was no association observed between the loss of seizure control and 
generic substitution; however, the authors suggested close monitoring when substituting 
antiepileptic drugs (Kesselheim et al., 2010).  
It is very important for healthcare professionals and providers to realise that there are 
many misconceptions and misinterpretation in the literature regarding bioequivalence 
studies. For example, many bioequivalence studies in the literature would conclude that 
the generic drug was bioequivalent and therefore interchangeable with its branded 
counterpart medicines (Christians et al., 2010, Schall and Endrenyi, 2010, Singla et al., 
2009). Other studies would indicate that the generic drug was bioequivalent and therefore 
therapeutically equivalent to its branded counterpart drug (Christians et al., 2010, Schall 
and Endrenyi, 2010). However, bioequivalence studies within the regulated limits are 
Chapter 6 Bioequivalence 
Page 255 of 446 
conducted to prove that both drugs are bioequivalent and therefore, prescribable. 
Bioequivalence studies are not designed to assure that both drugs are interchangeable or 
therapeutically equivalent.  
In order to prove that bioequivalent drugs are interchangeable, a large number of subjects 
or individual bioequivalence and a detailed pharmacokinetic studies are suggested 
(Yacobi et al., 2000). Otherwise, generic substitution of these drugs should be applied 
with caution and under the supervision of physicians and should not be randomly 
substituted under the assumption of dose equivalence. Consequently, many regulatory 
agencies including the EMA are considering tightening the limits of bioequivalence for 
some drugs such as the critical dose and narrow therapeutic index drugs (Health Canada, 
2006, Mannion, 2011, Tamboli et al., 2010). 
According to the World Health Organisation (WHO), generic drugs which are 
considered bioequivalent to the branded counterpart may or may not be 
therapeutically equivalent (World Health Organization, 2005). This is also confirmed 
by the EMA who indicated that “equivalence does not necessarily imply bioequivalence 
as differences in the excipients and/or manufacturing process can lead to faster or slower 
dissolution and/or absorption” (European Medicines Agency, 2001). This was also 
approved in chapter 5 in this thesis (Al Ameri et al., 2012). A generic drug is 
considered therapeutically equivalent to its branded counterpart if it contains the 
same active substance and has the same clinical effect and safety when 
administered to patients under the conditions specified in the drug label (European 
Medicines Agency, 2001). To ensure that both drugs are therapeutically equivalent, 
further efficacy and safety assessment should be carried out, such as conducting 
bioequivalent studies in patients after food intake. 
In general, average bioequivalence analysis is sufficient to evaluate the 
prescribability of most generic drugs but does not ensure interchangeability 
between prescribable formulations. Generic substitution must be considered in the 
light of the fact that standard bioequivalence testing is not designed to reveal 
pharmaceutical differences in individual patients. In addition, when two 
formulations are proved to be bioequivalent, they cannot necessary be considered 
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therapeutically equivalent. Therefore, indiscriminate switching between branded 
and generic formulations or among generics themselves could result in differences 
in the rate and extent of absorption (Colaizzi and Lowenthal, 1986). This, 
definitely, can affect patients’ clinical outcomes as approved in the literature and in 
this thesis (Doshi et al., 2009, Himmel et al., 2005, Meredith, 2003).  
There are many studies in the literature showed that some approved generic medicines 
are not equivalent to the innovator product. For example, a study comparing the quality 
of 65 generic clarithromycin products manufactured in 18 countries to the innovator 
product revealed that many of the generic products fell short of the approved 
specifications developed for the innovator product (Nightingale, 2005). Another study 
evaluated the quality of 40 generic clarithromycin products from Latin America and 
Asia revealed that 33% (6/18) of generic tablets collected from Latin America and 
20% (8/40) of all generic tablets tested fell short to comply with the approved 
registered specification of the innovator product when failed to contain the same 
amount of clarithromycin claimed in the label. It was concluded that generic tablets 
are not always equivalent to the innovator product raising concerns that clinical trial 
results achieved with the branded drug should not be extrapolated to generics 
(Nightingale, 2000).  
There are many factors that can affect the bioavailability and absorption of generic drugs 
especially the critical dose and narrow therapeutic index drugs. These include food, 
disease, age and the manufacturer. For example, a study in 26 healthy volunteers found 
that food intake immediately before administration of clarithromycin immediate-release 
tablets increased the bioavailability of clarithromycin by 25%. Although this increased 
might have little clinical effect with respect to drug side effect, authors concluded that 
clarithromycin can be taken with disregard of food (Chu et al., 1992). In Another study, it 
was found that administrating extended-release clarithromycin tablets under fasting 
conditions was associated with 30% lower clarithromycin bioavailability relative to 
administration with food (Guay et al., 2001). Therefore, it was recommended that 
clarithromycin extended-release tablet to be administered with food.  
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Moreover, another bioequivalence study of two formulations of clarithromycin extended-
release 500 mg tablet under fasting and fed conditions revealed that variation in the rate 
of absorption was lower under fasting condition (Alkhalidi et al., 2008). A different study 
on 20 healthy volunteers found statistically significant differences in transit times 
between the generic formulations of alendronic acid 70 mg and its branded counterpart. 
The generic formulations had longer transit times than their branded counterpart which 
can result in oesophagitis (Perkins et al., 2008). It was also shown in another study that 
ciclosporin A is absorbed from the proximal small intestine and absorption is greatly 
influenced by intestinal transit time, presence or absence of food and the gastrointestinal 
disease (Johnston and Holt, 1998).  
A study evaluating the effect of disease states on the drug interchangeability revealed that 
the absorption of ciclosporin A differs between healthy volunteers and transplant patients 
(Johnston et al., 2004). Therefore, the standard bioequivalence testing may be inadequate 
to promote safe interchangeability. As a consequence, many authors suggested that 
bioequivalence studies should be conducted on patients rather than healthy volunteers 
(Johnston et al., 2004, Mould, 2002). Variable clinical response in different age group 
patients to the same dosage form of a drug product has also been reported. For example, a 
study illustrated that the pharmacokinetics of omeprazole in children showed a trend 
towards higher metabolic capacity with decreasing age. This indicates that children 
would need higher doses of omeprazole per kilogram compared to adults (Andersson et 
al., 2000). Similar study in the elderly reported that the bioavailability of digoxin from 
the capsules was lower than expected, which can result in lower therapeutic serum 
concentrations (Pouwels et al., 1991). 
Different manufacturers or manufacturing processes can also lead to different drug 
bioavailability and absorption. For example, a study which evaluated the pharmaceutical 
equivalence of ten brands of ciprofloxacin tablets revealed that all the tested drugs 
complied with official specifications for uniformity of weight and friability test but only 
six of them could be considered bioequivalent to the innovator product (Adegbolagun et 
al., 2007). A pharmacokinetic analysis on two approved bioequivalent drugs to Neoral 
(ciclosporin) found that the absorption profiles of GengrafTm (Abbott Labortories, Abbott 
Park, Illinois) and Hexal (Hexal AG, Holzkirchen, Germany) were significantly different 
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from that of Neoral® (Pollard et al., 2003). It concluded that ciclosporin A exposure could 
be reduced when substituting Neoral with equivalent doses of Hexal or Gengraf. This 
could, as a result, affect graft survival (Pollard et al., 2003). However, Gengraf is 
considered to be bioequivalent and interchangeable with Neoral® (Food and Drug 
Administration, 2009, Roza et al., 2002).  
Another study showed that the differences in pharmacokinetic properties between 
different formulations of ciclosporin A can affect the incidence of graft rejection. For 
example, it was proposed that transplant recipient patients who receive Neoral have a 
lower incidence of organ rejection than patients who receive Sandimmune (Shah et al., 
1999). Overall, to demonstrate that the bioequivalence criteria were met between the 
generic and its branded clarithromycin, this study was conducted in fasting healthy 
volunteers in accordance with EMA and the FDA guidance. The Resclar 500 mg tablet 
did meet the regulatory definition of bioequivalence with Klacic® 500 mg as the 
innovator product based on a single dose comparative bioavailability study under 
fasting conditions in the selected healthy volunteers. Therefore, Resclar 500 mg 
tablet, with monitoring, could provide an acceptable prescribable alternative to 
Klacic® 500 mg.  
6.6 Main limitations of the study 
The design of this study does not detect a possible subject-by-formulation interaction. A 
further study considering the use of an individual bioequivalence approach through 
replicate administration design studies, in which both the branded and generic drugs are 
given twice on two different occasions in a four-way crossover design is required to 
provide more data and assurance that both drugs are interchangeable. Additional study is 
also required to assess the cost savings from promoting Resclar over Klacid 500 mg. At 
last but not least GLP (Good Laboratory Practice) Certificate should be signed off for this 
study. 
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7 Chapter 7 General discussion and conclusions 
This thesis explored in details the issues surrounding generic and therapeutic substitution 
from the ethical, patients’ and physicians’ point of view and from the potential 
differences in actual formulations between the branded and generic medicines. This was 
achieved by conducting a series of studies such as an ethical review, multicenter surveys 
to explore patients’ and physicians’ views on drug substitution and other in-vitro and in-
vivo comparisons between different formulations of the branded medicines and their 
generic counterparts. The aim of this thesis was mainly to promote high quality strategic 
logistic planning and effective managing of drug formularies in hospitals by encouraging 
safe and effective drug substitution.  
Many healthcare settings are currently considering generic and therapeutic substitution 
practice as a simple issue. This practice intends to draw its public legitimacy from the 
presumption that the cheaper drug is equivalent or at least not inferior to the more 
expensive one. A presumption that presupposes that any saving that does not compromise 
the quality of care is essentially ethical. The practice, so it seems, promises to be 
ultimately patient-centred. But does it really deliver on its promise? It was explored in 
this thesis that once generic drugs are approved based on bioequivalent and/or non-
inferiority trials, they are, mistakably, considered identical to its branded counterpart.  
A bioequivalence clinical trial usually aims at showing that the two treatments are similar 
in characteristics within defined limits set by regulations (80-125%) (European 
Medicines Agency, 2001, Lesaffre, 2008). Bioequivalence should thus not be seen as 
semantically equal to identical. In a non-inferiority trial, the aim is to show that the tested 
treatment is not worse than the standard treatment (Lesaffre, 2008). It basically suggests 
that a treatment is good merely because it is not bad (Blakwelder, 2002). The 
presumption that the cheaper drug is equivalent or at least not inferior to the more 
expensive one may perhaps seem logical, when in fact it may be utterly fictitious: it may 
be true, but it is not necessarily true. As long as the specific effects and side effects of the 
cheaper drug are unknown, or as long as they are known to be different from those of the 
branded drug, it must be taken with a grain of salt.  
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As things are currently standing, there is no escape from the conclusion that sweeping, 
indiscriminate, and empirically poor substitutions clearly give financial savings exclusive 
priority over any other considerations. However, they cannot even presume to be cost-
effective. Indeed, as explained in this thesis, a number of authors have questioned the 
cost-effectiveness of generic and therapeutic substitutions (Doshi et al., 2009, Johnston et 
al., 2010, Lister, 2010, Phillips et al., 2007). They indicated that any cost savings waived 
through such substitution may be offset by the perceived long-term costs associated with 
disease control and/or adverse events (Haskins et al., 2005). In other words, “costing less 
could mean costing more” (Gafni and Birch, 2007).  
As described in the ethics review presented in this thesis (AlAmeri et al., 2010) 
healthcare providers must realise that the additional monitoring needed for effective 
generic and therapeutic substitution may offset any potential cost saving. This may also 
result in compromising patient adherence. As long as healthcare providers adhere to 
patient-centred medicine, they should not support substitutions that lack sufficient data 
assuring clinical equivalence. Moreover, in the literature, it has been reported that many 
healthcare decision makers focus on the societal perspective to the detriment of the 
individual patient's perspective (Simoens, 2011). They made clear that health economics 
perceives to be the societal perspective. Resting on the premise of limited resources, they 
advocate ranking health technologies according to their cost-effectiveness.  
This entails that, in principle, substitution could maximise health outcomes in a given 
budget, even if the generic medicine was less effective than the reference medicine. In 
addition, prescribing the more expensive reference medicine, which may perhaps 
improve the outcomes in the individual case, could result in overall decrease in 
population health (Duerden and Hughes, 2010). However, it is fully understood that 
working on the assumption of limited resources, in an affluent society that has enough 
wealth to provide the best medical care for all, has nothing to do with good medicine or 
with any genuine 'societal perspective'. The social role of health economics is to ensure 
that the distribution and redistribution of resources in our society will benefit the few at 
the expense of the many (Al Ameri et al., 2011a). Certainly, patients believe that 
physicians ought to have no role other than taking care of their interests. If there are not 
enough resources for that, they should insist that more is brought in. This should be the 
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notion of 'societal perspective'. In another way “Does the need of the many outweigh the 
needs of the one”? 
7.1 Patients and drug substitution 
After evaluating the ethical point of view on drug substitution, it became essential to 
evaluate patients’ views in the same issue since they are the end-users and the evaluators. 
This was achieved by conducting a series of multicentre surveys in the UK and in the 
UAE. It was clearly explored in these surveys that there are factors framing patients’ 
views and acceptance of drug substitution. These factors also acquire healthcare 
professionals to step in and participate in promoting safe and effective drug substitution. 
According to the multicentre, different countries, surveys presented in this thesis, factors 
such as patients’ knowledge, level of education, severity of a disease, generic 
effectiveness and involvement of patients in decisions regarding their health played major 
roles in driving patients’ views and acceptance of drug substitution.  
For example, it was found that highly educated patients were more knowledgeable about 
their generic medicines and substitution. Consequently, they were more likely to accept 
drug substitution compared to the less educated patients. However, some suspicion about 
generic medicines and substitution were still detected among highly educated patients 
who were not assured, by their healthcare professionals, about the safety and the 
effectiveness of the prescribed medicine (Al Ameri et al., 2011b). Most patients reported 
that they were not provided with background information regarding their generic 
medicine upon substitution and very few reported that they were monitored after 
substitution. This highlights the impact of educating patients on their acceptance of drug 
substitution. 
Many other patients had reported that information, if any, was mainly given in a verbal 
form. Yet, it is recommended in the literature that patients should be given information as 
a written form to allow reviewing and remembering the complex medical information 
whenever needed (Weinman, 1990). Several other patients were doubtful that generics 
have the same quality as the branded medicines. As a result, they were not convinced and 
were dissatisfied with generic medicines and substitution. The majority of patients 
favoured being informed upon switching their medicines and many reported that they 
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would agree to accept drug substitution and adhere to the treatment if they were informed 
and educated by their healthcare professionals. This indicates that the effort and time 
spent by healthcare professionals in monitoring patients after switching their medicine is 
contributing as an important tool to assure medicine adherence.  
The severity of the disease (mild or chronic) was also found to play a major role in 
patients’ acceptance of generic substitution. Many patients participated in the surveys in 
this thesis reported that they would be more reluctant to accept generic substitution if 
they were diagnosed with chronic disease compared to the mild disease. This was also 
confirmed in the literature. There are many studies in the literature confirmed that 
people’s beliefs and acceptance of generic drugs and substitution is associated with the 
nature of their illness (Al Ameri et al., 2011b, Figueiras et al., 2008). Another study 
indicated that these attitudes might be related to the belief that the cheaper medicine must 
be inferior to the more expensive branded medicines (Meredith, 2003). 
These results were also discussed in many other studies in the literature (Berg et al., 
2008a, Decollogny et al., 2011, Gossell-Williams, 2007). Some studies indicated that 
patients need to be adequately informed about the equivalence of the branded and the 
generic medicines otherwise generic substitution will be challenging and problematic 
(Decollogny et al., 2011, Himmel et al., 2005, Meredith, 1996, Meredith, 2003). A survey 
conducted in Finland has reported that many patients refused to substitute their medicine 
because of their positive experience with medicines they have used previously and many 
of them think that the main reason for substitution was to save money (Heikkila et al., 
2007).  
Another medical database study was conducted using 32,804 patients to evaluate the 
differences in persistence between the branded alendronate (osteoporosis treatment) and 
its generic counterparts. It revealed that the risk of discontinuation doubled in patients 
initiated with generic alendronate compared to those who started on the branded 
counterpart (Sheehy et al., 2009). This can be related to the inadequate information and 
assurance that patients were given regarding their new substituted drug.  
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7.2 Physicians and drug substitution 
Many patients participated in the surveys presented in this thesis indicted that prescribers 
are considered the key factor to influence their acceptance or rejection of drug 
substitution (Al Ameri et al., 2011b). Physicians are the key decision-making agent to 
determine whether patients receive either branded or generic drugs. Therefore, 
physicians’ views and attitudes towards generic medicines and substitution were also 
evaluated in this thesis. It was explored that physicians were more confident prescribing 
branded medicines than generics, especially for patients with chronic conditions. On the 
other hand, physicians were still prescribing generic medicines on occasions where health 
complications may be more susceptible to happen as well as increase health expenditure.  
Prescribers in this thesis were found more willing to prescribe branded medicines than 
generics, especially for patients with chronic conditions. For example, drugs such as 
digoxin, anticholesterolamic and antihypertensive agents were prescribed in their branded 
forms in considerably high volumes. On the other hand, almost half [43% (95% CI 35-
51)] of the immunosuppressant agents were prescribed in their generic forms. However, 
many clinicians approved that the generic prescribing of immunosuppressant agents 
without patient monitoring can lead to organ rejection and, as a result, to re-
transplantation (Kovarik et al., 2006, Qazi et al., 2006, Taber et al., 2005). Moreover, the 
volume of branded prescriptions of metformin (anti-diabetic), in the study presented in 
this thesis, was also in the lower range compared to other medicines used to treat chronic 
conditions. This can be acceptable as long as the generic alternative was therapeutically 
equivalent, safe and effective and patients are monitored (Johnston et al., 2011). 
Additionally, physicians were still prescribing high volume of generic medicines on 
occasions where health complications may be more susceptible to occur as well as 
increase health expenditure. For example, there was a high volume of generic prescribing 
of medicines such as warfarin (anticoagulant) and Tenormin (antihypertensive agent). 
The generic prescribing of these agents is not recommended to avoid health 
complications (Snow et al., 2003, Wandel et al., 2003); especially if they were prescribed 
for a long period of time when patients cannot be monitored.  
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These results were related to the lack of knowledge and education among healthcare staff 
regarding effective generic prescribing and substitution. It was demonstrated in this thesis 
that improving awareness and education among physicians and medical staff regarding 
generic medicines is essential for effective prescribing and substitution. This, as a 
consequence, can contribute in lowering the overall healthcare expenditure. It was clearly 
recommended that in the case of chronic diseases, physicians should provide close 
supervision and monitoring if they decide to switch patients from a drug form to another.  
In general, this attitude might be related to prescribers’ less knowledge and doubtful 
about generic drug and substitution. For example, it was reported in the literature that 
many physicians were still doubtful about whether bioequivalence of a generic is similar 
to therapeutic equivalence of the branded drug (Banahan and Kolassa, 1997, Berg et al., 
2008a, Gossell-Williams, 2007, Rubak et al., 2000, Tilyard et al., 1990). Many 
physicians also believe that not all interchangeable medicines are effective and safe. For 
example, a survey conducted in Finland to evaluate physicians’ views on generic 
substitution revealed that more than half of the 49 participating physicians thought that 
interchangeable medicines in certain medicine groups such as beta blockers, 
anticholesterolaemic and antidepressant agents were not equally effective and safe 
(Heikkila et al., 2007).  
In Mississippi, USA, 57% of physicians opposed generic drugs and substitution (Banahan 
and Kolassa, 1997) and in New Zealand, 52% of physicians refused the government’s 
proposal to allow generic substitution (Tilyard et al., 1990). Other physicians clearly 
testified, in an FDA hearing, that their patients had experienced therapeutic failures with 
approved generic drugs (Gerbino and Joseph, 1993). Moreover, in a survey conducted in 
Jamaica, 33% of participating physicians admitted that they faced at least one case of 
clinical problems with generic substitution that they thought would not happen with the 
innovator product in the year before the survey (Gossell-Williams, 2007).  
Overall, these results are still raising concerns about the therapeutic equivalency of 
interchangeable generic medicines. This can also raise a concern that if prescribers are 
still doubtful about the generic medicines and prescribing, how can they effectively 
promote drug substitution? It should be clarified that the appropriateness of physician 
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prescribing habits does not only require the use of cheaper medicines, but it also requires 
the use of more costly drugs, in some circumstances. Physicians’ lack of knowledge of 
drug cost may also contribute to the inefficient use of societal resources and rising 
pharmaceutical spending (Zaoui et al., 2011 ).  
Educating physicians and healthcare staff about the cost of medicines was proved to have 
an impact on physicians’ habits of prescribing. For example, a study was conducted to 
determine if a low-cost administrative intervention would decrease the use of branded 
NSAIDs (non-steroidal anti-inflammatory drugs). The intervention requested physicians 
to complete a short form listing two generic names NSAID that the patient had already 
tried if they wished to prescribe a branded NSAID. During the 8.5 months before any 
intervention, 10% of 65,404 NSAID prescriptions were written on brand name products. 
During the intervention, physicians wrote 62,521 NSAID prescriptions, of which 6.9% 
were branded drugs. This represents a 34% decrease in brand name NSAID prescriptions. 
This had led to a cost saving of $92,914 for the 8.5 months. It was concluded that a low 
cost administrative intervention can have a significant impact on physician prescribing 
habits and result in cost savings to the institution (Ahluwalia et al., 1996). In addition, an 
observational study, conducted in the Trent Region of England, comparing prescribing 
costs in three groups of practices has shown that low growth in prescribing costs was 
associated with a reduction in the overall volume of prescribing, a reduction in costs per 
unit volume and an increase in generic prescribing (Avery et al., 2000).  
Nevertheless, prescribing should be opposed to become cash limited because physicians’ 
performance might be affected and forced to focus on reducing costs rather than 
increasing quality. As a result, there are some initiatives have been introduced with the 
aim of improving the efficiency of physicians' prescribing habits. These include 
providing data on Prescribing Analysis and Cost (PACT), indicative prescribing budgets 
and general practice fund holding. The English PACT scheme disseminates information 
about prescribing behaviour to general practitioners in order to increase their awareness 
of costs. Several countries have information feedback systems for physicians similar to 
the PACT scheme.  
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However, most of these strategies are not enforced and information may be ignored. This 
is thought to be the case in France, where data on prescription costs in relation to 
consultations are tracked and sent back to physicians to enable them to monitor their own 
prescribing patterns. In Germany, sickness funds compare doctors' prescribing with the 
average levels of prescribing by colleagues. In New Zealand, the Preferred Medicines 
Concept provides information on general practitioners' prescribing patterns in relation to 
the national average. In the Netherlands information is provided to prescribing physicians 
on the relative value of drugs in practice (Ess et al., 2003). All these schemes are 
advisory and provide information on the volume of prescribing and on cost. However, 
they do not give information on the cost-effectiveness of prescribing and so may penalise 
the use of expensive drugs that have benefits worth the extra cost.  
Several years ago it was reported that nearly one in three doctors in the US were 
withholding information from patients about useful medical services because they were 
not covered by the patients’ health insurance company (Gottlieb, 2003). This indicates 
that coverage limitations imposed by managed care companies are infiltrating physician-
patient communication. Another survey about how often physicians had decided not to 
offer a “useful service to a patient because of health plan rules” was performed among 
1,124 U.S. physicians. A total of 31% of the respondents reported having at times not 
offered their patients useful services because of perceived coverage restrictions. In 
addition, 35% reported doing so more often in the most recent years than they did five 
years ago. The study has shown that doctors whose own salaries are closely tied to 
controlling costs were more likely than other doctors to report withholding information 
(Gottlieb, 2003). Health insurance companies are also accused of pressurising doctors to 
alter the treatment of patients even if another better method was available (Melchior, 
2009). 
Furthermore, there are current regulations that limit the quantity of drugs that can be 
prescribed under the reimbursement scheme, with the aim of preventing waste and 
excessive use of drugs through high quantity prescriptions. In France, a national contract 
has introduced national medical guidelines for doctors with respect to diagnosis and 
treatments, including prescriptions for antibiotics, NSAIDs, drugs for elderly patients and 
oral contraceptives. Currently, 147 guidelines are in force covering a total of 47 areas of 
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medicine, and about 12 of these relate to the prescribing of drugs. As an incentive for 
following these guidelines, doctors were awarded 5% increase in their fees, and those 
who fail dramatically to comply with the guidelines face fines. Surveys suggest that 75% 
of French doctors are prescribing in line with the new treatment guidelines (Bloor and 
Freemantle, 1996). Though, it is worth noting that prescribing should not be cost 
centered, it should be patient centered. Physician should provide close supervision and 
monitoring when switching their patients from branded formulations to a generic one. 
Monitoring can be accomplished by supplying the new medicines for a short period of 
time. This will allow patients to evaluate the effectiveness and side effects of the newly 
prescribed medicine and will enable them to participate in the decision of switching. 
7.3  Differences in dissolution behaviour between the branded 
and generic medicines 
In-vitro dissolution comparisons between the branded and generic medicines were also 
studied in this thesis to confirm patients’ and physicians’ opinions and previous findings 
regarding generic medicines and substitution (Al Ameri et al., 2012). The main aim of 
this study was to compare the potential differences in dissolution behaviour between the 
branded medicines and their generic counterparts which were collected nationally and 
internationally. The results of this study had confirmed that there are differences in the 
dissolution behaviour between the branded and generic medicines.  
It was found that a total of 21% of the generic medicines showed statistically 
significantly differences in their dissolution behaviour compared to their branded 
counterpart at 60 minutes. Also, a total of 54% of the generic medicines showed 
statistically significantly differences in their dissolution behaviour compared to their 
branded counterpart at 120 minutes. In this study, some generics showed incomplete and 
different dissolution behaviour compared to their branded counterpart medicines. Other 
generics showed statistically significant slower or faster dissolution rate compared to 
their branded counterpart medicines. In addition, some generics from the same 
manufacturer with different batches of the same drug showed significant differences in 
their dissolution rate. Nevertheless, some generics violated the EMA and the FDA 
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guidelines when they failed to achieve the 85% dissolution in 60 minutes (European 
Medicines Agency, 2001, Food and Drug Administration, 1997).  
Similarly, another generic drug had also violated the EMA and the FDA bioequivalence 
guidelines when it failed to keep the same dosage form as its branded counterpart. This 
generic drug was found in capsule dosage form compared to the tablet dosage form of its 
branded counterpart. However, according to the EMA and FDA, a medicinal product are 
considered equivalent to the original product if they contain the same amount of the same 
active ingredient(s) in the same dosage forms that meet the same or comparable standards 
(European Medicines Agency, 2001, Food and Drug Administration, 1997). Differences 
in dosage forms can impact patients’ clinical outcomes by affecting and altering the 
bioavailability of a drug as well as its effectiveness and side effects. For example, a study 
comparing the serum concentration of digoxin in tablets and capsules revealed that the 
bioavailability of digoxin from the capsules exceeded that from the tablets when used by 
a healthy person (Pouwels et al., 1991).  
Moreover, differences in weight, size, shape, colour and packaging between the branded 
and generic medicines were also detected and confirmed by patients surveyed in this 
thesis (Al Ameri et al., 2011b). Depending on the cause of these differences, it might 
elevate the side effects and/or drug interactions. For example, many studies in the 
literature confirmed that medicine adherence was greatly influenced by the decline of 
swallowing ability especially for elderly and patients with oesophagus diseases (Epstein 
et al., 2005, Overgaard et al., 2001). Another study, demonstrated that the main reason 
causing the difficulty of swallowing was the size of the tablet followed by the surface, 
form of the tablet (Overgaard et al., 2001). This as a consequence can affect patients’ 
adherence of medications’ regime. 
These differences in dissolution behaviour between the branded medicines and their 
generic counterparts were also reported in the literature. For example, a study compared 
two formulations of mycophenolate sodium 360 mg (immunosuppressant agent). It 
revealed that the content of both formulations was within the 90 to 110% range of the 
claimed label dose and no impurities were present. However, when performing 
dissolution tests on both formulations at pH 1.2 and 6.8 to mimic conditions in the 
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stomach and the small intestine, respectively, it was found that the differences between 
formulations were statistically significant and the intra-tablet variability with the generic 
formulation was unacceptable. It concluded that both formulations were not equivalent as 
well as not interchangeable and one of them could lead to inadequate immunosuppressive 
efficacy (Esquivel et al., 2010).  
A similar study was performed on three commercial solid dosage forms of levothyroxine 
which is considered a narrow therapeutic index drug used as a hormone replacement for 
patients with thyroid problems. It revealed that the three products had drastically different 
dissolution profiles with respect to both shape and percentage of levothyroxine dissolved. 
This can impact on the oral absorption and bioavailability of the active ingredient which 
may result in bioequivalence problems between various available products (Pabla et al., 
2009). Related to this matter, recently, the MHRA suspended the license of the generic 
Teva (levothyroxine 100 mcg) tablets over dissolution fears. The interchangeability 
between Teva and its branded counterpart was questioned by the MHRA and its license 
was suspended (Walley et al., 2004). 
Another dissolution study was performed to evaluate and compare 25 internationally 
available piroxicam (non-steroidal anti-inflammatory drug) products using the US 
Pharmacopeia specifications. It revealed that 72% of the tested drugs failed to meet the 
USP requirement, several by a wide margin. Also, when the dissolution test for the 
capsules was applied to 5 different formulations of piroxicam tablets, 80% of the tablets 
failed to meet the USP requirement (Barone et al., 1988). Moreover, a study had 
compared 13 generic alendronate preparations from Latin-America with the innovator 
product. It revealed that nine generics showed faster dissolution and three generics 
showed slower dissolution than their branded counterparts. It was suggested that slower 
disintegration may reduce efficacy and faster disintegration could increase the risk of 
oesophagitis (prolong contact of the oesophageal mucosa with the drug). It concluded 
that the current bioavailability studies may not be adequate for meaningful assessment of 
the safety and efficacy of bisphosphonate preparations (Epstein et al., 2003).  
Other studies on different drugs also comply with this result. For example, a study 
evaluated 18 generic copies of PLAVIX® tablets (clopidogrel, antiplatelete agent) 
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reported that most of the generic copies were not similar to the branded drug product. 
Their amount of impurities was higher, the dissolution profile different and the content of 
clopidogrel lower (Gomez et al., 2004). Another study on 16 formulation of generic 
ciprofloxacin tablets showed that three formulation have a lower ciprofloxacin and one 
showed a higher concentration compared to the innovator drug product (Trefi et al., 
2007). Similar study was conducted to assess the pharmaceutical quality of 14 generic 
isotretinion products (acne treatment) compared with its branded Roaccutane®. It 
revealed that 13 generic products failed to match Roaccutane® in one or more tests. It 
concluded that it cannot be assumed that all generic isotretinoin products are as 
therapeutically effective or as safe as Roaccutane® (Taylor and Keenan, 2006). 
Hierarchically  
Furthermore, a dissolution test was performed on different brands of alendronic acid and 
showed that the highest release was found for the branded drug and the dissolution rate of 
the generic formulations was significantly lower than their branded counterpart in the 
early stage of dissolution (Lamprecht, 2009). A similar in-vitro study of oesophageal 
adhesiveness of different formulations containing alendronate revealed that there were 
differences in oesophageal tolerance between the branded Fosamax® and its generic 
counterparts. It concluded that differences in safety between the branded and its generics 
counterparts cannot be eliminated. Therefore, therapeutic equivalence between the 
marketed generics and the branded Fosamax® cannot be assured (Shakweh et al., 2007).  
These differences in dissolution rates can be related to an inappropriate amount of the 
drug in the tested form. For example, a study compared 31 docetaxel generic 
formulations (narrow therapeutic window, anti cancer agent) to its originator drug 
product. The study revealed that most generic formulations contained insufficient active 
drug and/or a high level of impurities and different excipients. This can affect both the 
safety and efficacy of the generic formulations (Vial et al., 2008). These results clearly 
demonstrated that random switching between branded medicines and their generic 
counterparts or switching among generic medicines is not recommended because of some 
differences in the dissolution rate that may appear. 
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7.4 Bioequivalence trials  
Generic drug acceptance is mainly based on conducting bioequivalence trial. According 
to the bioequivalence guidelines of the EMA and FDA, a generic drug should have 80%-
125% bioavailability of the original branded drug (European Medicines Agency, 2001, 
Food and Drug Administration, 2009). This indicates that a difference of ±20% is 
allowed to be demonstrated in the bioequivalence study for a generic medicine to be 
officially approved. However, according the result of this thesis the difference range of 
±20% between the branded and generic medicines is considered high and can lead to the 
approval of medicines different than their innovators. For example, if a patient ingested a 
generic drug with a bioavailability of 80% (80/100) compared to its branded counterpart 
medicine, then this generic drug was substituted to another generic with a bioavailability 
of 125% (100/80) compared to its branded counterpart medicine, the patient will face an 
increase of 20% in the bioavailability of the drug concentration in the blood stream. This, 
however, can cause toxicity and more side effects. In this case, although both generic 
medicines comply with the bioequivalent guidelines of the EMA and FDA, they are not 
interchangeable.  
A single dose bioequivalence study presented in this thesis explored that both 
clarithromycin formulations (Resclar 500 mg and Klacid® 500 mg) are 
bioequivalent within limits (80-125%). Both formulations were well tolerated in the 
studied population and no relevant differences in the safety profiles were observed. 
However, this study confirmed that the generic drug is prescribable but could not 
prove that it is interchangeable with its branded counterpart. In order to establish 
interchangeability between these drugs, multiple dose and individual 
bioequivalence studies are required because differences can be more apparent after 
multiple doses. (Chen et al., 2001, El-Tahtawy et al., 1995, El-Tahtawy et al., 
1994). 
In general, generic substitution must be considered based on the fact that standard 
bioequivalence testing is not designed to reveal pharmaceutical differences in 
individual patients and further efficacy and safety assessment should be carried out, 
such as conducting individual bioequivalent studies. Ideally, bioequivalent studies 
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should be carried out in patients (Mould, 2002). It is important to clarify that complying 
with the bioequivalent limits can prove that both drugs are bioequivalent and prescribable 
but does not prove that both drugs are interchangeable. Therefore, bioequivalent limit 
might need to be stringent especially for some drugs such as the critical dose and narrow 
therapeutic index drugs. This will reduce the differences in the safety and efficacy profile 
between the bioequivalent formulations. This recommendation is on line with others 
currently presented in the EMA and Health Canada. They recommend that the average 
bioequivalence limit to be tightened to 90-111% for critical dose and narrow therapeutic 
index drugs (Health Canada, 2006, Mannion, 2011, Tamboli et al., 2010).  
Furthermore, many authors in the literature are raising the need for additional metrics to 
assess therapeutic equivalence especially for some multiphase modified-release products. 
They recommend that once chosen drugs, especially the modified preparations, it is 
advisable to maintain the same preparations to derive the maximum clinical effect 
(Kondra et al., 2011, Mould, 2002). This is very important because in the real healthcare 
settings a large group of physicians with different backgrounds prescribe drugs to a more 
heterogeneous group of patients who undergo less intensive management compared to a 
trial population (Grima et al., 2008). In addition, as mentioned in this thesis, the present 
of other factors such as food, disease, age or combination of drugs can alter the 
bioequivalence status obtained from a clinical trial. For example, a bioequivalence study 
of two tacrolimus formulations (immunosuppressant agent) under fasting conditions 
concluded that both the branded and the generic formulations were found bioequivalent 
according to the European Regulatory Bioequivalence Guidelines (Mathew et al., 2011). 
However, another study revealed that the presence of food decreased the rate and extent 
of tacrolimus absorption (Steiner and Feist, 2011). 
Another study revealed that patients who received generic ciclosporin A had a 10% lower 
one year graft survival compared with those who received Neoral (Pollard et al., 2003). 
Consequently, this has encouraged the EMA to recommend the bioequivalence criteria 
for tacrolimus to be tightened to 90-111% for AUC (Steiner and Feist, 2011). Yet, the 
current FDA guidance indicates that the traditional bioequivalence range remains 
unchanged for narrow therapeutic index drugs. The Office of Generic Drugs in the FDA 
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has recently prepared new approaches for approving bioequivalence of these drug 
products (Food and Drug Administration, 2003). 
Another way to prove that both the branded and generic drugs are interchangeable is by 
conducting individual bioequivalence trial (Yacobi et al., 2000). Considering the use of 
individual bioequivalence approach through replicate administration design studies, in 
which both the branded and generic drugs are given twice in two different occasions in a 
four-way crossover design, is required to provide more data and assurance that the 
generic drugs are interchangeable with their branded counterparts. Detailed 
pharmacokinetic studies should also be performed to approve generic substitution 
of these drugs. Otherwise, generic substitution should be applied with caution and 
under supervision of medical staff. As a result, random generic and therapeutic 
substitution should not be promoted under the assumption of dose equivalence.  
There is also a problem with reporting of bioequivalence trials comparing generic to 
branded drugs. For example, a study found that important information to judge the 
validity and relevance of results is frequently missing in published reports of trials 
assessing generic drugs (van der Meersch et al., 2011). Lack of transparency was also 
shown in published reports of trials (van der Meersch et al., 2011). For example, many 
bioequivalence studies in the literature would make misinterpretation by concluding that 
the generic drug was proven bioequivalent and therefore interchangeable to its branded 
counterpart medicines (Christians et al., 2010, Schall and Endrenyi, 2010, Singla et al., 
2009). Other studies would indicate that the generic drug was bioequivalent and therefore 
therapeutically equivalent to its branded counterpart drug (Christians et al., 2010, Schall 
and Endrenyi, 2010). However, bioequivalence studies within the regulated limits are 
conducted to prove that both drugs are bioequivalent and only prescribable.  
Ideally, harmonisation of regulatory requirements would decrease the number of in-vivo 
bioequivalence studies, avoid unnecessary drug exposure to humans and reduce the cost 
of generic drug development. In general, manufacturers must refocus their energy to 
conduct cost-effectiveness studies and discover superior drugs that will indisputably help 
sick people. The differences in cost-effectiveness versus efficacy are a function of a 
number of aspects that more varied in actual practice than in clinical trials. For example, 
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a study presented at the annual conference of the American Heart Association in March 
2004 indicated that spending on antihypertensive drugs essentially doubled (from 
approximately $6 billion to approximately $12 billion) between 1990 and 2002. 
Therefore, it was recommended that cost-effectiveness and clinical effectiveness should 
be pursued simultaneously (Pater, 2004). 
7.5 Reducing healthcare expenditure by promoting drug 
substitution  
Many economic studies and healthcare providers focus on simple drug cost when 
comparing the costs between the branded and generic medicines. However, the greater 
concern should be the clinical value of drug therapy which includes the function of its 
benefit compared to its cost. When comparing generic medicine to its branded 
counterpart, cost means not only acquisition cost of a drug, nor even all monetary costs, 
but should include distress and time lost from work. Pharmaceutical industry argued that 
such a focus was flawed as it considered only the costs of drug therapy without 
considering the benefit or value of a drug. This might be expensive but either be a better 
use of limited resources in terms of health gain achieved or save money elsewhere in the 
healthcare system (Walley, 2010).  
It was explored in this thesis that many healthcare authorities, patients and prescribers 
believe that drug substitution is mainly promoted to reduce healthcare expenditure; but 
does it really save money? For example, in the British NHS there was a national 
switching program from atorvastatin 10 mg/20 mg to simvastatin 40 mg after the 
simvastatin patent expiry. From 2006 to 2008 the total number of atorvastatin 10 mg 
prescriptions was halved giving an anticipated saving of £1 billion in 2011 (Usher-Smith 
et al., 2008). With society faces major challenges with new expensive drugs, an aging 
population and limited resources; surly, it is unfair and wasteful to use expensive drugs 
with no added value. However, switching from atorvastatin to simvastatin in primary care 
is now known to be associated with a significant increase in morbidity (major 
cardiovascular events), mortality and in treatment discontinuation compared with patients 
who did not switch (Phillips et al., 2007). 
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Nevertheless, many authors in the literature have reported that attempting to reduce costs 
on treating chronic conditions by drug substitution might lead to an increase in the overall 
healthcare expenditure (Andersson et al., 2005, Gafni and Birch, 2007, Johnston et al., 
2010, Richton-Hewett et al., 1988). Promoting random use of cheaper medicines can 
have an economic burden when prescribed to patients because of its more side effects and 
less effectiveness. Even after full approval of a generic drug as bioequivalent, cost-
effectiveness studies are important to define true cost differences using methods for 
economic evaluation of healthcare with respect to generic substitution (Olyaei et al., 
1999).  
As mentioned in this thesis, there are number of factors and aspects of therapy needed to 
be taken into account when switching to drugs with lower acquisition cost, despite the 
fact that there is a potential saving. These include the impact on patient satisfaction of 
switching, adherence and persistence, the cost involved in implementing the switch and 
managing the consequences of switching (Garfield and Caro, 1999, Thiebaud et al., 2005, 
Wilson et al., 2005, Yiannakopoulou et al., 2005); and the safety and efficacy of the 
substituted drugs relative to the original choice. For example, a study was conducted to 
evaluate the cost-effectiveness of the most used oral hypoglycaemic agents in the 
treatment of type two outpatients in Mexico City. It revealed that Glibenclamide 
($272.63/QALY) was the most cost effective treatment for the present study outpatient 
population compared to metformin ($296.48/QALY) or acarbose ($409.86/QALY) 
(León-Castañeda et al., 2012). This indicates the importance of conducting detailed cost-
effectiveness study ensure safe, effective and efficient drug substitution. 
A study in the literature examined the economic impact of switching from branded 
ciclosporin A to its generic counterpart. It revealed that the total healthcare costs were 
significantly higher for patients receiving generic ciclosporin A compared to the branded 
form. The main driver for the difference was the cost associated with 
immunosuppressants other than ciclosporin A (Helderman et al., 2010). Another study 
reported that patients treated with the branded ciclosporin A had fewer hospitalisation 
days and lower physician costs for inpatient and outpatient procedures. This resulted in 
lower overall healthcare costs (Kingma et al., 1997). Another study compared the effect 
of valsartan to other cheaper angiotensin receptor blockers (ARB). It concluded that 
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hypertensive patients who were switched to the cheaper ARB experienced an increase in 
medication discontinuation, healthcare resource use as well as costs compared with those 
who were maintained on valsartan treatment (Cox et al., 1978).  
Another study found that the NHS is reimbursing generic medicines at too high prices 
which can offset its potential savings from using generics (Kanavos, 2007). Many 
countries such as the UK, Australia, Canada and Sweden implemented an explicit or 
semi-explicit approach to guiding resource-allocation decisions by formal health 
economic analysis (Eichler et al., 2004). This shows that there is an increasing awareness 
that resource allocation must be addressed in a systematic rather than intuitive manner. 
However, in most other countries, formal economic analysis is not yet a key input into 
the decision-making process (Eichler et al., 2004).  
Moreover, research by pharmaceutical companies is usually viewed with suspicion as 
they have vested interests in demonstrating poor treatment outcomes in patients who have 
been switched from their products. In the literature, there is evidence of publication bias 
related to economic evaluation studies. For example, a total of 92% of 
pharmacoeconomics studies in most journals came down in favour of the drug in question 
which was also funded by the drug in question manufacturer (Sacristan et al., 1997). In 
addition, the generalisability of economic findings requires careful exploration of 
changes in resource implications, outcomes and unit prices. Therefore a process 
facilitated again by transparent reporting of methods, adjustment for baseline risk and 
potentially by recent statistical developments intended to deal with hierarchically 
structured data (Mason and Mason, 2006). 
7.6 Conclusions  
In conclusion, switching and substituting drug is not a new concept. Countries with 
different attitudes to risks and facing different budget constraints could promote random 
drug substitution to save costs. However, health services do not exist to save money, but 
to use the available resources efficiently by achieving the greatest health improvement for 
the population. Therefore, drug costs should not be considered alone without considering 
their benefits. Nowadays, there are an exploding market demand from an aging 
population that has unparalleled unmet medical needs.  
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As a consequence, there are strong demand for controlling costs from healthcare 
providers, while the pharmaceutical companies struggles to produce novel drugs and 
remain profitable (Pitluk and Khalil, 2007). It is apparent that there is no healthcare 
system that can provide every medical intervention which offers benefits to everyone. 
Every system must confront the question how and on what basis to deny potentially 
beneficial care to some people. Even during times of economic hardship, medicines 
continue to be an essential purchase.  
It was illustrated in this thesis that in the case of generic and therapeutic substitution the 
absence of evidence of differences is not tantamount to evidence of no differences. Many 
studies included in this thesis and in the literature have shown that similar treatments can 
have different clinical outcomes. This indicates that promoting generic and therapeutic 
substitution on economic grounds alone and on acquisition costs in particular is 
potentially harmful to patients and can be unethical. Drug substitution should always take 
place with the interest of individual patient in mind and not solely to reduce costs. All of 
us support cheaper medicines but not if it costs us our health. 
A lack of transparency around the practice of generic substitution was also marked in this 
thesis. Thereby, proper patient education, monitoring and involving patients in decisions 
regarding their health would improve transparency, enhance patients’ assurance and 
promote efficient generic prescribing and substitution. Patients need to be assured that 
substitutions involve therapeutically equivalent drugs only. Healthcare professionals 
being the key decision-making agent to determine whether patients receive either branded 
or generic drugs should also be educated to implement appropriate drug substitution. 
Physicians and pharmacists should be legally obliged to inform patients about all 
available therapeutically equivalent alternatives to their branded drug; then it is up to the 
patient to whether accept or reject the drug substitution. 
A question was raised in this thesis about the interchangeability between branded 
medicines and their generic counterparts and also among generics themselves. In general, 
indiscriminate switching among different formulations of the same drug could 
result in differences in the rate and extent of absorption. An average bioequivalence 
study is sufficient to ensure the prescribability of most generic medicines but does 
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not guarantee interchangeability between prescribable formulations. Therefore, 
random switching between branded and generic medicines or among generics can 
be risky to patients. This should be highly considered when a clinical choice between 
two drugs is required. Thus, assessing patients after performing drug substitution is 
strongly recommended.  
According to the results of this thesis, random switching among generics is not 
recommended. Many studies in the literature are in harmony with this implication 
(Colaizzi and Lowenthal, 1986, Duerden and Hughes, 2010). Indiscriminate switching 
among generic medicines could potentially result in 40 to 60% differences in rate or 
extent of absorption (Colaizzi and Lowenthal, 1986). This result was also confirmed by 
the dissolution study presented in this thesis (Al Ameri et al., 2012). Substitution among 
generic medicines is not usually based on scientific data but on a wrong assumption. The 
assumption is that when a generic drug is proved to be bioequivalent to its branded 
counterpart medicine, then it is assumed to be bioequivalent to other generics of the same 
branded medicines. However, it was proven in this thesis that this assumption is 
incorrect; unless a bioequivalent study was conducted among generics confirming their 
interchangeability. Furthermore, many authors in the literature confirmed that generic 
tablets are not always equivalent to the innovator product raising concerns that the 
results of the bioequivalent trials achieved with the branded drug should not be 
extrapolated to generics (Colaizzi and Lowenthal, 1986, Nightingale, 2000, 
Nightingale, 2005).  
In general, bioequivalence testing is not designed to reveal pharmaceutical 
differences in individual patients. According to the literature a standard single dose, 
two-way crossover study design is routinely required to establish bioequivalence between 
branded and generic medicines. This design does not detect a possible subject-by-
formulation interaction. Therefore, considering the use of an individual bioequivalence is 
required to provide more data and assurance that the generic drugs are interchangeable 
with their branded counterparts (Hauck et al., 2000).  
Although restricting the approval process is not good for patients; only safe drugs should 
be approved. Therefore, the role and regulations surrounding drug substitution and 
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approving bioequivalent generic medicines should be strengthened to maintain the quality 
of care. It is suggested in this thesis that the average bioequivalence limit should be 
tightened to 90-111% especially for critical dose and narrow therapeutic index drugs to 
ensure that only high quality and interchangeable medicines are approved. Moreover, 
healthcare providers should take into account that definitely generic medicines save 
money, but are they good for us?  
Overall, generic prescribing and substitution can be effectively promoted when the 
medical or clinical outcomes are easily measurable such as pain, headache and infections 
and avoided when the consequences of under-dosing or overdosing are greater such as for 
critical and narrow therapeutic index drugs. In conclusion, to achieve excellent strategic 
logistic planning and effective drug formularies in hospitals, generic and therapeutic 
substitution should be solely based on providing patients with the best possible care and 
quality medicines. 
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8 Chapter 8 Planned future studies  
The following studies were planned but unfinished because of the time constrain and the 
long approval process. For example, it required more than 18 months to grant the 
approval of using the General Practice Research Database (GPRD) in these studies. 
Overall, research is hard to be enclosed within a specific time limit. 
8.1 The impact of switching from atorvastatin to simvastatin on 
patients’ cardiovascular outcomes in the UK: A study using 
the General Practice Research Database.  
8.1.1 Introduction 
Statins are well known cholesterol-lowering agents with extensive evidence, high 
efficacy and excellent safety (Bandolier, 2007). As a consequence, statins represent the 
largest drug cost to the NHS in 2004 (Moon and Bogle, 2006). This exponential rise has 
led the British NHS and many other healthcare providers to promote statins substitution 
in attempt to contain their costs (Department of Health, 2010, National Health Service, 
2009). However, little is currently known of the effect on cardiovascular outcomes of 
switching patients established on cholesterol-lowering therapy to another agent in the 
same class (Phillips et al., 2007).  
Switching patients to drugs with lower acquisition costs is a common approach to cost 
containment. Though, we need to be sure that promoting this substitution will reduce 
healthcare expenditure without compromising patients’ quality of care. This study is a 
retrospective cohort study using the General Practice Research Database (GPRD) within 
UK general practice setting (Sjöström et al., 1999, Wilson and Cohen, 2011). This study 
is aimed at comparing the cardiovascular outcomes in patients who are switched from 
atorvastatin to simvastatin to those who did not and the vice-versa.  
It is assumed that switching might cause different cardiovascular outcomes. This might 
have a significant effect on patients’ quality of care as well as total healthcare costs. A 
recent study funded by Pfizer (the manufacturer of Lipitor®) using The Health 
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Improvement Network (THIN) database found that major cardiovascular adverse events 
were recorded with patients switching from atorvastatin to simvastatin compared to those 
who did not switch (Phillips et al., 2007). THIN is known to have a large unknown 
overlapping with GPRD data-base. However, this study will overcome this limitation 
because Pfizer’s study was commenced on December 2007 and this study will include all 
patients enrolled in the GPRD from January 2002 to December 2010. The included group 
of patients in this study would be different from those used in Pfizer's study because of 
the different time-period. This will help either confirm or reject Phillips et al.’s drawn 
conclusions.  
Usually, research by pharma companies is viewed with suspicion as they have vested 
interests in demonstrating poor treatment outcomes in patients who have been switched 
from their products. For example, although Pfizer’s study found that major 
cardiovascular adverse events were recorded with patients switching from atorvastatin to 
simvastatin compared to others who did not switch (Phillips et al., 2007), a number of 
authors are questioning the results of this study claiming that it has major limitations 
(Duerden and Hughes, 2010, Goldsmith and Duerden, 2008).  
These limitations include that the study was performed by the manufacturer which can 
lead to accusations of influence and bias in the results. Other limitations include that 
results were influenced by the confounding factors and the study protocol was not 
designed to evaluate the reasons why patients were switched and was not powered for 
detailed subgroup analysis or to assess particular dosage switches from atorvastatin to 
simvastatin. This planned future study will overcome these limitations by evaluating a 
different group of patients in a different time-period and will be performed independently 
from any manufacturer to eliminate any positional influence or bias in the results. In 
addition, the study group will be matched to their controls very closely to overcome the 
influence of the confounding factors. The reasons of switching will also be evaluated, if 
applicable.  
Moreover, Phillips et al.’s study evaluated only the switch from atorvastatin to 
simvastatin which shows that the aim of the study was driven by the cost consideration 
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and not comparing the clinical outcomes between the two treatments. Finally, Phillips et 
al.’s study was exploratory and the study needs to be repeated to confirm that the 
observed results are real and repeatable. Therefore, this is an independent cohort study 
with a methodology based on that developed by of Phillips et al. (2007) from Pfizer  
using a different data source, time-period and overcoming its limitations. If this confirms 
their findings of negative consequences when switching statin treatments on 
cardiovascular outcome we will attempt to allocate the source of the effect; is it the drugs 
or the action of switching per se?  
Nevertheless, there are no “subtle clinical criteria” for switching. Lack of therapeutic 
efficacy or adverse events are the only clinical criteria that should result in patients being 
switched. This goes to the heart of the question “are patients being switched for economic 
reasons only, and if so, are there adverse consequences?” Drug substitution remains an 
option if it saves money and does not negatively impact on patients’ outcomes. Currently 
it is proceeding without an evidence base (Phillips et al., 2007) and the immediate cost 
reduction by promoting generic and therapeutic substitution may be offset by a reduction 
in treatment quality and/or safety (Hellstrom and Rudholm, 2004, Andersson et al., 
2005).  
8.1.2 Objectives 
The objective of this study is to compare the cardiovascular outcomes in patients who 
were switched from atorvastatin to simvastatin with those who did not and the vice-versa.  
8.1.3 Method 
This study is an observational cohort study using the General Practice Research Database 
within the UK general practice setting. The methodology of this study is based on that 
developed by Philips et al. (2007) to evaluate the effects of switching statins on 
cardiovascular adverse events. The design of this study is hypothesis generating since it 
aims at revealing patterns associated with therapeutic substitution without an emphasis on 
pre-specified hypotheses. It is worth noting that the approval of this study required more 
than a year and is expected to be completed within one year under the MRC Agreement. 
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This study has not yet commenced and data are waiting to be collected by the GPRD 
administrators. The approval, protocol and the response of the MHRA regarding this 
study are in Appendix 15 and Appendix 16. 
8.1.3.1 Subjects 
All subjects are required to be enrolled in the GPRD for at least one year prior to the 
index date to verify that they were switched after at least 6 months. Each patient will be 
selected according to the drug treatment and matched to a control that remained on 
atorvastatin. All patients who had received atorvastatin or simvastatin from January 2002 
to December 2010 will be included (Table 35). This will allow a follow-up period of 
eight years. The risk of death or first major cardiovascular event will be compared. Both 
groups will be matched according to the duration of treatment before switch, covariates, 
prior exposure and baseline cholesterol level (total cholesterol < 5.0 mmol/L). 
Discontinuation from assigned therapy of at least 90 days is defined as a non-exposure.  
Table 35: Drug codes for atorvastatin and simvastatin obtained from the GPRD 
database. 
GPRD code Multilex code Drug name 
28 10688001 Atorvastatin tablets 10mg 
75 10688002 Atorvastatin tablets 20mg 
745 10688003 Atorvastatin tablets 40mg 
5775 09689001 Atorvastatin tablets 80mg 
3411 10693001 Lipitor tablets 10mg 
7374 10693002 Lipitor tablets 20mg 
2955 10693003 Lipitor tablets 40mg 
17683 09690001 Lipitor tablets 80mg 
34560 
13041 
31930 
34481 
34535 
40340 
34955 
04448009 
12081001 
12626001 
04516009 
04548009 
04504009 
04491009 
Simvastatin tablets 10mg 
25 
9920 
34476 
33082 
34316 
34312 
34366 
34746 
39060 
34814 
06380002 
12082001 
04449009 
04497009 
04505009 
04549009 
04517009 
04524009 
04721009 
04512009 
Simvastatin tablets 20mg 
Chapter 8 Planned future studies 
 
Page 284 of 446 
GPRD code Multilex code Drug name 
40601 
34891 
05592009 
04527009 
51 
802 
34545 
34376 
34353 
34381 
34907 
34502 
34879 
34969 
37434 
06380003 
12083001 
04450009 
04506009 
04550009 
04518009 
04513009 
04498009 
04525009 
04521009 
04594009 
Simvastatin tablets 40mg 
5148 
41657 
32909 
39870 
07779001 
04814009 
04499009 
16969001 
Simvastatin tablets 80mg 
2718 06379001 Zocor tablets 10mg 
7196 06379002 Zocor tablets 20mg 
6168 06379003 Zocor tablets 40mg 
22579 07528001 Zocor tablets 80mg 
Inclusion criteria: 
1. Males and females. 
2. Over 18 years old. 
3. Have at least 12 months of research standard data. 
4. Have diagnosis of hypercholesterolaemia (See Table 36 for clinical codes). 
5. Switched to simvastatin after using atorvastatin for at least 6 months or switched 
to atorvastatin after using simvastatin for at least 6 months. 
6. Cholesterol measurements are available. 
Exclusion criteria: 
1. Patients with inadequate cholesterol control at baseline (total cholesterol < 5.0 
mmol/L or clinical code indicating poor hypertension control).  
2. Cholesterol measurements are not available.  
3. Patients who were not coded with a diagnosis of hypercholesterolemia, but were 
treated on the basis of blood tests with a tentative diagnosis in the free text. 
4. Patients with a history of intolerance to atorvastatin or simvastatin. 
5. Patients temporarily registered with their general practice. 
Chapter 8 Planned future studies 
 
Page 285 of 446 
Table 36: Clinical codes for cholesterol. 
Read/OXMIS codes Clinical term 
C320.00 Pure hypercholesterolaemia 
44P..00 Serum cholesterol 
1269.00 Family history of familial hypercholesterolaemia 
1262.11 FH: cholesterol high 
44P4.00 Serum cholesterol very high 
662X.00 Target cholesterol level 
44PH.00 Total cholesterol measurement 
44P1.00 Serum cholesterol normal 
44P2.00 Serum cholesterol borderline 
44P3.00 Serum cholesterol raised 
6879.11 Cholesterol screen 
13B3.00 Low cholesterol diet 
662X.00 Target cholesterol level 
C320000 Familial hypercholesterolaemia 
44P6.00 Serum LDL cholesterol level 
44PK.00 Serum fasting total cholesterol 
44I2.00 Cholesterol/HDL ratio 
44OE.00 Plasma total cholesterol level 
44dB.00 Plasma LDL cholesterol level 
44PJ.00 Serum total cholesterol level 
662a.00 Pre-treatment serum cholesterol level 
44PF.00 Total cholesterol: HDL ratio 
813w.00 Cholesterol test declined 
4I30.00 Fluid sample cholesterol level 
The primary outcome measure is the time of death or discontinuation of therapy or first 
major cardiovascular event (defined as angina, myocardial infarction (MI), stroke or heart 
failure) recorded after the index date (Table 37) (Mattson, 1999, Munro and Bentley, 
2004). One of the key covariates that will be considered is the difference in baseline 
cholesterol level between the switch patients and the control group. The matching 
covariates would include age, gender, history of myocardial infarction (Table 38) 
(Berger et al., 2011), general practitioner (GP) practice, diabetes, (Table 39) (Hoffmann, 
1994), obesity (recorded obesity codes or a body mass > 30) (Table 37), cerebrovascular 
disease, Hypertension (relevant diagnostic codes or a bloods pressure recorded as > 
115/95 mmHg for two separate consecutive readings) (Table 37), cholesterol level 
(Table 36) and time since last statins exposure and the total treatment duration of both 
drugs (prior and during the study period).  
Algorithms will be developed to validate cases of myocardial infarction, stroke, heart 
failure and diabetes based on those used in previous studies (Berger et al., 2011, 
Hoffmann, 1994, McGinnity and Pluth, 1994, Martin et al., 2010, Munro and Bentley, 
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2004, Mattson, 1999). However, if the covariates need to be reduced, the following 
covariates can be added; age, gender, history of myocardial infarction (Table 38) (Berger 
et al., 2011), diabetes (Table 39) (Hoffmann, 1994), cerebrovascular disease, 
hypertension (relevant diagnostic codes or a blood pressure recorded as >115/95 mmHg 
for two separate consecutive readings) (Table 37), cholesterol level (Table 36) and time 
since last statin exposure and the total treatment duration of both drugs (prior and during 
the study period). 
Table 37: Codes for major cardiovascular events (angina, myocardial infarction, 
stroke or heart failure) and the key covariates obtained from the GPRD 
database. 
Read/OXMIS codes Clinical term 
12C..14 Angina 
G311100 Unstable angina 
G33z700 Stable angina 
323..00 ECG: Myocardial infarction (MI) 
G30..15 MI (acute myocardial infarction) 
12C4.12 Stroke 
SN20.00 Heat stroke and sunstroke 
8HBJ.00 Stroke/ transient ischaemic attack referral 
G58.00 Heart failure 
G580.00 Congestive heart failure 
G580100 Chronic congestive heart failure 
1I10.00 Heart failure excluded 
C38..00 Obesity and other hyperalimentation  
C380400 Central obesity 
C380500 Generalized obesity 
212Q.00 Obesity resolved 
G20.00 Essential hypertension 
6628.00 Poor hypertension control 
G24..00 Secondary hypertension 
212K.00 Hypertension resolved 
Table 38: Clinical codes of myocardial infarction obtained from the GPRD database. 
Read/OXMIS codes Clinical term 
G30..15 MI (acute myocardial infarction) 
12C3.12 MI (myocardial infarct >60) 
12C2.12 MI (myocardial infarct <60) 
ZV71900 Observation for suspected MI 
G32..12 Personal history of MI 
G38..00 Postoperative MI 
14AH.00 H/O: MI in last year 
G30y.00 Other acute MI 
G32.00 Old MI 
G32..11 Healed MI 
G30..17 Silent MI 
3232.00 ECG: Old MI 
G30..14 Heart attack 
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Table 39: Clinical codes for diabetes obtained from the GPRD database. 
Read/OXMIS codes Clinical term 
C10..00 Diabetes mellitus 
C10N.00 Secondary diabetes mellitus 
9OLA.11 Diabetes monitored 
R102.11 Pre-diabetes 
1434.00 H/O: Diabetes mellitus 
ZV18011 Family history of diabetes mellitus 
2126300 Diabetes resolved 
C10E.00 Type 1 diabetes mellitus 
C10F.00 Type 2 diabetes mellitus 
1228.00 No family history of diabetes 
C108.00 Insulin dependent diabetes mellitus 
C100112 Non-insulin dependent diabetes mellitus 
1408.00 At risk diabetes mellitus 
1I0.00 Diabetes mellitus excluded 
C10E800 Type 1 diabetes mellitus- poor control 
C10F700 Type 2 diabetes mellitus- poor control 
C108800 Insulin dependent diabetes mellitus- poor control 
L180500 Pre-existing diabetes mellitus, insulin dependent 
C10E400 Unstable type 1 diabetes mellitus 
C108400 Unstable Insulin dependent diabetes mellitus 
66AJ.11 Unstable diabetes 
8.1.4 Main limitations of the study 
A key limitation is that the database does not record compliance or adherence to the 
treatment. It is not known if the prescription was filled or that the patient is compliant. 
This is important as switched patients may be less likely to comply, hence some 
cardiovascular events may not be due to ineffective drug but rather poor compliance or 
adherence to treatment. Therefore, indicators to assess patient’s compliance such as 
timelines of prescription refill and the total prescription time at any given period from the 
index date with and without a switch should be considered. Overall, this study is an 
authentic, real life assessment which sometimes investigators cannot overcome its 
limitations. 
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8.2  The impact of switching from valsartan to losartan on 
patients’ clinical outcomes in the UK: a study using the 
General Practice Research Database  
8.2.1 Introduction 
Hypertension is considered a major risk factor for stroke and cardiovascular disease. It 
accounts for 30% of all deaths worldwide and is associated with metabolic syndromes 
including lipid abnormalities and insulin resistance. Approximately one billion adults 
globally are currently affected with hypertension (Nixon et al., 2009). The benefits of 
reducing hypertension on the risks of major cardiovascular disease are well established, 
but uncertainty still occurs about the comparative effects of different antihypertensive 
treatments (Nixon et al., 2009).  
This is an independent project using the GPRD to overcome any suggestion of bias 
expected from pharmaceutical industry (Duerden and Hughes, 2010, Goldsmith and 
Duerden, 2008). Angiotensin II receptor antagonists (ARBs) are considered the most 
common single agents used as monotherapy to treat hypertension (Falaschetti et al., 
2009). Losartan (Cozaar®) was the first ARB to be marketed by Merck & Co. The patent 
of losartan has expired and generic losartan is on the market. As a consequence, 
switching from valsartan to losartan can be randomly applied in the primary care setting 
to reduce healthcare expenditure.  
Switching patients to drugs with lower acquisition costs is a common approach to cost 
containment. According to this thesis and the existing literature, generic and therapeutic 
substitutions are considered contentious issues for patients and healthcare providers alike. 
For example, a study found that administering valsartan at 160 mg or 320 mg is more 
effective at lowering blood pressure than losartan 100 mg, and shows comparable 
efficacy to other ARBs in patients with essential hypertension (Nixon et al., 2009). 
Therefore, we need to be sure that promoting this substitution from valsartan to losartan 
will reduce healthcare expenditure without compromising patients’ quality of care.  
Chapter 8 Planned future studies 
 
Page 289 of 446 
8.2.2 Objectives 
The objective of this study is to compare the clinical outcomes in patients who are 
switched from valsartan to losartan with those who did not and the vice-versa.  
8.2.3 Method 
This study is an observational cohort study using GPRD within the UK general practice 
setting. The methodology of this study is based on that developed by Philips et al. (2007) 
to evaluate the effects of switching from valsartan to losartan on patients’ clinical 
outcomes. This study is considered hypotheses generating since it aims at revealing 
patterns associated with therapeutic substitution without an emphasis on pre-specified 
hypotheses. This project is expected to be completed within one year under the MRC 
Agreement. This study is not yet commenced waiting for the previous statins’ study to be 
conducted. The protocol and the response of the MHRA regarding this study are in 
Appendix 17, Appendix 18.  
8.2.3.1 Subjects 
All recruited subjects are required to be enrolled in the GPRD for at least one year prior 
to the index date to verify that they were switched after at least 6 months. Each patient 
will be selected according to the drug treatment and matched to a control that remained 
on valsartan. All patients who had received valsartan or losartan from January 2002 to 
December 2010 will be included in the study (Table 40). This will allow a follow-up 
period of eight years. The first major cardiovascular event will be compared. Both groups 
will be matched according to the duration of treatment before switch, covariates, prior 
exposure and baseline blood pressure level (seated diastolic blood pressure < 115mm Hg 
and ≥ 95mm Hg). Discontinuation from assigned therapy of at least 90 days is defined as 
a non-exposure.  
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Table 40: Drug codes for losartan and valsartan obtained from the GPRD database. 
GPRD code Multilex code Drug name 
575 10485001 Valsartan capsules 40mg 
3222 10485002 Valsartan capsules 80mg 
4645 10485003 Valsartan capsules 160mg 
11251 10486001 Diovan capsules 40mg 
11252 10486002 Diovan capsules 80mg 
6518 10486003 Diovan capsules 160mg 
14943 12846001 Valsartan tablets 40mg 
38395 14583001 Valsartan tablets 80mg 
37573 15830001 Valsartan tablets 320mg 
24359 12847001 Diovan tablets 40mg 
39199 15831001 Diovan tablets 320mg 
39944 17104001 Losartan tablets 12.5mg 
Inclusion criteria: 
1. Males and females. 
2. Over 18 years old. 
3. Have at least 12 months of research standard data. 
4. Have a diagnosis of hypertension (Table 41). 
5. Switched to losartan after using valsartan for at least 6 months or switched to 
valsartan after using losartan for at least 6 months. 
6. Blood pressure measurements available. 
Exclusion criteria: 
1. Patients with inadequate hypertension control at baseline (seated diastolic blood 
pressure >115 mm Hg or clinical code indicating poor hypertension control).  
2. Patients with a history of intolerance to losartan or valsartan. 
3. Patients temporarily registered to their general practice. 
Table 41: Clinical codes for hypertension obtained from the GPRD database. 
Read/OXMIS codes Clinical term 
G20.00 Essential hypertension 
G200.00 Malignant essential hypertension 
1227.00 No FH: hypertension 
12C1.00 FH: hypertension 
662P.00 Hypertension monitoring 
662c.00 Hypertension 6 months review 
G202.00 Systolic hypertension 
6627.00 Good hypertension control 
662b.00 Moderate hypertension control 
6628.00 Poor hypertension control 
662O.00 On treatment for hypertension 
662H.00 Hypertension treatment stopped 
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Read/OXMIS codes Clinical term 
813N.00 Hypertension treatment refused 
G24z100 Hypertension secondary to drug 
212K.00 Hypertension resolved 
G203.00 Diastolic hypertension 
G24..00 Secondary hypertension 
9O12.00 Refuses hypertension monitor 
The primary outcome measure is the time of death or the time of discontinuation of 
therapy or first major cardiovascular event recorded after the index date defined as 
angina, myocardial infarction, stroke or heart failure (Table 37) (Mattson, 1999, Munro 
and Bentley, 2004).  
One of the key covariates that will be considered is the difference in baseline blood 
pressure level between the switched patients and the control group. The matching 
covariates will include age, gender, history of myocardial infarction (Table 38) (Berger 
et al., 2011), general practitioner (GP) practice, diabetes (Table 39) (Hoffmann, 1994), 
obesity (recorded obesity codes or a body mass > 30) (Table 37), cerebrovascular 
disease, high cholesterol (relevant diagnostic codes or prescription issued for a statin 
drug) (Table 37), hypertension (relevant diagnostic codes or a blood pressure recorded as 
> 115/95 mmHg for two separate consecutive readings) (Table 41), time since last ARBs 
exposure and the total treatment duration of valsartan (prior and during the study period). 
Algorithms will be developed to validate cases of myocardial infarction, stroke, heart 
failure and diabetes based on those used in previous studies (Berger et al., 2011, 
Hoffmann, 1994, Martin et al., 2010, Mattson, 1999, McGinnity and Pluth, 1994). 
8.2.4 Main limitations of the study  
A key limitation is that the database does not record compliance or adherence to the 
treatment. It is not known if a prescription was filled or that the patient was compliant. 
This is important as switched patients may be less likely to comply, hence some clinical 
events may not be due to ineffective drug but rather poor compliance or adherence to 
treatment. Therefore, indicators to assess patient’s compliance such as timelines of 
prescription refill and the total prescription time at any given period from the index date 
with and without a switch should be considered. This study is an authentic, real life 
assessment which sometimes investigators cannot overcome its limitations. 
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8.3 Economic evaluation of using branded Taxotere® versus 
generic docetaxel: Based on decision tree model 
8.3.1 Introduction 
Health economic evaluation is about making choices between options which should be 
fundamentally comparative. It weighs the cost and effectiveness of one intervention 
against those of another. To pharmaceuticals, health economics is considered as a 
common response to limited resources available for medical care. The main branch of 
health economics that particularly considers drug therapy is called pharmacoeconomics. 
It started as a science driven by the pharmaceutical industry as a way of promoting the 
value of its therapy and defending its market. However, it has turned into powerful tool in 
the hand of regulatory agencies to improve the efficiency of therapies in healthcare 
settings (Walley, 2010).  
Pharmacoeconomic evaluation is considered an important section of the evaluation of any 
therapy. It justifies how the available resources should be spent to maintain the public 
good. The principles of pharmacoeconomics are very well documented (Zaoui et al., 
2011 ) and now globally accepted. Many countries hired government-funded agencies 
with responsibility for pharmacoeconomics’ application such as the National Institute for 
Health and Clinical Excellence (NICE) in England. This has also forced the FDA into a 
territory of judging the merits of economic evaluations (Neumann et al., 1996). 
In many reported cases in the literature, healthcare authorities or other payer such as 
insurance companies believe that spending on drugs is an area where savings can be 
made quickly, obviously and without determent to patients. Thereby, they try many 
attempts to contain these costs. These include co-payment, restricted access to drugs 
through limited hospital formularies which mostly contains generic drugs or by price 
negotiation (Walley et al., 2004).  
Decision tree analysis is a probabilistic method for modelling problems under 
uncertainty. Analysis of cost-effectiveness represents a typical example of such a 
problem since they are performed for decision making regarding reimbursement of drugs 
or allocation of healthcare budget in presence of uncertainty (Baio and Jansen, 2005). In 
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general, modelling in health economics is aimed at simplifying the issues relevant to 
decision making while avoiding the problems of inaccuracy. They are typically used to 
decide between two or more treatments if the relevant clinical trial have not been 
conducted or was not designed to capture economic data (Walley et al., 2004). Decision 
tree is considered the most common type of modelling used in economic evaluation that 
do not involve interaction between individuals (such as infections) (Barton et al., 2004).  
In general, decision tree is used to inform health policy decisions since it offers a 
framework that can be used to achieve some of the key tasks in reimbursement decisions. 
The main aim of this model is to synthesis data for the purpose of making a decision. 
Usually, the end result of a model is an estimate of cost per quality adjusted life years 
(QALY) gained or other measure of value-for-money (Weinstein et al., 2003). The output 
of a model must not be regarded as claims about the facts or as predictions about the 
future. Rather, its aim is to synthesize evidence and assumptions in a way that allows end 
users to gain insight into the implications of those inputs for valued costs and 
consequence (Weinstein et al., 2003).  
Models synthesize evidence on health consequences and costs from many different 
sources such as clinical trials, observational studies, public health statistics, insurance 
claim database and preference survey (Weinstein et al., 2003). Some authors define a 
model as a representation of reality itself based on interrelationships derived from theory 
or observation (Weinstein, 2006). It is a mathematical one with probabilities interacting 
to produce simulated patients or fraction of a population in different health states over 
time. To these simulated outcomes combined utilities and costs are attached to form the 
denominators and numerators of cost-effectiveness ratios. Model can refer to a simplified 
representation of reality’s essential relationships and properties such as cause/effect, 
logical and quantitative. Simulation refers to models in which an actual or proposed 
system is replaced by a functioning or interactive representation of the system under 
study as opposed to merely theoretical models such as mathematical formula (Stahl, 
2008).  
One of the advantages of using models over clinical trials is that models can be used to 
generalise results from one setting to another and from one country to another; however, 
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should be with caution. Unlike the result of clinical trials which cannot be generalised to 
the general population because patients in clinical trials are much more compliant than 
patients in the real world (Walley et al., 2004). Overall, modelling analysis is considered 
as a method to help healthcare decision makers reach the best choices under conditions of 
uncertainty, conflicting objects and resources constraints. It helps decision makers to use 
the available evidence to arrive at a decision that they cannot avoid (Weinstein, 2006).  
8.3.2 Objective 
The objective of this study is to evaluate the cost-effectiveness of prescribing branded 
Taxotere® vs. generic docetaxel to patients diagnosed with breast cancer in the NHS 
setting. 
8.3.3 Method 
A previously published decision tree model will be developed in order to assess the cost-
effectiveness of using branded Taxotere® vs. its generic counterpart docetaxel in the UK 
NHS. In the perspective of health services, only direct costs should be considered. 
However, if the perspective was from that of the societal perspective, the direct and 
indirect costs should be studied (Jacobs et al., 2005). The primary outcome measure for 
the economic evaluation of this study is QALYs. Discount rate for the cost will be set at 
6% and at 1.5% for the benefit to comply with the current recommendation of the 
department of Health (National Institute for Clinical Excellence, 2001).  
8.3.4 Main limitations of the study 
In any pharmacoeconomic evaluation, there is a risk of industry driven bias and a draw of 
money into the evaluated areas such as acute therapies rather than those not considered 
such as long term therapies. Unlike clinical studies where the results are usually 
universally applicable, pharmacoeconomic studies are usually applicable only to the 
health service in which they are conducted. This can be related to the differences in 
pattern of care and drug costs between countries. Some important transferability factors 
such as prices, life expectancy, practice variation and disease spread will not be 
considereded.   
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Appendices 
Appendix 1: The protocol of the survey to determine the renal transplant patients’ 
views on generic substitution in the UK. 
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Appendix 2: The William Harvey Research Institute Research Governance Compliance 
Certificate for the survey to determine renal transplant patients’ views on 
generic substitution in the UK. 
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Appendix 3: The ethics’ approval to conduct the survey to determine the renal 
transplant patients’ views on generic substitution in the UK. 
The following is the raised questions from the ethics’ committee: 
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A letter responding to the raised questions from the ethics’ committee: 
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The granted Ethics’ Approval (REC Number: 10/H0704/16). 
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Appendix 4: The questionnaire (English) used in the survey to determine patients’ 
views on generic substitution in the UK.  
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Appendix 5: The protocol of the survey to determine the renal patients’ views on 
generic substitution in the United Arab Emirates for both the UAE 
General Hospital and the UAE University Hospital. 
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Appendix 6: The ethics approval from the UAE General Hospital to conduct a survey to 
determine the renal patients’ and physicians’ views on generic substitution 
in the United Arab Emirates. 
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Appendix 7: The ethics approval granted from the UAE University Hospital to conduct 
a survey to determine the renal patients’ views on generic substitution in 
the United Arab Emirates. 
Raised question from the ethics’ committee regarding the survey: 
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The response to the raised question: 
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The granted ethics approval of Abu Dhabi University hospital (REC Number: CRD 
101/10): 
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Appendix 8: The questionnaire (Arabic and English) used in the survey to determine 
the renal patients’ views on generic substitution in the United Arab 
Emirates.  
Note: Question number 3 was only asked in the UAE University Hospital as per their request for 
their own use. 
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Appendix 9: The protocol of the bioequivalence study comparing Resclar 500 mg (test 
product) to Klacid® 500 mg (reference product) in healthy volunteers. 
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Appendix 10: The Research Ethics Committee (REC) approval for the bioequivalence 
study comparing Resclar 500 mg (test product) to Klacid® 500 mg 
(reference product). 
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Appendix 11: Raw data for all subjects who participated in the bioequivalence study 
between Resclar 500 mg, test product (Neopharma, UAE) and Klacid® 
500 mg, reference product (Abbott Laboratories Ltd, England). 
Table 42: Study schematic. 
Procedure Study Period
iv
 
Screeningv Period I Period II Follow upvi 
Subject identification         
Informed consentvii      
Selection criteriaviii      
Demographic data      
Medical history      
Physical examination       
Vital signs         
Hepatitis B      
Hepatitis C      
HIV      
Alcohol screening test       
Drugs of abuse test       
Haematology      
Biochemistry     ix  ix 
Urinalysis      
Study drug 
administration       
Check for other 
medication        
Blood sampling for 
pharmacokinetics       
Check for adverse 
events        
ECG     x  
     
 
 
                                                 
iv
 There was a washout period of at least 7 days between the two administrations of study drug. 
v
 Between 14 days and approximately 1 day before first study drug administration in period I 
vi
 Follow-up was done within at least 24 hours of the last blood sample. 
vii
 Before screening examination, the subjects signed an informed consent form (ICF) 
viii
 To be eligible for participation in the study, the subjects met all the selection criteria before the first 
study drug administration in period I was established. 
ix
 Lever enzyme tests were done on follow up and prior to admission to period II. 
x
 Was done prior to admission to period II. 
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Table 43: Schedule of assessment of each period. 
Study Day Nominal time 
(h) relative to 
sudy’s drug 
administration 
Blood Collection Vital Signs Hospitalisation 
-1 -10.00 at least Standardise dinner   
 1 Pre-dose       
 1 0.00 Study drug administration*  
 1 0.33      
 1 0.66       
 1 1.00       
 1 1.33      
 1 1.66       
 1 2.00       
 1 2.50       
 1 3.00       
 1 4.00       
Standardised Lunch** 
 1 5.00      
 1 6.00       
 1 8.00       
Snack** 
 1 10.00      
 1 11.00      
 1 12.00      
Standardised dinner** 
 1 16.00      
 2 24.00       
 2 36.00     
* Study drug was administered with 240 mL of water. Fluids intake was not allowed from one hour 
prior drug administration until one hour after drug administration. Thereafter, subjects are allowed to 
drink water as desired. 
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Table 44: The clinical assessment for all subjects for the bioequivalence study 
between Resclar 500 mg, test product (Neopharma, UAE) and Klacid® 
500 mg, reference product (Abbott Laboratories Ltd, England). 
Subject No. 
Resclar 500 mg 
tablet was well 
tolerated (test 
product) 
Klacid® 500 mg 
tablet was well 
tolerated 
(reference 
product) 
The subject left 
the study without 
changes from the 
baseline condition 
1 Yes Yes Yes 
3 Yes Yes Yes 
4 Yes Yes Yes 
5 Yes Yes Yes 
6 Yes Yes Yes 
8 Yes Yes Yes 
9 Yes Yes Yes 
10 Yes Yes Yes 
11 Yes Yes Yes 
12 Yes Yes Yes 
13 Yes Yes Yes 
14 Yes Yes Yes 
15 Yes No Yes 
16 Yes Yes Yes 
17 Yes No Yes 
18 Yes Yes Yes 
19 Yes Yes Yes 
20 Yes Yes Yes 
21 Yes Yes Yes 
22 No No Yes 
23 Yes No Yes 
24 Yes Yes Yes 
25 Yes Yes Yes 
26 Yes No Yes 
27 Yes Yes Yes 
28 Yes Yes Yes 
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Table 45: Study drug administration times for all subjects for the bioequivalence 
study between Resclar 500 mg, test product (Neopharma, UAE) and 
Klacid® 500 mg, reference product (Abbott Laboratories Ltd, England). 
Subject No. 
Period I Period II 
Date 
(DD/MM/YY) 
Time         
(HH: MM) 
Date 
(DD/MM/YY) 
Time         
(HH: MM) 
1 26/04/2009 08:00 03/05/2009 08:00 
3 26/04/2009 08:04 03/05/2009 08:04 
4 26/04/2009 08:06 03/05/2009 08:06 
5 26/04/2009 08:08 03/05/2009 08:08 
6 26/04/2009 08:10 03/05/2009 08:10 
8 26/04/2009 08:14 03/05/2009 08:14 
9 26/04/2009 08:16 03/05/2009 08:16 
10 26/04/2009 08:18 03/05/2009 08:18 
11 26/04/2009 08:20 03/05/2009 08:20 
12 26/04/2009 08:22 03/05/2009 08:22 
13 26/04/2009 08:24 03/05/2009 08:24 
14 26/04/2009 08:32 03/05/2009 08:26 
15 26/04/2009 08:00 03/05/2009 08:00 
16 26/04/2009 08:02 03/05/2009 08:02 
17 26/04/2009 08:04 03/05/2009 08:04 
18 26/04/2009 08:06 03/05/2009 08:06 
19 26/04/2009 08:08 03/05/2009 08:08 
20 26/04/2009 08:10 03/05/2009 08:10 
21 26/04/2009 08:12 03/05/2009 08:12 
22 26/04/2009 08:14 03/05/2009 08:14 
23 26/04/2009 08:16 03/05/2009 08:16 
24 26/04/2009 08:18 03/05/2009 08:18 
25 26/04/2009 08:20 03/05/2009 08:20 
26 26/04/2009 08:22 03/05/2009 08:22 
27 26/04/2009 08:24 03/05/2009 08:24 
28 26/04/2009 08:26 03/05/2009 08:26 
Minimum 
Maximum 
8:00 
8:32 
Minimum 
Maximum 
8:00 
8:26 
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Table 46: Adverse events for the bioequivalence study between Resclar 500 mg 
(test, Neopharma, UAE) tablets and Klacid® 500 mg (reference, Abbott 
Laboratories ltd, England). 
Subject No. Adverse Event(s) Occurred 
1 No* 
3 No 
4 No 
5 No 
6 No 
8 No 
9 No 
10 No 
11 No 
12 No 
13 No 
14 No 
15 Yes** 
16 No 
17 Yes 
18 No 
19 No 
20 No 
21 No 
22 Yes 
23 Yes 
24 No 
25 No 
26 Yes 
27 No 
28 No 
*No: Adverse event(s) did not occur. 
**Yes: Adverse event(s) did occur 
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Appendix 12: Subjects who withdrew from the bioequivalence study between Resclar 
500 mg, test product (Neopharma, UAE) and Klacid® 500 mg, reference 
product (Abbott Laboratories Ltd, England). 
Withdrawn Subject Group* Reason For Withdrawal 
MMW 1 Personal reason 
AAA 1 Abnormal Lab. results 
BIT 1 Abnormal Lab. results 
WBA 1 Abnormal Lab. results 
MAH 1 Abnormal Lab. results 
FFM I Abnormal Lab. results 
NFI 1 Abnormal Lab. results 
MAA 1 Abnormal Lab. results 
OOM 1 Abnormal Lab. results 
MHA 1 Personal reason 
AME 1 Personal reason 
ABA 1 Medical condition 
FMM 1 Medical condition 
MJM 1 
Excluded by IPRC investigators due to 
protocol violation 
SMA 1 
Excluded by IPRC investigators due to 
protocol violation 
MAK 1 Personal reason 
ASS I Personal reason 
MMS 1 Personal reason 
MFM 1 Personal reason 
OJS 1 Personal reason 
MYA 1 Personal reason 
IMI 1 Personal reason 
ANS (07) 2 Medical condition 
SFM (02) 2 Medical condition 
* Withdrawal group 1: Withdrawal after screening procedures have been performed but before the 
administration of the study drug in study period I.  
Withdrawal group 2: Withdrawal after administering the study drug in study period I but before 
administering the study drug in study period II.  
Withdrawal group 3: withdrawal after administering the study drug in study period II. 
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Appendix 13: Variation from the study protocol for the bioequivalence study between 
Resclar 500 mg, test product (Neopharma, UAE) and Klacid® 500 mg, 
reference product (Abbott Laboratories Ltd, England). 
Variation from the 
clinical protocol 
Subject 
No. 
Pharmaco-
kinetic 
outcomes 
Impact on the study outcome 
D
ef
in
ite
l
y 
no
ne
 
M
o
st
 
lik
el
y 
n
o
n
e 
po
ss
ib
le
 
Li
ke
ly
 
D
ef
in
ite
 
Cl
in
ic
al
 
la
b 
re
su
lts
 
(be
gi
n
n
in
g) 
HB is slightly 
below 
reference 
range 
04, 05, 08, 
10, 13, 19, 
23, 25 
CS 
PK 
  
  
    
Crystals are 
present in 
urine 
20, 23 CS 
PK 
  
      
Mucus is 
present in 
urine 
03, 06, 10, 
12, 20, 24, 
27, 28 
CS 
PK 
  
      
WBC count 
is slightly 
below 
reference 
range 
26 CS 
PK 
  
  
    
Creatinine is 
slightly 
below 
reference 
range 
08, 20 CS 
PK 
  
  
    
Specific 
gravity is 
slightly 
above 
reference 
range in urine 
03 CS 
PK 
  
  
    
RBC is 
slightly 
above 
reference 
range in urine 
03, 20 CS 
PK 
  
  
    
Alkaline 
phosphatise 
is slightly 
above 
reference 
range 
18 CS 
PK 
  
  
    
Glucose is 
slightly 
above 
reference 
10, 12 CS 
PK 
  
  
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Variation from the 
clinical protocol 
Subject 
No. 
Pharmaco-
kinetic 
outcomes 
Impact on the study outcome 
D
ef
in
ite
l
y 
no
ne
 
M
o
st
 
lik
el
y 
n
o
n
e 
po
ss
ib
le
 
Li
ke
ly
 
D
ef
in
ite
 
range 
RBC (HB) is 
present in 
urine 
03 CS 
PK 
  
      
HB is slightly 
above 
reference 
range 
28 CS 
PK 
  
  
    
PCV is 
slightly 
below 
reference 
range 
19 CS 
PK 
  
  
    
Cl
in
ic
al
 
la
b 
re
su
lts
 
(be
fo
re
 
ad
m
iss
io
n
 to
 
pe
rio
d 
II)
 
T.BIL is 
slightly 
above 
reference 
range 
22 CS 
PK 
  
  
    
ALT is 
slightly 
above 
reference 
range 
09, 11, 16, 
28 
CS 
PK 
  
  
    
AST is 
slightly 
above 
reference 
range 
08 CS 
PK 
  
  
    
Cl
in
ic
al
 
la
b 
re
su
lts
 
(fo
llo
w
 
u
p) 
ALT is 
slightly 
above 
reference 
range 
11, 14, 28 CS 
PK 
  
  
    
T.BIL is 
slightly 
above 
reference 
range 
20 CS 
PK 
  
  
    
AST is 
slightly 
above 
reference 
range 
28 CS 
PK 
  
  
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Variation from the 
clinical protocol 
Subject 
No. 
Pharmaco-
kinetic 
outcomes 
Impact on the study outcome 
D
ef
in
ite
l
y 
no
ne
 
M
o
st
 
lik
el
y 
n
o
n
e 
po
ss
ib
le
 
Li
ke
ly
 
D
ef
in
ite
 
Sa
m
pl
in
g 
tim
e 
v
ar
ia
tio
n
 (p
er
io
d 
I) 
Sampling 
no.09 was 
withdrawn 
earlier by 06 
minutes 
14 CS 
PK 
  
  
    
Sample no. 
10 was 
withdrawn 
delayed by 
03 minutes 
26 CS 
PK 
  
  
    
Sample no.17 
was 
withdrawn 
earlier by 01 
hour and 02 
minutes 
24 CS 
PK 
  
  
    
Sa
m
pl
in
g 
tim
e 
v
ar
ia
tio
n
 (p
er
io
d 
II)
 
Sample no. 
17 was 
withdrawn 
earlier by 01 
hour and 14 
minutes 
12 CS 
PK 
  
  
    
Sample no. 
17 was 
withdrawn 
earlier by 01 
hour and 20 
minutes 
14 CS 
PK 
  
  
    
Sample no. 
17 was 
withdrawn 
earlier by 01 
hour and 06 
minutes 
27 CS 
PK 
  
  
    
Sample no. 
17 was 
withdrawn 
earlier by 01 
hour and 10 
minutes 
28 CS 
PK 
  
  
    
T. BIL: Total Bilirubin, PCV: Packed Cell Volume, ALT: Alanine transaminase, AST: Aspartate 
aminotransferase, CS: Clinical safety study, PK: Pharmacokinetics study outcome. 
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Appendix 14: The informed consent and other forms used in the bioequivalence study 
between Resclar 500 mg, test product (Neopharma, UAE) and Klacid® 
500 mg, reference product (Abbott Laboratories Ltd, England). 
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Appendix 15: The protocol to evaluate the effect of switching from atorvastatin to 
simvastatin on patients’ cardiovascular outcomes using General 
Practice Research Database (GPRD). 
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Appendix 16: The granted approval from the MHRA (the UK Medicines and 
Healthcare products Regulatory Agency) regarding the use of the 
General Practice Research Database to evaluate the impact of switching 
statins on patients’ cardiovascular outcomes. 
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Appendix 17: The protocol of switching from valsartan to losartan using the General 
Practice Research Database. 
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Appendix 18:  The response of the MHRA (the UK Medicines and Healthcare 
products Regulatory Agency) regarding the use of the General Practice 
Research Database to compare valsartan to losartan.  
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